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Neurodevelopment is a highly dynamic process governed by the tight orchestration of events 
such as neurogenesis, neuronal migration, morphogenesis and synaptogenesis that ultimately 
shape the brain. These neurodevelopmental events are tightly regulated by the interplay of 
cell-extrinsic and intrinsic mechanisms. Over the past decades, the ubiquitin proteasome 
system has emerged as an intrinsic regulator of neurodevelopment as well as disease. In this 
study, I explored the function of the CNS-specific F-box protein FBXO41 in vivo and 
established it as a key regulator of cerebellar development. I found that loss of FBXO41 
results in a severely ataxic and uncoordinated gait in mice, along with impaired granule 
neuron migration, neurodegeneration and axon growth defects in the cerebellum. In addition, 
I identified FBXO41 as the second F-box protein to form an SCF-like E3 ligase complex with 
cullin7. Furthermore, I discovered that FBXO41-Cul7 non-proteolytically ubiquitinates the 
cytoskeletal protein neurofilament medium polypeptide (NFM), thereby stabilizing it. Last 
but not the least, I uncovered that FBXO41-Cul7 operates upstream of NFM in the pathway 
of axon growth regulation. Collectively, my study has uncovered the function of FBXO41 in 
cerebellar development and has identified FBXO41-Cul7 as a novel E3 ligase providing the 
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1.1 The cerebellum: It is all about timing! 
The cerebellum also known as the little brain is indispensable for proper motor control and 
coordination. Although the cerebellum itself does not initiate movement, it serves as an 
integration system, receiving inputs from the sensory system, spinal cord and various cortical 
regions thereby calibrating the precision and timing of any given movement (Glickstein and 
Doron, 2008; Mauk et al., 2000; Middleton and Strick, 1998). This is further illustrated by 
the fact that various malformations or atrophy affecting the cellular composition and 
architecture of the cerebellum consistently lead to motor deficits (Chizhikov and Millen, 
2003; Millen and Gleeson, 2008). Typical symptoms of cerebellar dysfunction include ataxic 
gait, postural instability, dysmetria, nysthagmus, dysarthria, improper reflexes and 
dysdiadochokinesia (Assadi et al., 2008; Millen and Gleeson, 2008; Trouillas et al., 1997). 
Recent studies have also implicated the cerebellum in reflex control, motor learning, 
cognition, language and emotion (Boyden et al., 2004; Ferrucci et al., 2012; Leggio et al., 
2000; Marien et al., 2001; Middleton and Strick, 1998; Rapoport et al., 2000; Stoodley, 
2012; Strata et al., 2011; Strick et al., 2009). In order to fully appreciate the role of the 
cerebellum in motor coordination and higher cognitive functions, we must first understand its 
architecture and composition.  
 
1.2 Cerebellar architecture and composition: Simplicity is the ultimate sophistication- 
Leonardo da Vinci 
The cerebellum is a distinct structure from the cerebrum, having its own characteristic 
morphological and cellular architecture. At a morphological level, it is defined by two 
cerebellar hemispheres that are fused at the midline by the protruding vermis. The surface of 
the cerebellum has fissures that give it a foliated morphology. The foliation of the cerebellum 
is thought to increase its surface area to accommodate the diverse and functionally complex 
circuits that can be highly organized within specific micro-domains in certain folias 
(Cerminara et al., 2015; Goldowitz and Hamre, 1998; Sillitoe and Joyner, 2007; Sotelo, 





types of neurons including the Purkinje cells, cerebellar granule neurons (CGNs), stellate 
cells, basket cells, Golgi cells, Lugaro cells, the recently identified unipolar bush cells and 
candelabrum cells (Cerminara et al., 2015; Goldowitz and Hamre, 1998; Sotelo, 2004; 
Voogd and Glickstein, 1998a; White and Sillitoe, 2013) (Figure 1.1). Except for CGNs and 
unipolar bush cells that use glutamate as their neurotransmitter, the other neuronal types are 
GABAergic (Goldowitz and Hamre, 1998; Sotelo, 2004; Voogd and Glickstein, 1998a; White 
and Sillitoe, 2013). Most of the cerebellar cell types are evenly distributed across all the folia 
to give rise to a uniform architecture consisting of three major layers, namely the molecular 
layer (ML), Purkinje cell layer (PCL) and the internal granule cell layer (IGL) (Altman and 
Bayer, 1978). The ML is the site of extensive synaptic exchange housing the dendritic arbors 
of the Purkinje neurons and the parallel fibers (axons) of the CGNs. With the exception of 
small interneurons, the stellate and basket cells, the ML is devoid of cell bodies. At the 
border of the ML and IGL reside the Purkinje cells. They posses large somas and are 
arranged in a “string of pearls”-like fashion forming the PCL. Their elaborate dendritic 
branches span the entire ML. Additionally the GABAergic candelabrum interneurons are also 
distributed within the PCL. Below the PCL lie the densely packed CGNs that form the IGL. 
An average adult (human) cerebellum consists of ~50 billion CGNs that are densely packed 
in the IGL, making them the most numerous cell-type in the entire brain (Altman and Bayer, 
1978; White and Sillitoe, 2013). CGNs have a small soma, with the nucleus occupying most 
of the space. They have 3-4 short dendrites harboring claw-shaped tips and bifurcating axons 
that reside in the ML forming the parallel fibers. The IGL also houses the GABAergic Lugaro 
and Golgi interneurons.  
The three layers, namely the ML, PCL and the IGL together form the cerebellar cortex. 
Below the cerebellar cortex is the white matter of the cerebellum consisting of the major 
efferent tracts of the cerebellum. Within the white matter lies a small cluster of grey matter 
called the deep cerebellar nuclei (DCN), representing the final output and checkpoint of the 
cerebellum (Altman and Bayer, 1978; Glickstein and Doron, 2008; Goldowitz and Hamre, 








Figure 1.1. Cellular composition of the cerebellum: Schematic depicts the various layers of the cerebellar 
cortex and their cellular composition. Abbreviations: wm= white matter, gcl= granule cell layer, pc= Purkinje 
cell layer, ml= molecular layer. (modified from Sillitoe and Joyner, 2007). 
 
1.3 Cerebellar circuitry: Don’t get all your wires crossed just yet! 
The different neurons of the cerebellum are connected via a well-defined circuitry. The 
cerebellar cortex receives afferent inputs from the climbing fibers, mossy fibers, diffused 
mono-aminergic and cholinergic fibers while the Purkinje cell axons serve as the sole efferent 
output of the cerebellar cortex that project onto the DCN (Sotelo, 2004; Voogd and 
Glickstein, 1998b).  
The climbing fibers arise from the inferior olive (IO), which in turn relays afferent inputs 
coming from the certain cortical areas, brain stem and the spinal cord. While each climbing 
fiber from the IO synapses onto the dendritic arbors of exactly one Purkinje neuron, it 
synapses multiple times along the dendrites of the same cell (Cerminara et al., 2015; Sotelo, 





glutamate as their neurotransmitter and generate strong EPSPs on the recipient Purkinje 
neuron (Ito, 2006; Sillitoe and Joyner, 2007; Sotelo, 2004; Voogd and Glickstein, 1998b; 
White and Sillitoe, 2013). The mossy fibers arising from the pontine nuclei, vestibular nuclei 
and the spinal cord also use glutamate as their neurotransmitter (Cerminara et al., 2015; Ito, 
2006; Sillitoe and Joyner, 2007; White and Sillitoe, 2013). Each mossy fiber forms an 
enlarged rosette in the IGL that synapses onto dendritic claws from ~20 different CGNs (R R 
Llinas, 2004). This synaptic cluster is ensheathed by glia and in turn receives inhibitory 
inputs from the Golgi interneurons. While climbing fibers and Purkinje cells maintain a one 
to one ratio, each mossy fiber can send out collaterals to several cerebellar folias resulting in 
20-30 rosettes thus synapsing on ~400-600 CGNs at a time (Mark F Bear, 2006; R R Llinas, 
2004). The CGN axonal tracts reside in the ML where they bifurcate into T shaped 
unmyelinated parallel fibers that run bidirectionally, synapsing on the Purkinje cell dendrites, 
which are flattened and oriented perpendicular to the direction of the parallel fibers (Sotelo, 
2004; Voogd and Glickstein, 1998b). While each parallel fiber synapses only once onto each 
Purkinje cell, it synapses onto several Purkinje cells along its path. Correspondingly, each 
Purkinje cell can receive excitatory inputs from several parallel fibers (Eccles et al., 1966a, b, 
c; Mark F Bear, 2006; R R Llinas, 2004). Taken together a single Purkinje cell receives 
inputs from a single climbing fiber, but several parallel fibers. These synapses are further 
regulated by the inhibitory synapses from the stellate and basket cells, which result in a feed 
forward inhibition of the Purkinje cells (Eccles et al., 1966a, b, c; Voogd and Glickstein, 
1998a). The climbing fiber inputs are often regarded as a “teaching” signal, since the strong 
excitatory post synaptic potentials (EPSPs) produced by them are known to modulate the 
synapses between Purkinje cells and parallel fibers by long term depression (LTD), which is 
thought to contribute to motor learning (Ito, 2006); (Albus., 1989). The GABAergic efferents 
of the Purkinje cell finally synapse onto the DCN neurons, which send excitatory efferents 
out of the cerebellum onto effector regions. The DCN serves as the final output center of the 
cerebellum, which apart from the inhibitory Purkinje efferents, also receives excitatory inputs 
from the IO and the pontine nucleus (Ito, 2006) (Figure 1.2). A small subset of GABAergic 
neurons in the DCN are also known to form a feed back loop by synapsing on the IO 
(Middleton and Strick, 1998). The inhibitory Purkinje efferents are thought to be the 
regulatory signal that modulates the output of the cerebellum at the DCN, thus contributing 
significantly in precision and central timing of movements (Cerminara et al., 2015; Ito, 






Figure 1.2. Circuitry of the cerebellum: Schematic depicts the circuitry of the cerebellum, 
demonstrating the efferent and afferent connections. Abbreviations: LTD= long term depression. (with 
permission from Ito, 2002b). Nature publishing group license number 3614321463665. 
 
1.4 Cerebellar development: You can't play a symphony alone; it takes an orchestra to play 
it.- Navjoth Singh Siddhu  
The cerebellum develops from the constriction at the border of the mesencephalon and 
metencephalon called the isthmic organizer, a derivative of the hindbrain rhombomere 1. The 
isthmic organizer expresses a number of growth and transcription factors such as Wnt1, En1 
and En2, Pax2, Pax5 and Fgf8, all of which are shown to be crucial for the induction of the 
cerebellar primordium. The cerebellar primordium spans from the caudal third of the 
mesencephalic vesicle up until the anterior part of rhombomere 2 (Sgaier et al., 2005; Sotelo, 
2004; Wingate, 2001). After the induction of the cerbellar fate, several neurodevelopmental 
events such as progenitor proliferation, neuronal differentiation, neuronal migration, axon 
outgrowth and synaptogenesis have to be precisely timed, so that proper lamination and 
circuitry of the cerebellum can be achieved (Komuro and Yacubova, 2003; Sillitoe and 





various disorders, such as Dandy-Walker Malformations, Jouberts syndrome and Cayman 
type ataxia (Chizhikov and Millen, 2003; Itoh et al., 2011; Millen and Gleeson, 2008). In the 
following sections, I will focus on key neurodevelopmental events namely, neuronal 
migration, axon growth and apoptosis in the developing cerebellum, with an emphasis on 
CGN development.  
 
1.4.1 Granule neuron migration during cerebellar development:  
Neuronal migration is a highly dynamic event, defined by neuronal precursor cells and 
newborn neurons travelling large distances across the brain to reach their destined locations 
to give rise to mature neurons. These neurons in turn form the appropriate synaptic 
connections that eventually compose the fully functional brain (Ghashghaei et al., 2007; 
Hatten, 1999). Disturbances in neuronal migration often result in improper lamination of the 
brain leading to several neurological conditions including, schizophrenias, autism spectrum 
disorders and ataxias, depending on the region affected (Gleeson and Walsh, 2000; 
Nadarajah and Parnavelas, 2002).  
Radial and tangential migrations are two of the most well characterized types of neuronal 
migration. Radial migration occurs radially inward or outward via the support of radial glial 
scaffolds, also referred to as gliophilic migration. Tangential migration on the other hand 
occurs tangentially via the help of neuronal processes and cell bodies. Tangential migration is 
thus also referred to as neurophilic migration. While radial migration is mostly observed in 
newborn neurons, tangential migration is observed in neuronal precursor cells that must reach 
their destined location, where they divide further or differentiate (Ghashghaei et al., 2007; 
Hatten, 1999; Nadarajah and Parnavelas, 2002). Both radial and tangential migration occur 
extensively during cerebellar development (Hatten, 1999; Sotelo, 2004).  
Cells of the developing cerebellum originate from two different germinal centers, the 
subventricular zone of the fourth ventricle as well as from the rhombic lip (interface between 
the dorsal roof plate and dorsal neuroepithelium of the alar plate) of rhombomere 1. While 
the Purkinje cells and Golgi cells originate from the former, the CGN precursors originate 
from the latter (Hatten and Heintz, 1995; Sgaier et al., 2005; Sotelo, 2004). Newborn 
Purkinje and Golgi neurons migrate embryonically from the subventricular zone of the fourth 





stellate cells, originate from neuronal precursor cells within the white matter of the 
cerebellum, proliferate further by interstitial proliferation and migrate to the ML (Sotelo, 
2004). Unlike the other cerebellar cell types, the CGN precursors migrate dorsolaterally from 
the rhombic lip to the cerebellar primordium (E10-E15), where they form a second 
proliferative region called the external granule layer (EGL). The EGL spans the entire surface 
of the cerebellar primordium and initially consists of a single layer of CGN precursor cells 
(Alder et al., 1996; Sgaier et al., 2005; Sotelo, 2004). Postnatally E16-P10), these precursor 
cells undergo several rounds of cell division, resulting in a 6-7-fold expansion of the 
thickness of this layer (Altman and Bayer, 1985; Hatten and Heintz, 1995; Sillitoe and 
Joyner, 2007; Sotelo, 2004). By P7, the EGL consists of two distinctive regions, the upper 
EGL consisting of neuronal precursors that are proliferative, and the lower EGL consisting of 
newly differentiated neurons (Altman, 1972b; Chedotal, 2010; Sillitoe and Joyner, 2007). 
The neuronal precursors of the EGL differentiate to give rise to the CGNs, which then 
migrate tangentially to reach their destined folia before migrating radially inward to the IGL 
by gliophilic migration. During the process of tangential migration, the newborn CGNs 
extend two processes, a longer leading process and a shorter trailing process (Chedotal, 2010; 
Komuro and Yacubova, 2003; Komuro et al., 2001; Sotelo, 2004). The leading and trailing 
processes go through repetitive cycles of contraction and extension. The leading process 
constantly extends and retracts leading to a net elongation, consequently the cell soma is 
dragged into the leading process, followed by a contraction of the trailing leading to cellular 
movement (Edmondson and Hatten, 1987; Komuro and Yacubova, 2003). Upon completion 
of tangential migration, the CGNs from the lower EGL migrate across the ML into the IGL 
with the help of astrocytic radial glial scaffolds that span the entire ML from the pia to the 
IGL (Chedotal, 2010; Goldowitz and Hamre, 1998; Hatten and Heintz, 1995; Sotelo, 2004; 
Wang and Zoghbi, 2001) (Figure 1.3). The migration of CGNs is a long-lasting process that 
continues up until the third postnatal week. As neuronal migration proceeds, the EGL 
becomes thinner and disappears by P15 or P16 (Altman, 1972b; Chedotal, 2010; Sgaier et al., 
2005; Sotelo, 2004). Once neuronal migration is complete the astrocytic radial glia lose their 
radial glia properties and mature into Bergmann glia spanning the entire ML in the adult 
cerebellum (Sotelo, 2004). Proper neuronal migration in the cerebellum is indispensible as it 
ensures the correct lamination of the cerebellum (Millen and Gleeson, 2008). The majorly 





attractive model system to study neuronal migration and development (Alder et al., 1996; 
Hatten and Heintz, 1995). 
 
Figure 1.3. CGN migration in the developing cerebellum: Schematic demonstrates the migration of 
CGN from the EGL to the IGL, highlighting their expansive proliferation in the EGL and subsequent 
differentiation and migration across the ML and PCL to the IGL. Abbreviations: EGZ= external germinal 
layer (zone), ML= molecular layer, PCL= Purkinje cell layer, GL= granule cell layer, WM= white matter, 
CN=cerebellar nuclei. (modified from Marzban et al., 2014). Licensed by Creative Commons (CC BY 4.0) 
http://creativecommons.org/licenses/by/4.0/  
 
1.4.1.1 Molecular regulation of granule neuron migration in the cerebellum:  
 
Neuronal migration in the cerebellum is governed by the interplay of various cell-extrinsic 
and intrinsic factors. Extrinsic secretory molecules, such as the semaphorins, netrins and slits 
comprise a large family of guidance cues that are well characterized in neuronal migration 
(Casazza et al., 2007; Lai Wing Sun et al., 2011; Marin et al., 2003). These molecules act as 
chemo-attractants or repellents eliciting intracellular signaling cascades that control the 
cytoskeletal dynamics of the migrating neuron thereby guiding the newborn neurons to their 
correct destination (Ghashghaei et al., 2007; Komuro and Yacubova, 2003; Yacubova and 
Komuro, 2003). Studies in the past decades have further highlighted the role of these extrinsic 
guidance molecules in the context of cerebellar development. Sema6A and its interaction to 
the receptor plexin A2 was found to be crucial for centrosome-mediated nucleokinesis of the 
granule cell soma and the initiation of radial migration of postmitotic CGNs in the cerebellum 





from the lower rhombic lip, however, it also functions as a chemo-repellent by steering the 
migrating CGNs away from the EGL towards the ML (Alcantara et al., 2000; Marin and 
Rubenstein, 2001). Studies have also demonstrated that the brain derived growth factor 
(BDNF) and its receptor TrkB are crucial for proper radial neuronal migration in the 
cerebellum as loss of BDNF in BDNF-/- mice leads to impaired migration of CGNs 
(Borghesani et al., 2002; Komuro and Yacubova, 2003). Moreover, neuregulin and its 
receptor ErbB4 have been implicated in proper adhesion and migration of CGNs along radial 
glia (Komuro and Yacubova, 2003; Rio et al., 1997). 
Apart from the various extrinsic factors, the migrating neuron itself has an array of intrinsic 
molecular cascades that can be modulated to shape the cytoskeleton thereby influencing its 
migration. Examples include regulation at the transcriptional level or posttranslational 
modification (PTM) of key regulator proteins thereby changing the activity state of their 
respective pathways (Coskun and Luskin, 2002; Frank and Tsai, 2009; Govek et al., 2011). 
As such, cycline-dependent kinase 5 (Cdk5) was recently found to be crucial for CGN 
migration in the cerebellum. Oshima and colleagues demonstrated that loss of CDK5 in the 
cdk5 -/- chimeric cerebellum lead to stalled CGNs in the ML of the adult mice cerebella 
(Komuro and Yacubova, 2003; Ohshima et al., 1999). PTM of cytoskeletal regulators of actin 
and microtubules directly influences cell motility and neuronal migration (da Silva and Dotti, 
2002; Kuijpers and Hoogenraad, 2011). A recent study demonstrated that ubiquitination and 
proteolytic degradation of the RhoGTPase RhoA by the E3 ligase Smurf1 lead to impaired 
axon growth and neuronal migration in the developing rat cerebellum (Kannan et al., 2012b). 
 
1.4.2 Parallel fiber formation and axon growth regulation in cerebellar granule 
neurons:  
 
Neurite extension and axon growth are fundamental events of neurodevelopment that ensure 
the proper connectivity of the adult brain. Neurite outgrowth and axon specification in vivo 
are strongly related to neuronal migration. Upon completion of neuronal migration, the 
leading process of the migrating cell gives rise to dendrites whereas the trailing process gives 






The postnatal differentiation and maturation of CGNs in rodents makes them a suitable model 
to study axon growth and guidance in vivo as well as in vitro (Hatten and Heintz, 1995). 
During cerebellar development, the newborn CGNs adopt a bipolar shape by extending two 
processes, the leading and trailing processes, prior to radial migration. These processes grow 
in parallel to the pial surface and aid in tangential migration of the CGN across the EGL of 
the cerebellar cortex. Upon completion of tangential migration, these neurons migrate 
radially inward towards the IGL by extension of a third process perpendicular to the two 
previously formed processes. This third process now assumes the role of the new leading 
process that translocates the nucleus inward (nucleokinesis) to the IGL along the radial glia. 
The inward migration of the CGN cell body causes the two initially created processes to fuse, 
resulting in T-shaped axons that are connected to the migrating soma of the CGN. The T-
shaped axonal processes of the CGNs are restricted to the ML and are oriented in parallel to 
the EGL. They grow and elongate bidrectionally to give rise to the fasciculated, unmyelinated 
axonal bundles of the parallel fibers in the ML in the developed cerebellum (Altman, 1972a, 
b; Kawaji et al., 2004). Dissociated CGN cultures have been long used to study axon 
specification and growth in vitro (Bilimoria and Bonni, 2008; Hatten, 1985; Holubowska et 
al., 2014; Segal et al., 1995; Stegmuller et al., 2006). They recapitulate well-defined phases 
from being unpolarized to polarized with specified processes, similar to other in vitro 
neuronal model systems such as hippocampal or cortical neurons (Arimura and Kaibuchi, 
2007; Polleux and Snider, 2010) (Figure 1.4). 
During neurodevelopment, axons are guided to their final destination by the growth cone, a 
highly dynamic structure at the tip of the axon that is receptive and reactive to stimuli from 
its environment. The growth cone comprises the peripheral P-domain and the central C-
domain that are different in their structure and molecular identity. The P-domain is highly 
dynamic consisting of the flattened lamellipodia and its finger-like protrusions, the filopodia. 
It is rich in actin and is invaded by single dynamic microtubules. On the other hand, the C-
domain is less dynamic and mainly characterized by intense polymerization of microtubules 






Figure 1.4. Polarization and neurite extension in CGNs in culture: Schematic recapitulates the 
different stages of maturation and neurite outgrowth in cultured CGNs from DIV 0 until DIV 6. The cells 
at DIV 1 start slowly sprouting neurites and become polarized by DIV2. By DIV 4 axon growth is 
ongoing, leading to a mature axon by DIV6-8 (adapted from Arimura and Kaibuchi, 2007). 
Axon growth and elongation is compartmentalized into three steps: i) Protrusion: 
lamellipodia and filopodia are formed as a result of actin polymerization. ii) Engorgement: 
vesicles and organelle transport is directed to the growth cone. iii) Consolidation: the 
proximal part of the axon forms the extension of the axon and bidirectional movement of 
vesicles and organelles is established (Dent and Gertler, 2003; Lowery and Van Vactor, 
2009).  
 
1.4.2.1 Molecular regulation of axon growth in CGNs: 
 Cytoskeletal dynamics are the major driving force behind axon growth and elongation in 
developing neurons. While actin polymerization and depolymerization at the growth cone 
mainly influences axon guidance, microtubule polymerization regulates axon growth. Factors 
that affect the cytokeletal dynamics directly influence axon extension and pathfinding (Dent 
and Gertler, 2003; Dent et al., 2011; Kalil and Dent, 2005). Much like neuronal migration, 
axon growth is also guided by various extracellular cues, such as semaphorins, netrins and 





(neurotrophin 3) that act at the growth cone by binding to their receptors and eliciting 
intracellular signaling cascades (Bixby and Harris, 1991; Kennedy, 2000; Kullander and 
Klein, 2002; Pasterkamp and Kolodkin, 2003; Segal et al., 1995; Zhou and Snider, 2006). 
Apart from the cell-extrinsic factors, a number of cell intrinsic regulators have been identified 
to play a direct role in axon growth and elongation. Cytoskeletal regulators such as CDC42 
and Rac1 have been reported to stimulate actin protein 2/3 (Arp2/3) activity by binding to 
their effectors neuronal Wiskott-Aldrich syndrome protein (N-WASP) and WAVE1 
respectively, leading neurite extension (Goley et al., 2006; Goley and Welch, 2006; Pak et 
al., 2008). Microtubule-associated protein 1B (MAP1B) levels at the growth cone also 
influence neurite extension (Gonzalez-Billault et al., 2004). Several transcriptional regulators, 
such as SnoN and Id2, have been shown to promote axon growth in CGNs (Lasorella et al., 
2006; Stegmuller et al., 2006). On the other hand, posttranslational modifications, such as 
phosphorylation of collapsing-response mediator protein2 (CRMP2) by GSK-3ß prevents it 
from stabilizing microtubules resulting in a negative regulatory effect on axon growth 
(Yoshimura et al., 2005). C-Jun N-terminal kinase (JNK) and Cdk5 have been implicated in 
axon growth regulation (Connell-Crowley et al., 2000; Hirai et al., 2006). Recent evidences 
also implicate the UPS components and E3 ligases in axon growth regulation.  FBXO31-SCF 
reportedly ubiquitinates and degrades its substrate Par6 resulting in axon growth (Vadhvani et 
al., 2013). Similarly, the E3 ligase Smurf-1 was identified to ubiquitinate and degrade the 
RhoGTPase RhoA in order to promote axon growth in CGNs (Kannan et al., 2012b). The 
interplay of signaling cascades regulated by the various cell-extrinsic and -intrinsic factors 
ultimately exert their effect on the growing axon by dynamically remodeling its cytoskeleton. 
As a result, the continual assembly and disassembly of the actin cytoskeleton together with 
the ongoing polymerization of microtubules regulate axon growth and guidance to ensure 
proper wiring (Bixby and Harris, 1991; Dent and Gertler, 2003; Dent et al., 2011; Kalil and 
Dent, 2005; Polleux and Snider, 2010).  
 
1.4.3 Neuronal number and cell integrity within the cerebellum:   
The cerebellum is a highly organized structure with a defined number of all of its cell types. 
During cerebellar development the proper number of cells is maintained on one hand by the 
tight regulation of progenitor proliferation and differentiation and on the other hand by 





progenitors differentiate into neurons that get integrated into functional circuits resulting in 
apoptosis of these excess cells. Thus, regulating the neuronal progenitor pool is crucial to 
ensure the right number of cells in the developing cerebellum (Chizhikov and Millen, 2003). 
Previously, studies have identified several mechanisms that regulate progenitor proliferation. 
Cell-extrinsic events such as Purkinje cell and CGN progenitor interactions mediated by Shh 
signaling, or notch2-mediated signal transduction in the EGL have been found to positively 
influence cell numbers within the EGL (Chizhikov and Millen, 2003; Goldowitz and Hamre, 
1998; Solecki et al., 2001). Cell-intrinsic pathways governed by transcription factors such as 
Zipro1, Zic1 (zinc finger protein in cerebellum 1) and Zic2 (zinc finger protein in cerebellum 
2) have been implicated in keeping a check on CGN progenitor population in the developing 
cerebellum (Aruga et al., 1998; Chizhikov and Millen, 2003; Goldowitz and Hamre, 1998; 
Yang et al., 1999). Moreover, several cell cycle regulators including cyclin D2, p27 Kip1 and 
N-myc were also found to regulate the CGN progenitor pool in the EGL (Huard et al., 1999; 
Knoepfler et al., 2002; Miyazawa et al., 2000). Following neuronal differentiation, it is 
important to maintain proper cellular health for maintenance of cell number and structural 
integrity of the cerebellum. Examination of mouse models with a hypoplastic cerebellum and 
neurodegerative phenotypes such as lurcher, tottering and weaver have helped to identify 
several genes which encode for ion channel subunits, thus highlighting the role of ionic 
homeostasis in survival of CGNs and Purkinje cells in the developing cerebellum (Heintz and 
Zoghbi, 2000; Lalonde and Strazielle, 2001). The transcription factor NeuroD for example 
was found to be crucial for survival of postmitotic CGNs, as loss of NeuroD resulted in large-
scale apoptosis of CGNs (Chizhikov and Millen, 2003; Miyata et al., 1999). Recent studies 
have also implicated E3 ligases such as E6-AP and RNF 157 as critical regulators of neuronal 
survival in the developing cerebellum (Cummings et al., 1999; Matz et al., 2015). 
 
1.5 Ubiquitination as a means of cell-intrinsic regulation of cerebellar development: To 
be or not to be? – William Shakespeare 
As previously introduced, various neurodevelopmental events rely heavily on both cell-
extrinsic and cell-autonomous mechanisms. While cell-extrinsic mechanisms have been 
extensively studied, the contribution of cell-intrinsic regulators still remains poorly 
understood. Advances in recent decades have not only shed light on the role of transcriptional 





proteins as a major contributor of intrinsic regulation of neurodevelopment (Kawabe and 
Brose, 2011; Lancaster et al., 2011b; Moore and Goldberg, 2011; Trakhtenberg and 
Goldberg, 2012). Following synthesis, a protein can be modified by the addition of functional 
groups such as phosphates, carbohydrates, lipids, acetates or nitrates. Similarly, the covalent 
addition of the small, 76 aa protein ubiquitin onto substrates is another type of 
posttranslational modification referred to as ubiquitination. Protein ubiquitination occurs in 
all cells of the eukaryotic organism regulating protein activity as well as spatial and temporal 
expression (Chen et al., 2001; Hochstrasser, 1996; Welchman et al., 2005). Several studies 
have previously implicated ubiquitination as a major cell-intrinsic regulator of 
neurodevelopment (Kawabe and Brose, 2011). 
 
1.5.1 The ubiquitnation cascade:  
Ubiquitination occurs via a 3-step enzymatic cascade that was first characterized by Avaram 
Hershko, Aron Ciechanover and Irwin Rose in the 1980s, for which they were awarded the 
Nobel Prize in chemistry in 2004. The cascade is initiated by the E1 ubiquitin-activating 
enzyme (E1) that catalyzes the activation of ubiquitin in an ATP-dependent manner, resulting 
in the formation of a thioester bond between the C-terminus of ubiquitin and the catalytic 
cystine of the E1. Subsequently, the E2 ubiquitin-conjugating enzyme (E2) mediates the 
transfer of the activated ubiquitin onto itself by thioesterification. In the final step the E3 
ubiquitin ligase enzyme (E3) recruits the E2-ubiquitin as well as a specific protein substrate, 
thus mediating the transfer of ubiquitin from E2 onto a lysine residue of the substrate. 
Ubiquitination of the substrate occurs by the formation of an amide-isopeptide bond between 
Gly 76 of the ubiquitin-ATP conjugate and a lysine residue on the substrate protein (Hershko 






Figure 1.5. Overview of the ubiquitin proteasome system: Schematic displays the mechanism of protein 
ubiquitination by the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the E3 
ubiquitin ligase. The E1 brings about the catalytic activation of ubiquitin in an ATP-dependent manner, 
resulting in the formation of a thioester E1-ubiquitin intermediate. Subsequently, the E2 transfers the 
ubiquitin onto itself, forming an E2 thioester intermediate. In the final step, the E3 recruits specific 
substrates and mediates the transfer of ubiquitin from the E2 onto the substrate. The ubiquitinated 
substrate can then be turned over by the proteasome. Abbreviations: Ub= ubiquitin, E1= ubiquitin 
activating enzyme, E2= E2 ubiquitin conjugating enzyme, E3= E3 ubiquitin ligase. (With permission from 
Maupin-Furlow, 2012). Nature publishing group license number 3614400042383. 
Ubiquitination may have very different consequences on the protein’s fate. Studies have 
previously implicated mono- or multi-monoubiquitination in influencing protein interactions, 
localization and substrate activity (Figure 1.6 a). However, the outcome of 
polyubiquitination can vary from proteolytic protein degradation to regulation of signaling 
cascades, depending on the ubiquitin chain type. Polyubiquitination occurs by the addition of 
another ubiquitin onto the lysine of an existing ubiquitin on the substrate. Different chain 
types of polyubiquitination can be formed based on the ubiquitin lysine (K) residue at which 
further chain extension occurs, including K6, K11, K27, K29, K33, K48 and K63. Depending 
on the type of lysine linkage and the structure of the polyubiquitin chain, the ubiquitinated 
protein can have very different fates. Non-linear chains with closed conformations, as 
observed in K11- or K48- mediated polyubiquitination are readily recognized by the 26S 
proteasome and lead to proteolytic degradation of the substrate. In contrast, linear chains with 
open conformations, as seen in K63-mediated polyubiquitination are implicated in regulation 





NF-kB activation, DNA repair pair, protein stability as well as lysosomal degradation of 
certain substrates (Figure 1.6 b). The outcome of K6-, K27-, K29- and K33-linked 
polyubiquitination however still is poorly understood (Bocquet et al., 2009; Komander and 
Rape, 2012).  
 
Figure 1.6. Different types of ubiquitination on substrates: a. Schematic depicts the different 
topologies of ubiquitination that can occur on protein substrates, ranging from mono or multi mono 
ubiquitination, to polyubiquitination. b. The kind of ubiquitnation determines the fate of the ubiquitinated 
protein. While K48-linked polyubiquitination leads to proteasomal degradation, K63-linked linear chains 
serve as non-proteolytic modifications. K= lysine, Ub= ubiquitin. (Adapted from Komander and Rape, 
2012). 
 
1.5.2 E3 ligases and their role in proper cerebellar development: 
E3 ligases are responsible for identifying and recruiting specific protein substrates for 
ubiquitination. While there are only 2 E1s and ~30 E2s identified in the mammalian genome, 
it is predicted to contain more than 600 E3s (Artinian et al., 2008). Since the total number of 





ubiquitination, it is not surprising that several studies have reported E3 ligases having 
multiple protein ubiquitination substrates (Peters, 2006). One of the well-known E3 ligases 
exemplifying the aforementioned is Cdh1-APC (Peters, 2006). It ubiquitinates several 
substrates, including the transcription factors SnoN and Id2, the E3 ligase Smurf1 as well as 
the Rho GTPase activator p250GAP for proteolytic degradation in order to regulate axon 
growth and migration in the developing cerebellum (Kannan et al., 2012a; Kannan et al., 
2012b; Lasorella et al., 2006; Stegmuller et al., 2006). Another example is the SCF E3 ligase 
Skp2, that ubiquitinates several targets such as p21, p27, p57 as well as cycline A/D1 and E, 
in order to regulate cell cycle progression (Bornstein et al., 2003; Carrano et al., 1999; 
Frescas and Pagano, 2008; Nakayama et al., 2004; Pateras et al., 2006). In this section, I 
will elaborate on the two major classes of E3 ligases and highlight a few notable members 
from each class that have been implicated in regulating cerebellar development. 
 
Figure 1.7. HECT and RING E3 ligases: Schematic displays the mechanism of protein ubiquitination by 
two different classes of E3 ubiquitin ligases. a. HECT E3 ligases harbor a HECT domain, which recruits 
the E2, while the substrate is recruited via its other domains. The HECT ligases mediate the transfer of 
ubiquitn from the E2 onto itself, forming an E3-ubiquitin conjugate. Subsequently, it transfers the 
ubiquitin onto the substrate. b. RING ligases recruit E2s at their RING domain, and they bring the 
substrate and E2-ubiquitin conjugate in very close proximity, thereby mediating the direct transfer of 
ubiquitin from the E2 onto the substrate. While HECT ligases are single subunit E3 ligases, RING ligases 
can be either single or multisubunit in nature. Abbreviations: Ub= ubiquitin, S= substrate, E2= E2 
ubiquitnn conjugating enzyme. (With permission from Rotin and Kumar, 2009). Nature publishing group 
license number 3614410726001. 
The sheer number of E3 ligases and their multiple substrates makes them one of the most 
diverse and versatile members of the ubiquitin cascade. Most E3 ligases can be classified into 
two major classes - the HECT type and the RING type ligases (Figure 1.7 a, b). The HECT 
type ligases share the homologous to E6-AP carboxy terminal (HECT) domain. They bind to 





thioester intermediate. Subsequently, it transfers the ubiquitin onto a lysine of the recruited 
protein substrate (Rotin and Kumar, 2009). Several HECT ligases have been implicated in 
proper cerebellar development. For instance, the E3 ligase Huwe1 is found to be critical for 
proper cerebellar development as it regulates the CGN progenitor pool by ubiquitinating and 
degrading its substrates N-myc and Atoh1 (Forget et al., 2014; Zhao et al., 2008). It is also 
crucial for Bergmann glial differentiation and proper migration of CGNs across the ML to the 
IGL (D'Arca et al., 2010). The HECT ligase Itch was recently implicated in ubiquitination 
and degradation of the Shh transcription factor Gli1, thus suppressing the Shh signaling in the 
developing cerebellum. By ubiquitinating Gli1, Itch keeps a check on CGN progenitor 
proliferation and promotes neuronal differentiation (Di Marcotullio et al., 2006). Other 
studies have also reported that the HECT ligase Smurf1 regulates axon growth and neuronal 
migration in the developing cerebellum by targeting the Rho GTPase RhoA for degradation 
(Kannan et al., 2012b). 
The RING ligases comprise the largest family of E3 ligases, sharing a common, really 
interesting new gene (RING) domain. The RING E3 ligases bind to the E2 enzyme using 
their RING domain and mediate the direct transfer of ubiquitin from the E2 onto the recruited 
substrate. They act like a scaffold that brings the E2 and the substrate in very close proximity 
to facilitate the ubiquitin transfer. RING ligases can be classified into single subunit or multi-
subunit RING ligases (Deshaies and Joazeiro, 2009; Pickart, 2001; Pickart and Eddins, 
2004). The anaphase-promoting complex (APC) and the Skp1-Cullin1-Fbox protein (SCF) 
complexes among other cullin-RING ligases comprise the largest groups and are the most 
well characterized subfamilies of the multi-subunit RING E3 ligases (Deshaies and Joazeiro, 
2009; Peters, 1998, 2006; Pickart, 2001). The SCF complexes and the other cullin-RING 
ligases will be discussed in greater depth under section 1.5.3. A number of studies have 
implicated RING ligases in the regulation of cerebellar development. As previously 
mentioned, the E3 ligase Cdh1-APC has been implicated in control of axon growth in CGNs 
(Konishi et al., 2004). Similarly, the related cell cycle regulator Cdc20-APC, too, has been 
found to influence dendritogenesis, having no effect on axons in the developing cerebellum 
(Kim et al., 2009). Interestingly, it was also implicated in presynaptic differentiation of CGNs 
by targeting the transcription factor NeuroD2 for degradation (Fang et al., 2009; Yang and 
Bonni, 2010). Several other studies have also identified SCF-complexes and cullin-based 






1.5.3 SCF complexes and their contribution in neurodevelopment and disease: 
The SCF complex type E3 ligases were first identified in yeast (Feldman et al., 1997; 
Skowyra et al., 1997). They are one of the largest and most studied subfamilies of the multi-
subunit RING ligases. The SCF complex comprises of four components: Skp1 (S-phase-
kinase-associated protein1), Cul1 (cullin1), F-box protein and the small RING finger protein 
RBX1 or RBX2 (RING-box protein1 or 2) (Figure 1.8. a). F-box proteins serve as the 
interchangeable protein adaptors that recruit specific substrates to the E3 complex for 
ubiquitination (Zheng et al., 2002). All members of the F-box protein family share the 
common, approximately 40 amino acid long F-box domain. Based on the additional motifs or 
domains present on the protein apart from its F-box domain, the members of the F-box family 
can be classified into three categories: The FBXLs, FBXWs and FBXOs. The FBXWs harbor 
WD40 domains, the FBXLs harbor leucine-rich repeats and the FBXOs (F-box other) may or 
may not harbor other domains. While these additional domains are speculated to be 
responsible for substrate binding, the F-box domain is known to be indispensable for 
mediating the interaction of the F-box protein with Skp1 and cullin1 and thus maintaining the 
integrity of the complex (Deshaies, 1999; Jin et al., 2004; Kipreos and Pagano, 2000). Apart 
from the cullin1-based SCF complex, several other cullin-based RING ligases have been 
reported that use different cullins and substrate-recruiting adaptors (Skaar et al., 2013). 
Besides cullin1, the only other cullin identified to interact with both Skp1 and F-box proteins 
to form a multi-subunit E3 SCF-like complex is cullin7. To date, the only cullin7-based 
atypical SCF-like complex reported is formed together with the F-box protein FBXW8 
(Sarikas et al., 2008) (Figure 1.8. b).  
 





components of the canonical SCF complex E3 ligases, namely the RING protein Rbx1 that 
recruits the E2-ubiquitin thioester to the complex, the scaffold protein cullin1, the adaptor 
protein Skp1 and the substrate recruiting F-box protein. b. Schematic of the atypical cullin7-
based SCF complex, with the components Rbx1, cullin7, Skp1 and the substrate-recruiting F-box 
protein. Ub= ubiquitin. 
Although 68 F-box proteins have been identified in the mammalian genome so far, only a few 
of them have been well characterized. A majority of the F-box protein SCF complexes 
including FBXW7-SCF, ß-TrCP-SCF and Skp2-SCF have been studied in the context of cell 
cycle and cancer (Skaar et al., 2013). Recent studies have also identified a role for many of 
them in neurodevelopment and disease. For instance ß-TrCP-SCF ensures the proper 
differentiation of neuronal progenitors during neurogenesis by mediating the degradation of 
its substrate REST (RE1-silencing transcription factor) (Westbrook et al., 2008). FBXO45 
regulates proper axonal pathfinding in the cortex, as loss of FBXO45 in mice resulted in 
defects in cortical axon tracts and improper innervation of the diaphragm (Saiga et al., 2009). 
FBXW7 on the other hand regulates proliferation of CGN precursors in the developing 
cerebellum, prevents premature migration of CGNs and additionally regulates Purkinje cell 
number and axonal arborization. It is speculated that FBXW7 exerts its function in the 
developing cerebellum by regulating the levels of its substrates including notch, N-myc and 
c-Jun (Jandke et al., 2011). Recent studies also identified FBXW8 and FBXO31 as important 
players of cerebellar development. While FBXW8 was found to regulate dendrite growth 
(Litterman et al., 2011), FBXO31 was identified as a key player in the control of axon growth 
and neuronal migration (Vadhvani et al., 2013). Interestingly, a recent study reported a 
truncated form of FBXO31-SCF that caused non-syndromic autosomal recessive intellectual 
disability in a Pakistani family (Mir et al., 2014). FBXO31 and FBXO21 have additionally 
also been linked to other neurodevelopment disorders including schizophrenia (Chen et al., 
2008; Narayan et al., 2008). 
Apart from neurodevelopment, recent studies also implicate several F-box proteins in 
neurodegenerative diseases. For example, FBXO2 has previously been shown to regulate the 
processing of APP by targeting the APP-cleaving ß-secretase for degradation (Gong et al., 
2010). A recent study has identified APP itself as a target of FBXO2 thus presenting FBXO2 
as a potential therapeutic target of Alzheimer’s disease (Atkin et al., 2014). Numerous 





gene to be responsible for early-onset Juvenile Parkinsonism in certain Iranian, Dutch, 
Turkish, Italian and Pakistani families (Di Fonzo et al., 2009; Paisan-Ruiz et al., 2010). 
1.6 Aim and scope of the study: 
As previously discussed, F-box proteins have been thoroughly studied in the control of cell 
cycle in cancer, but have only recently emerged as important players in neurodevelopment 
and disease. Of the ~70 mammalian F-box proteins identified so far several are highly 
expressed in the nervous system. However, only a handful has been investigated regarding 
their function in the brain and the underlying implications in neurological diseases. It is thus 
essential to characterize the functions of the several understudied F-box proteins and identify 
the underlying pathways regulated by them. The F-box protein FBXO41 has been previously 
proposed as a genetic marker for multiple system atrophy (Langerveld et al., 2007), and 
certain SNPs in the Fbxo41 gene are speculated as risk factors for Parkinson’s disease in the 
Chinese Han population (Liang et al., 2013). A previous study from our lab has presented the 
initial characterization of FBXO41 in the nervous system. It has identified FBXO41 as brain-
dominant cytoplasmic neuronal F-box protein, harboring a C2H2 zinc finger domain at its N-
terminus and the F-box domain at its C-terminus. The study also reported a potential role of 
FBXO41 in regulation of axon growth and neuronal migration in the developing rat 
cerebellum (Holubowska, 2013).  
As a first aim of the study, I investigated the implications of loss of FBXO41 in vivo using an 
FBXO41 knockout mouse model. Behavioral and histological analysis of the FBXO41 
knockout mice further led to better understanding of some of the neurodevelopmental events 
governed by FBXO41 in the developing cerebellum. As a second aim, I complemented my in 
vivo findings with in vitro cell culture, imaging and supporting biochemical techniques to 
establish FBXO41 as a novel E3 ligase and to identify putative molecular players that may 
act in the same pathway as FBXO41. Combining mouse genetics and molecular techniques, 
this study establishes FBXO41 as a crucial cell-intrinsic regulator of cerebellar development. 	  




2 Materials and methods 
 
2.1 Lab equipment: 
The following equipments were used to carry out experiments: pipettes (Gilson, USA), 
plastic ware (Eppendorf, Germany, Sarstedt AG, Germany and Greiner Bio-One, Germany), 
centrifuges (Eppendorf), rocker and shaker (Heidolph, Germany), thermocycler (Biometra, 
Germany), heater block (Grant Instruments, UK), spectrophotometer (GE, UK), fluorescent 
microscope (Eclipse Ti), inverted light microscope (Eclipse TS100), dissection microscope 
(SMZ645) (Nikon, Japan), brightfield light microscope (Zeiss Axiophot), Flourescent 
microscope (Zeiss observer Z.1), confocal microscope (Leica SP5), rotarod (Ugo Basile, 
Comerio, Varese, Italy), open field area (custom made ), elevated plus maze (custom made), 
12mm and 6mm beams used in balance beam tests (custom made), pole test (custom made). 
 
2.2 Chemical reagents and commercial kits: 
All the chemicals used during the study were purchased from Merk (Darmstadt, Germany), 
Sigma-Aldrich (Munich, Germany), Roth (Karlsruhe, Germany), Applichem (Darmstadt, 
Germany), Biomol (Hamburg, Germany), Serva Electrophoresis (Heidelberg, Germany), 
Invitrogen (Darmstadt, Germany), Becton Dickinson and Company (USA) and Worthington 
(UK) unless mentioned otherwise. 
 
2.3 Common lab reagents and kits: 
All the cell culture mediums, supplements and reagents used are listed in table 2.1. 
Table 2.1 List of all cell culture reagents used in the study 
Reagent Manufacturer 
Dulbecco’s modified eagle’s medium (DMEM) 
GIBCO®, Life TechnologiesTM 
(Darmstadt) 




Hank’s Balanced Salt Soulution (HBSS) 
GIBCO®, Life TechnologiesTM 
(Darmstadt) 
Basal Medium Eagle (BME) 
GIBCO®, Life TechnologiesTM 
(Darmstadt) 
Trypsin Worthington 
Fetal bovine serum (FBS) Biochrom, Germany 
Calf serum (CS) Hyclone, Germany 
Horse serum (HS) PAA, Coelbe Germany 
Goat serum (GS) Sigma Aldrich 
Poly-L-ornithine hydrobromide Sigma Aldrich 
 
The DNA and protein ladders used were also obtained from Fermentas. N -Ethylmaleimide 
(NEM) and the ECL western blotting detection kit from Thermo Fischer Scientific. Protein 
A-Sepharose beads and Flag-sepharose beads from GE Healthcare and Sigma Alrich 
respectively. 
The commercially available kits used in the study are listed in table 2.2 and were used as per 
manufacturer’s instructions: 




Nucleobond® Xtra Midi EF kit Macherey-Nagel (Dueren, Germany). 
NucleoSpin® Plasmid QuickPure 
kits 
Macherey-Nagel (Dueren, Germany). 
NucleoSpin® Gel and PCR Clean-
up kit 
Macherey-Nagel (Dueren, Germany). 
QuickChanage II Site–Directed 
Mutagenesis Kits 
Agilent Technologies (USA) 









All primary and secondary antibodies used in the study are listed in table 2.3 and 2.4 below.  












α FBXO41 rabbit WB  1:250 Eurogentec (custom made) 
α pan-14-3-3 mouse WB 1:10000 Santa Cruz Biotechnology 
α –γ-Tubulin mouse WB 1:10000 Sigma-Aldrich 
α myc mouse WB 1:1000 Santa Cruz Biotechnology 
α Flag mouse WB 1:1000 Sigma-Aldrich 







α Cullin1 mouse WB 1:1000 Santa Cruz Biotechnology 
α Cullin7 mouse WB 1:1000 Sigma-Aldrich 
α SnoN rabbit WB 1:500 Santa Cruz Biotechnology 






Santa Cruz Biotechnology 
α Pericentrin 2 mouse ICC 1:500 Abcam 
α ß-galactosidase mouse ICC 1:100 Santa Cruz Biotechnology 




α Calbindin rabbit IHC (DAB) 1:100 Sigma-Aldrich 
α GFAP mouse IHC (DAB) 1:200 Nova Castra 
α Iba1 mouse IHC (DAB) 1:1000 WAKO 
α Tau rabbit IHC (FL) 1:2000 DAKO 
α PCNA rabbit IHC (DAB) 1:1000 Abcam 
α NeuN mouse IHC (DAB) 1:400 EMD Milipore 





rabbit IHC (FL) 1:100 Gift from Prof. K.A. Nave, 
MPI of Experimental 
Medicine, Göttingen 
 















α mouse IgG Goat HRP WB 1:10000 Dianova 
α rabbit IgG Goat HRP WB 1:10000 Dianova 
α mouse IgG Goat Cy2/ Alexi 488 ICC 1:1000 Dianova 
α rabbit IgG Goat Cy2/ Alexa488 ICC 1:1000 Dianova 
α mouse IgG Goat Cy3/ Alexa555 ICC 1:1000 Dianova 




The detailed sources of various enzymes used in this study are listed in table 2.5 below 
 





New England Biolabs 
GoTaq® DNA polymerase 
 
Promega 




Pfu DNA polymerase 
 
Thermo Scientific 
Alkaline calf intestinal phosphatase 
 
New England Biolabs 
T4 DNA ligase 
 
Fermentas 
T4 polynucleotide kinase 
 
New England Biolabs 




2.6 Buffers and Stock solutions: 
Listed below are all the solutions and buffers used during the course of this study: 
Buffers and media for primary neuron culture: 
HHGN: 1x HBSS, 2.5 mM HEPES pH 7.5, 35 mM glucose, 4 mM NaHCO3  
Cbc: BME [+] Earle’s salts [-] L-Glutamine, 10% calf serum (heat inactivated), 1% PSG, 25 
mM KCl 
DnB: 500 µl DNase (2ug/ul), 10ml BME [+] Earle’s salts [-] L-Glutamine 
TDn: 250 µl DNase (2ug/ul), 5ml HHGN, 50 mg Trypsin  
Media for HEK293T cell culture: 
HEK293T medium: DMEM [+] 4.5 g/l glucose [-] glutamine [-] pyruvate, 10% FBS, 1% 
GlutaMAX® 
Buffers for HEK293T cell and neuronal transfection 
2X HBSS: 50 mM HEPES pH 7.05-7.11, 10 mM KCl, 280 mM NaCl, 15 mM glucose, 1.5 
mM Na2HPO4 




2.5 M CaCl2 
Nucelofection plating media: DMEM [+] 4.5 g/l glucose [-] glutamine [-] pyruvate, 10% FCS 
(Hyclone) 
Buffers and medium used for molecular cloning: 
Annealing buffer: 100 mM CH3COOK, 30 mM HEPES-KOH, 2mM (CH3COO)2Mg  
2X TAE pH 8.5: 80 mM Tris-acetate, 2 mM EDTA  
2X YT (1000 ml): 16 g tryptone, 10 g yeast extract, 5 g NaCl  
Buffers and reagents used for biochemical techniques: 
Triton® X-100 lysis buffer: 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 1% Triton® X- 
100  
Co-IP buffer: 150 mM NaCl, 20 mM Tris-HCl pH 7.4, 1mM EDTA, 1% Nonidet P-40, 10% 
glycerol  
Mild Co-IP buffer: 150 mM NaCl, 20 mM Tris-HCl pH 7.4, 1mM EDTA, 0.5% Nonidet P-
40, 10% glycerol 
RIPA buffer: 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% sodium deoxycholate, 1% 
Nonidet P-40, 5 mM EDTA (0.1% SDS optional) 
SDS-sample buffer: 300 mM Tris-HCl pH 6.8, 10% SDS, 50% glycerol, 25% β-
mercaptoethanol, and 0.05% bromophenol blue  
Centrosomal purification buffer: 1 mM HEPES pH 7.2, 0.5% NP40, 0.5 mM MgCl2, 0.1% ß-
mercaptoethanol, cytochalasin D (1 µg/ml), nocodazole (0.2 µM) 
Lysis buffer for ubiquitination assay (denaturing protocol): 50 mM HEPES pH 7.5, 150 mM 
NaCl, 10% glycerol, 1.5 mM MgCl2, 1% TritonX100, (10 mM NEM, 1 mM NaVO3, 0.5 mM 
NaF) * 
NaVO3 1000 mM: 180 mg of NaVO3 in 1ml of H2O 
NaF 500 mM: 21 mg of NaF in 1ml of H2O 




HNTG buffer: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% TritonX100, 10% glycerol 
* = Added fresh before use  
Buffers used for SDS-PAGE 
Lower buffer: 1.5 M Tris pH 8.8, 0.4% SDS  
Upper buffer: 0.5 M Tris pH 6.8, 0.4% SDS  
Running buffer: 125 mM Tris, 1.25 M glycine, 0.5% SDS  
Transfer buffer: 20 mM Tris, 153 mM glycine, 20% methanol  
10X PBS pH 7.4: 1.37 M NaCl, 14.7 mM KCl, 78.1 mM Na2HPO4, 26.8 mM KH2PO4  
PBST: 1x PBS, 0.1% Tween-20  
Buffers used for genotyping: 
Tail lysis buffer: 200 mM NaCl, 10 mM Tris pH 8.0, 10 mM EDTA, 0.5 % SDS 
Proteinase K* 
* = Added fresh before use  
Buffers and reagents used for immunocytochemistry: 
BME + 10% Horse serum: BME  + 10% heat inactivated horse serum 
8% PFA: 375 ml sterile H2O at 60°C, 40 g PFA, 50 ml 10% PBS, 40 g sucrose, set pH to 7.4 
fill up with sterile H2O to 500 ml 
4% PFA: 50% [v/v] 8% PFA and 50% [v/v] PBS 
0.4% TX-100 lysis buffer: 0.4% [v/v] TX-100 in PBS 
Buffers and reagents for immunohistochemistry 
X-gal staining 
X-gal:  0.5 mg/ml X-gal, in PBS 




X-gal buffer: 2 mM MgCl2, 0.02% NP40, 0.01% sodium deoxycholate, 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide 
0.2M phosphate buffer (fixation buffer): 0.36% [w/v] NaH2PO4, 3.1% [w/v] Na2HPO4, 1% 
[w/v] NaCl 
4% [w/v] PFA for immunohistochemistry (paraffin embedding): 4% [w/v] PFA, 0.1M 
phosphate buffer (fixation buffer) 
Haematoxylin and Eosin staining: 
Hamatoxylin: ready to use mayer’s haematoxylin from Merck 
Eosin: 0.1% eosin dissolved in dd H2O and 12 drops of CH3COOH 
HCL-alcohol: 0.09% [v/v] HCL, 70% [v/v] ethanol 
Scott’s reagent: ready to use Scotts reagent from Thermo Scientific 
DAB staining: 
Citrate buffer for IHC: 1.8 mM C6H8O7xH2O, 8.2 mM C6H5Na3O7x2H2O (pH 6.0, always 
freshly prepared from stock solutions) 
Tris buffer for IHC:  0.9% [w/v] NaCl, 50 mM Tris-HCl pH 7.6, pH 7.6 
Tris buffer+ 2% Milk powder: 2% [w/v] Milk powder (Ferma) dissolved in Tris buffer for 
IHC 
Blocking buffer: 20% goat serum [v/v] dissolved in BSA/PBS 
BSA/PBS: 0.04M NaH2PO4, 0.16M Na2HPO4, 1.8%[w/v], NaCl, 1% [w/v] BSA 
Immunoflouresence staining of cryo-sections: 
Blocking buffer (IHC): 10% NGS, 3% BSA, 0.5% TX-100 in PBS 
Mounting media 
Mowiol mounting media:  6 g glycerol AR, 2.4 g Mowiol 4-88 (Calbiochem), 6 ml H2O, 12 
ml 0.2 M Tris-HCl pH 8.5 




Eukitt (Kindler, Freiburg, Germany) 
Aqua-poly/mount (Merck) 
Anesthetics 
Ketamine/xylazine: 10% ketamine [v/v] (10% Ketamine, Medistar, Arzneimttelvertrieb 
GMBH®), 5% xylazine (2% xylazine, CP Pharma®) 
 
2.7 Plasmids constructs and primers: 
All details concerning the various plasmids constructs and primers used in this study can be 
found listed in Appendices 1 and 2. 
 
2.8 Molecular cloning: 
In order to clone the desired cDNA sequence into a plasmid, the PCR recipe and program 
used are listed in table 2.6 and 2.7. The annealing temperature for the primers were set 5°C 
below the primer melting temperatures.  For the amplification, the elongation time was set at 
72°C depending on the length of the template (1 min/500 bp of template). 
Table 2.6 Recipie for general PCR reaction  
Reagent Volume 
Template DNA (10 ng/µl) 1 µl 
Forward primer (10 pmol/µl) 1 µl 
Reverse primer (10 pmol/µl) 1 µl 
dNTPs (25 mM) 0.4 µl 
Pfu DNA polymerase (2.5 units/ µl) 0.5 µl 
10X reaction buffer (+MgSO4) 5 µl 




H2O 41.1 µl 
 
Table 2.7 PCR program for general molecular cloning  
Temperature Cycles 
Denaturation 95°C 3 min  
Denaturation 95°C 30 sec 
Annealing X°C 30 sec 
Elongation 72°C X min 
30 cycles 
Final elongation 72°C 5 min  
 
In order to determine the size and quality of the PCR product, the product was subjected to 
gel electrophoresis in a 1% agarose gel. DNA fragments of the expected size were excised 
from the gel, extracted using NucleoSpin® Gel and PCR Clean-up kit and eluted in 40 µl 
H2O. 
The purified PCR product (insert) and the desired expression plasmid (2 µg) were digested 
using corresponding restriction enzymes for 1-2 hours at 37°C in a 50 µl reaction volume. 
Immediately after digestion, the insert was purified by the NucleoSpin® Gel and PCR clean-
up kit and eluted in 20 µl H2O.  5-7 µl of the linearized insert was used for ligation along with 
1 µg of the linearized vector. The recipe of the ligation mix is listed below in table 2.8  
Table 2.8 Recipe of the ligation reaction 
Reagent Volume 
Insert 5-7 µl 
Vector 1 µl 
ATP (10 mM) 1 µl 




10X T4 ligation buffer 1 µl 
T4 DNA ligase 1 µl 
Overnight in icy water (10°C) 
 
On the following day, the entire ligation reaction was used to transform 100 µl of chemically 
competent DH5 alpha E. coli cells. The bacteria were incubated on ice for 20 min, followed 
by a heat shocked at 37°C for 2 minutes and subsequent cool down on ice for 1 minute. 
Afterwards, 500 µl 2X YT media without antibiotics was added to the bacterial cells and then 
incubated for 30 minutes at 37°C by shaking. Next, the bacteria were centrifuged at 4000 rpm 
for 5 minutes and plated onto pre-warmed 2X YT agar plates with suitable antibiotics as per 
the resistance gene encoded in the vector. The plates were kept at 37°C overnight.  
To account for successful ligation, colonies from the plates were cultured overnight at 37°C 
in 2X YT media, supplemented with the corresponding antibiotic. On the next day, the 
plasmid DNA from each culture was extracted using the NucleoSpin® Plasmid Quick Pure 
kit. The plasmids were then digested with the appropriate enzymes to identify positive clones, 
which had been successfully transformed with the plasmid carrying the insert. The positive 
clones were sequenced by the AGCT lab (Central facility at the Max Planck Institute of 
Experimental Medicine, Goettingen, Germany). 
 
2.9 RNA interference: 
2.9.1 Generation of vector-based RNAi constructs: 
The shRNA targeting regions of FBXO41 and NFM are listed in Table 2.9. The constructs 
were generated by cloning an inverted repeat into the pBlueScript/U6 vector at the ApaI 
restriction enzyme site. Each 40-nucleotide-long inverted repeat, separated by a 9-nucleotide 
loop containing HindIII restriction site was inserted after the U6 promoter. An EcoRI 
restriction site was inserted downstream of antisense strand providing a blunt end for ligation 
with the vector while the ApaI restriction site provided the sticky end. The sense strand of the 
hairpin was homologous to a 20-nucleotide region in the FBXO41 or NFM mRNA target. 
Primers 16104/16105 were used to clone the FBXO41 RNAi #5 and primers20268/20269 for 
FBXO41 RNAi#8. Primers 24562/24563 were used to generate the NFM RNAi#5 and 




primers 24560/24561 for NFM RNAi#3 respectively. 
 
Table 2.9 List of the shRNA-targeting sequences of FBXO41 and NFM RNAis 
shRNA Nucleotide sequence Species specificity 
FBXO41 
RNAi#5 
5’-GGGTGCCGGCATCGAGAAGGT-3’ Human, mouse, rat 
FBXO41 
RNAi#8 
5’-AGCTGCTACTGCCGTGCCCT-3’ Human, mouse, rat 
NFM RNAi#5 5’-GGAAATGGCTCGTCATTTGC-3’ Human, mouse, rat 
NFM RNAi#3 5’-GAAGAGTGGTTCAAATGCCGC-3’ Human, mouse, rat 
 
2.9.2 Annealing of primers: 
Annealing of the sense and antisense primer pairs (2 µl each) was carried out by first, diluting 
the primers (2 µl each of 50 pmol/ µl) in 46 µl of annealing buffer. The annealing of primer 
pairs was carried out using a Biometra thermo cycler as per the indicated program shown in 
Table 2.10. 
 
Table 2.10: Annealing of primers 
Temperature Time 
95°C 4 minutes 
16°C 10 minutes, slow cool 0.1°C/sec 
 
2.9.3 Phosphorylation of oligos: 
20 µl of the annealed oligos were mixed with 5 µl of 10X PNK buffer, 10 U of 
polynucleotide kinase (PNK) and ATP to a final concentration of 1 mM in a 50 µl kinase 
reaction and subsequently incubated at 37°C for 30 minutes. 10 µl of phosphorylated oligos 
were used for ligation. 
 
2.9.4 Preparation of the U6/pBS vector and ligation: 
3 µg of pBS/U6 vector were digested with ApaI for 1 hour at 37°C and the linearized vector 
was purified using the gel extraction columns (Macherey Nagel kit). For generating blunt 
ends, the linearized plasmid was then incubated with T4 DNA polymerase at 12°C for 15 




minutes. The vector was then digested with EcoRI at 37°C for 1 hour followed by addition of 
calf intestinal phosphatase (CIP) for 1 hour to remove 5'-phosphate groups. The vector was 
purified using column and eluted in 50 µl sterile water. Lastly, a 20 µl ligation reaction was 
set up using 10 µl phosphorylated oligos, 1 µl digested vector, 2 µl 10X ligase buffer and 1 µl 
T4 DNA ligase. The reaction was incubated at 16°C overnight. 
 
2.9.5 Screening for positive ligation clones: 
The E.coli DH5 alpha cells were transformed by adding the entire ligation mix to the bacteria 
and first incubating the cells for 30 minutes on ice. Next the cells were subjected to a brief 2-
minute heat shock at 37°C, followed by 10 minutes incubation on ice. The bacteria were then 
resuspended in 500 µl of 2X YT media without antibiotics and grown for 30 minutes at 37°C. 
Lastly the bacterial cells were briefly centrifuged at 4000 rpm and the excess medium was 
removed. The bacterial pellet was subsequently resuspended in 100 µl of 2X YT medium and 
plated onto 2X YT plate with ampicillin and incubated at 37°C overnight. The next day, the 
bacterial colonies were selected and cultured overnight in liquid 2X YT media (supplemented 
with ampicillin). On the following day, plasmid DNA was isolated from each inoculate and 
digested with HpaI enzyme to screen for positive clones. Upon digestion with HpaI, the 
clones with ligated shRNA insert gave a linear band of approximately 3 kbp while the non-
ligated clones remained uncut. The plasmid DNA from positive clones was submitted to the 
AGCT lab for sequencing. 
 
2.10 Site-directed mutagenesis: 
In order to generate “rescue” constructs that are resistant to degradation by RNAi, site-
directed mutagenesis was performed. Primers harboring 4-6 silent nucleotide mutations in the 
RNAi targeting region were designed as per the instructions provided in the Quick Change 
site-directed mutagenesis manual. The PCR reaction was set up with 10 ng of plasmid DNA, 
10 pmol forward primer, 10 pmol reverse primer, 10X Pfu DNA polymerase buffer, 1 µl Pfu 
DNA polymerase and 25 mM dNTP in a 50 µl total volume reaction. The PCR reaction 
timings were set as shown in table Table 2.11. Following PCR, the samples were incubated 
on ice for 2 minutes followed by addition of DpnI and incubation for 1 hour at 37°C. 1-2 µl 
of reaction mix was used to transform E.coli DH5 alpha competent cells that were plated on 
2xYT-agar plate and incubated overnight at 37°C. The clones were sequenced to confirm the 
mutations in the vector. 





Table 2.11: Site-directed mutagenesis PCR 
Temperature Time 




30 seonds                 
30 seconds                  




72°C 5 minutes 
 
2.11 Fusion PCR for generating deletion mutants: 
Deletion mutants lacking specific domains of the protein of interest were generated by first 
performing two separate PCR reactions that amplify fragments from the start codon until 
right before the deletion domain and from right after the deletion domain until the stop codon. 
As a second step, a “fusion PCR’’ was performed using specific primers that fuse the two 
fragments, resulting in a protein lacking the desired domain. The reaction setup used to 
generate the N- and C-terminal fragments and the fusion PCR recipes are listed in tables 2.12 
and 2.13. 
 
Table 2.12 PCR recipe for N- and C- terminal fragments 
Reagent Volume 
Forward primer (10 pmol/ µl) 1 µl 
Reverse primer (10 pmol/ µl) 1 µl 
Template DNA 100 ng 
10X reaction buffer (+) Mg 5 µl 
dNTPs 0.6 µl 
Pfu DNA polymerase (2.5 units/ µl) 0.5 µl 
H2O 40.9 µl 
 
Table 2.13 PCR recipe for fusion PCR 
Reagent Volume 
Forward primer (10 pmol/ µl) 1 µl 




Reverse primer (10 pmol/ µl) 1 µl 
N-terminal fragment 1 µl 
C-terminal fragment 1 µl 
10X reaction buffer (+) Mg 5 µl 
dNTPs 0.6 µl 
Pfu DNA polymerase (2.5 units/ µl) 0.5 µl 
H2O 40.9 µl 
 
2.12 Cell culture: 
All cell culture work was carried out inside a biological safety cabinet (HERAsafe®, Thermo 
Scientific) under sterile conditions.  
2.12.1 HEK293T cell culture: 
HEK293T cells were cultured in DMEM (GIBCO®, Life TechnologiesTM, Catalog no. 
11960) supplemented with 10% FBS and 1 % GlutaMAX® at 37°C with 5% CO2 in an 
incubator (HERAsafe®, Thermo Scientific, Bonn). Once the cells achieved a confluency of > 
90%, they were regularly passaged onto 10 cm dishes or 6 well plates. When passaging, the 
cells were first rinsed briefly in sterile PBS, followed by incubation with 1 ml of trypsin-
EDTA at 37°C for 5 minutes. Cold DMEM supplemented with serum was added in order to 
stop the enzymatic reaction. HEK293T cells were then detached from their culture surface by 
means of gentle mechanical agitation as a result of pipetting up and down slowly. Cells in 
suspension were collected and centrifuged at 4°C 800 rpm for 5 minutes. The supernatant 
was discarded and the cell pellet was resuspended in fresh media. The cell suspension was 
subsequently plated onto either 10 cm plates for maintenance of the cell line or onto 6-well 
plates designed for biochemical experiments.    
2.12.2 Primary neuronal culture: 
Cerebellar granule neurons (CGNs) were cultured from isolated cerebella of postnatal day 6 
(P6) Wistar rat pups as previously described (Bilimoria and Bonni, 2008). Cerebella were 
isolated using fine forceps and the meninges and the surrounding tissues were removed. The 
dissected cerebella were briefly washed thrice in HBSS and incubated in 5 ml of TDn for 10 
minutes at 37°C and 10 minutes at RT. Next, the cerebella were washed thrice in HBSS and 




subsequently triturated in 4 ml of DnB until a homogenous suspension of cells was achieved. 
The suspension was centrifuged at 800 rpm at 4°C, the supernatant discarded and the pellet 
was resuspended in 20 ml of Cbc medium. The number of cells was determined using a 
haemocytometer. Neurons were cultured either onto polyornithine-coated glass coverslips or 
directly into the culture plates. The cultures were maintained in Cbc medium. The CGNs 
were cultured at the following densities: 50 million cells per 6 well plate, 20 million cells per 
24 well plate and 100 million cells per 10 cm petridish. For survival assays 24 million cells 
per 24 well plate were plated. In order to prevent non-neuronal cells from proliferating, the 
CGNs were treated at day in vitro (DIV) 1 with 10 µM of the mitotic inhibitor cytosine β-D-
arabinofuranoside (AraC). At DIV 3, 25 mM glucose was additionally supplemented into the 
conditioned medium to replenish the carbon source. 
 
2.13 Transfection of primary neurons and HEK293T cells: 
2.13.1 HEK293T cell transfection: 
The HEK293T cells used for biochemical experiments were transfected using the modified 
calcium phosphate method as previously described by Konishi et al 2004. One day prior to 
transfection, the HEK293T cells were split into 6 well plates to be used for biochemical 
assays. Once the cells reached 70-80% conflucency, the cells were transfected. For each well 
of the 6 well plates 10 ng-2 µg of DNA was diluted in sterile H2O. 10 µl of 2.5 M CaCl2 
followed by 100 µl of 2XHBSS were then added to the diluted DNA. The mixture was gently 
pipetted up and down to ensure proper mixing of the constituents followed by a 5-minute 
incubation at RT. This DNA mixture was then added drop-wise onto the cells. 
2.13.2 Primary neuron transfection: 
Rat CGNs cultured in 24 well plates were transfected at DIV 1 (for morphological analyses) 
or DIV2 (for survival assay) with the indicated plasmids using the modified calcium 
phosphate method. First, the conditioned medium in which the neurons were cultured was 
collected in a separate falcon and kept aside at 37°C. Cells were then gently washed twice 
with DMEM and followed by starvation in 500 µl of DMEM for 45-50 minutes at 37°C. In 
the meantime the to be transfected plasmid DNA was diluted in sterile H2O to achieve a final 
volume of 18 µl per well of the 24 well plate. The diluted DNA was then thoroughly mixed 




with 2 µl of 2.5M CaCl2 and 20 µl of 2XHBSS. The mixture was then allowed to incubate for 
at least 5 minutes at RT, following which it was added gently drop wise onto the starved 
neurons. The neurons were then incubated at 37°C for 15 minutes. Subsequently, the 
starvation media was aspirated off, cells were washed twice in DMEM and the previously 
collected conditioned medium returned.  
For nucleofection, 8 million rat CGNs were resuspended in 100 µl of DMEM. 10 µg of the 
indicated plasmid together with the anti-apoptotic plasmid Bcl-xL were added to the 
suspension, following which the neurons in suspension were electrically pulsed using the O-
005 program on the nucelofector (Amaxa, Lonza). The freshly pulsed neurons were then 
incubated in 1 ml of pre-warmed DMEM for 5 minutes at RT. Subsequently, the neurons 
were plated onto 6 well plates with pre-warmed DMEM supplemented with 10% FCS. 4 
hours after plating the medium was replaced by warm Cbc (neuron growth medium) medium. 
The nucleofected neurons were kept in culture for 4 days following which they were 
subjected to biochemical assays. 
 
2.14 Immunocytochemistry: 
CGNs, which were subjected to morphological assays, were washed twice with PBS and then 
fixed in 4% PFA for 10 minutes at RT, while the CGNs used for survival assay were directly 
fixed by adding equal volume of 8% PFA to the medium in which they were maintained. The 
cells were then washed twice in PBS and permeabilized using 0.04% Trition X-100 in PBS 
for 10 minutes at RT. Following two more washes in PBS the cells were blocked using BME 
supplemented with 10% horse serum (blocking buffer) for 30 minutes to 1 hour at RT. After 
blocking, the primary antibody diluted in blocking buffer was added to the cells and 
incubated for either 1 hour at RT or overnight at 4°C.  Following incubation with the primary 
antibody, cells were washed with the blocking buffer and then incubated with the secondary 
antibody diluted in the blocking buffer for 30 minutes at RT. Subsequently, the cells were 
washed in PBS and incubated with a DNA dye (bisbenzimide Hoechst 33258 or 4’6-
diamidino-2-phenylindole (DAPI)) for 10 minutes at RT. The coverslips were rinsed in PBS 
and then mounted onto glass slides (Marienfeld) using the anti-fade mounting medium 
Mowiol and stored at 4ºC until analysis. 





2.15 Morphological analyses of neurons: 
For all morphological analyses, the cultured CGNs prepared as mentioned in sections (culture 
and transfection) were transfected at DIV1 with 0.2 µg of GFP, which served as a 
transfection marker, together with the plasmids of interest. In order to rule out any effects on 
the cellular morphology as a result of compromised cell health, 0.2 µg of the anti-apoptotic 
Bcl-xL plasmid was co-transfected. At DIV5 the neurons were subjected to 
immunocytochemistry using the GFP antibody and the previously mentioned DNA dyes. 
Neurons were imaged using a fluorescent microscope and axonal lengths as well as dendrite 
lengths, when necessary, of transfected neurons were measured using the free imageJ (NIH) 
software as previously described (Holubowska et al., 2014; Kannan et al., 2012b; Konishi et 
al., 2004; Vadhvani et al., 2013). Image acquisition and analyses was done in a blinded 
manner using the Nikon Ti eclipse fluorescent microscope and the NIS-Elements Basic 
research software. The length of the longest process was measured as the axon using Image 
NIH (Holubowska et al., 2014). At least 40-60 neurons were included in the analyses per 
condition per experiment. GraphPad Prism 5.0 was used to perform statistical analysis using 
ANOVA (Bonferroni post hoc) test or the Student’s t test (unpaired t test), depending on the 
experimental design.  
 
2.16 Survival assay in neurons: 
The survival assay was performed as previously described (Matz et al., 2015). In summary, 
CGNs were cultured and transfected as previously mentioned in sections 2.12.2 and 2.13.2. 
At DIV2 the neurons were transfected with the indicated plasmids and 0.3 µg of ß-
galactosidase (ß-gal), which served as a transfection marker. At DIV6 the cultured neurons 
were subjected to immunocytochemistry using ß-gal and cleaved caspase-3 specific 
antibodies as well as the aforementioned DNA dyes. The ß-gal-positive neurons were 
examined for neuronal survival and death based on the integrity of the neurites, nuclear 
morphology and presence or absence of the apoptotic marker cleaved caspase-3. Cells were 
analyzed in a blinded manner under the Nikon Ti eclipse fluorescent microscope and the NIS-
Elements Basic research software. Approximately 100-150 cells were analyzed per condition 




per experiment. GraphPad Prism 5.0 was used to perform statistical analysis using ANOVA 
(Bonferroni post hoc) test.  
 
2.17 Biochemical techniques: 
2.17.1 Tissue lysate preparation: 
Mice or rats were sacrificed either by CO2 inhalation or decapitation (for pups only). The 
isolated tissues were immediately placed in ice-cold TX-100 lysis buffer with freshly added 
cocktail of protease inhibitors (1 mM DTT, 3 µg /ml aprotinin, 1 µg / µl leupeptin and 1 µg / 
µl pepstatin). The tissue-lysis buffer mix was then homogenized using a 2 ml dounce. 
Obtained lysates were incubated on ice for 30 minutes, followed by centrifugation at 10000 
rpm for 10 minutes at 4°C. The supernatant was collected in a fresh tube, and the pellet 
discarded. When not immediately using the lysates, the samples were snap frozen using 
liquid nitrogen and stored at -80°C. 
2.17.2 Cell lysate preparation: 
Lysates from HEK293T cells or primary neurons were harvested by first aspirating off the 
cultured medium and giving the cells a brief rinse in PBS. The PBS was aspirated off 
followed by addition of TX-100 lysis buffer freshly supplemented with protease inhibitors (1 
mM DTT, 3 µg /ml aprotinin, 1 µg / µl leupeptin and 1 µg / µl pepstatin). Adherent cells 
were scraped off the 6-well plate suface using a cell scraper, and lysates were collected in 
fresh tubes. Following 30 minutes incubation on ice, the samples were centrifuged at 10000 
rpm for 10 minutes at 4°C. The supernatants were transferred into fresh tubes and stored on 
ice for further biochemical experiments or immediately snapfrozen in liquid nitrogen and 
stored at -80°C for later use. 
2.17.3 Bradfords assay for protein concentration measurement: 
The Bradford reagent (Bio-Rad®) was used for determination of protein concentration. The 
reagent was diluted 1:5 in PBS. 2, 4, 6, 8 and 10 µg of bovine serum albumin (BSA) diluted 
in 1 ml of the Bio-Rad®/PBS solution was used to make a standard curve. 2 µl of the lysate of 
interest was added into 1 ml of the Bio-Rad®/PBS solution. The shift in absorbance as a result 
of protein binding to Coomassie Brilliant Blue G-250 was determined by a spectrophotometer 




(Amersham Biosciences, Ultro spec 3100 pro) at a wavelength of 595 nm. Finally, the protein 
concentration was determined using the BSA standard curve. 
2.17.4 Co-immunoprecipitation (CoIP): 
P9 cortices or cerebellum from mice or transfected HEK293T cells were briefly rinsed in 
PBS and lysed in ice-cold CoIP buffer freshly supplemented with protease inhibitors (1 mM 
DTT, 3 µg /ml aprotinin, 1 µg / µl leupeptin and 1 µg / µl pepstatin) on ice. Following 30 
minutes incubation on ice the samples were centrifuged at 4°C at 10000 rpm for 10 minutes. 
The supernatants were collected in fresh tubes and the protein concentration determined using 
the Bradfords assay. While 50 µg of each sample were set aside as input controls, 1 mg of 
tissue/cell lysate was incubated with the primary antibody, under constant rotation for at least 
3 hours at 4°C. Subsequently 30 µl of Protein A-sepharose beads (Protein A-SepharoseTM 
Fast Flow, GE Healthcare), previously washed and stored in CoIP buffer, were added to the 
samples and the samples were further incubated for 40-60 minutes at 4°C on the rotator. 
Next, the samples were centrifuged at 10000 rpm for 1 minute and the supernatant was 
discarded. The beads were washed 3 times with the TX-100 lysis buffer and once with PBS. 
Finally, the beads were boiled for 5 minutes at 95°C in 30 µl of SDS-sample buffer. The 
boiled samples and the input controls were either subsequently subjected to SDS-PAGE and 
western blot analyses or stored at -20°C until later use. 
2.17.5 Centrosomal purification: 
Centrosomal purification was performed as previously described (Vadhvani et al., 2013). 
Cultured CGNs were treated with cytochalasin D (1 µg/ml) and nocodazole (0.2 µM) for 1 
hour prior to lysis (1 mM HEPES pH 7.2, 0.5% NP40, 0.5 mM MgCl2, 0.1% ß-
mercaptoethanol supplemented with protease inhibitors 1 µg/ml pepstatin, 1 µg/ml aprotinin, 
1 µg/ml leupeptin and 1 mM PMSF). After lysis the lysates were subjected to a gradient 
centrifugation (60% sucrose, 10000g, 30 min, 4°C). The resulting centrosomal fractions were 
then purified using a discontinuous sucrose density gradient centrifugation (40%/50%/70% 
sucrose, 34000g, 1 hour, 4°C). The supernatant fractions were subjected to 
immunoprecipitation by FBXO41 antibody followed by immunoblotting analysis using the 
FBXO41 and γ-Tubulin antibodies. 
2.17.6 Ubiquitination assay: 




The cell-based ubiquitination assays were performed under denaturing conditions as per the 
protocol from Vadhvani et al, (Vadhvani et al., 2013) with a few modifications, in order to 
avoid detection of unspecific ubiquitin smears. In brief, transfected HEK293T cells were 
lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP40, 0.5% sodium 
deoxycholate, 5 mM EDTA) with freshly added protease inhibitors (1 µg/ml pepstatin, 3 
µg/ml aprotinin and 1 µg/ml leupeptin), 10 mM N-ethylmaleimide (NEM) and phosphatase 
inhibitors (0.5 mM NaVO3 and 1 mM NaF). 50 µg of protein per sample was collected 
separately as input control. 1 mg protein was incubated with 1% SDS on a shaker for 5 
minutes followed by boiling at 95°C for 15 minutes. The sample was further diluted to 0.1% 
SDS with lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% Glycerol, 1.5 mM 
MgCl2, 1% TritonX-100) and incubated with either a primary antibody or with antibody-
conjugated beads for immunoprecipitation overnight at 4°C on the rotator. Following 
immunoprecipitation, for non-conjugated antibodies, the samples were additionally incubated 
for 40 minutes with Protein A-Sepharose. The precipitated proteins bound to the beads were 
then washed twice with lysis buffer, twice with HNTG buffer (20 mM HEPES pH 7.5, 150 
mM NaCl, 0.1% Triton-X100, 10% Glycerol) and eluted from the beads into 30 µl of SDS-
sample buffer by boiling at 95°C for 5 minutes. Boiled samples and input controls were then 
analyzed by SDS-PAGE and western blotting. 
2.17.7 SDS-PAGE and western blot: 
The SDS-PAGE gels were cast in the gel casting system (Mini-PROTEAN Tetra 
Electrophoresis System, Bio-Rad®). A gel used for standard SDS-PAGE consists of two 
layers, the lower separating gel (contains 7-15% acrylamide depending on the experiment) 
and the upper stacking gel (contains 3.9% acrylamide). During the course of this study 7.5%, 
8%, 10% and 12% gel were used as per the experimental design. The reagents needed along 
with the recipe for make these gels are listed below in table 2.14. 
Table 2.14 Recipe of SDS-PAGE gels of containing varying percentages of acrylamide. 
 Separating gel Stacking gel 
% Acrylamide 7.5% 8% 10% 12% 3.9% 
30%Acrylamide 1.875 2 2.5 3 0.65 





Lower buffer (ml) 1.875 1.875 1.875 1.875 1.25 ml Upper buffer 
H2O ml 3.75 3.625 3.125 2.625 3.05 
10% APS (µl)                           30  25  
TEMED (µl)                            3  2.5 
 
The reagents of the separating gel were mixed and loaded onto the gel casting chambers and 
covered by a thin film of isopropanol. Gels were allowed to polymerize for 45-60 minutes, 
following which the isopropanol was rinsed out with H2O. The stacking gel was then added 
on top by inserting a 10-well comb. The upper gel was allowed to polymerize for 40 minutes. 
The lysates boiled in SDS sample buffer were loaded onto the gels along with a protein 
ladder and the proteins separated at 25 mA per gel. Following electrophoresis the proteins on 
the gel were transferred onto a nitrocellulose membrane using a Mini-Trans-Blot® cell (Bio-
Rad®) at 250 mA for 100 minutes. After transferring the proteins, the nitrocellulose 
membrane was blocked using PBST supplemented with 4% milk, for 30 minutes at RT. 
Following three 10 minute PBST washes, the membrane was incubated in the appropriate 
primary antibody diluted either in 3% BSA or 4% milk (in PBST) supplemented with 0.02% 
NaN3, for 1 hour at RT or overnight at 4°C. Subsequently, the membranes were again washed 
thrice for 10 minutes in PBST and incubated in secondary antibody (1:10000) diluted in 4% 
milk (in PBST) for 30 minutes at RT. The secondary antibodies used were coupled with 
horseradish peroxidase (HRP). After the last three 10 minutes PBST washes the membrane 
was incubated shortly in enhanced chemiluminescent (ECL) horseradish peroxidase 
substrates (Thermo Fischer Scientific).  A photographic film was exposed onto the membrane 
and developed using an automatic film processor (Kodak imaging station). 
2.17.8 Densitometric quantifications: 
The developed films from western blot analysis were subjected to densitometric analyses 
using the ImageJ Gel Analyzer plug-in, which measures the intensity of each band of interest. 
The intensity of each sample and that of their respective loading controls were always 




measured. In order to rule out differences due to loading, relative intensities for each sample 
were calculated by dividing the relative intensity of each sample by the relative intensity of 
its loading control. The obtained relative intensities were then compared using statistical 
analyses. GraphPad Prism was used to perform statistical analysis using ANOVA (Bonferroni 
post hoc) test or the Student’s t test (paired t test) as per experimental design.  
2.17.9 Reverse transcription PCR (RT-PCR): 
2.17.9.1 mRNA isolation: 
P20 male mice were sacrificed by CO2 inhalation, the organs of interest extracted and 
collected into clean autoclaved RNAse-free tubes. To the tissues extracted, 1 ml of trizol was 
added followed by gentle pipetting for homogenizing the tissue. Subsequently, 200 µl of 
chloroform was added gently and vortexed well. The samples were then incubated on ice for 
15 minutes and then subjected to centrifugation at 14000 rpm for 15 minutes at 4°C. At this 
point the sample has separated into 2 phases. The top phase was transferred into a fresh tube 
without disturbing the interphase. To the collected top phase an equal volume of isopropanol 
was added and mixed. The samples were then incubated on ice for 15 minutes followed by 
centrifugation at 14000 rpm for 15 minutes at 4°C. The supernatant was carefully discarded 
and the pellet was washed in 1 ml 70% ethanol by centrifugation at 10000 rpm for 10 minutes 
at 4°C. The supernatant was discarded and the excess liquid was allowed to air dry followed 
by resuspension of the pellet in H2O. The concentration of RNA in each sample was 
determined by using a spectrophotometer (Amersham Biosciences, Ultro spec 3100 pro) at a 
wavelength of 260/280 nm. 
2.17.9.2 cDNA synthesis and PCR: 
2-3 µg of the isolated mRNA was used to synthesize the cDNA using the SuperScriptTM III 
First-Strand Synthesis System for RT-PCR from Invitrogen life technologies, as per the 
manufacturer’s instructions.  
50 ng of the isolated cDNA was then used as template to amplify the gene of interest using 
specific forward and reverse primers and subjecting this mixture to 20-30 PCR cycles. The 
recipe for the PCR reaction used most often for this technique is provided in table 2.15 
below. 




Table 2.15 Recipe of reagents used for the PCR reaction for amplification of a gene from 
cDNA 
Reagent Volume 
10X PCR buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl) 5 µl 
50 mM MgCl2 1.5 µl 
10 mM dNTP Mix 1 µl 
Sense primer (10 µM) 1 µl 
Antisense primer (10 µM) 1 µl 
Taq polymerase (5 U/µl) 0.4 µl 
cDNA (from first strand reaction) 2 µl 
Sterile H2O 50 µl 
  
The amplified samples were visualized using agarose gel electrophoresis, wherein the 
samples were loaded onto 1% agarose gel containing the DNA staining gel-red and run in a 
chamber bathed in 2X TAE buffer. The gel was run at 50 V for 50 minutes. The amplified 
DNA in the gels could be visualized under UV light using a gel documentation system 
(INTAS). 
2.17.9.3 qRT-PCR: 
qRT-PCR was performed using the Roche Light cycler to evaluate the mRNA levels of NFM 
in P16 FBXO41+/+ and FBXO41-/- mice litter pairs. NFM- and GAPDH-specific primer 
pairs 32180/32181-2 and 4876/4877-2 were used for the qRT-PCR. mRNA isolation and 
cDNA synthesis was performed as mentioned in section 2.16.9.1 and 2.16.9.2. The NFM 
levels were normalized to GAPDH and represented relative to the cerebellar values for each 
age group. 
 
2.18 In vivo electroporation: 




In vivo electroporation was performed as previously described (Holubowska et al., 2014; 
Kannan et al., 2012a; Kannan et al., 2012b; Konishi et al., 2004; Stegmuller et al., 2006; 
Vadhvani et al., 2013). Briefly, the plasmid DNA was diluted in sterile PBS together with 
0.03% Fast Green. Using a Hamilton syringe with a 30-gauge needle, the plasmid DNA (3-4 
µl / animal) was injected into the cerebellar cortex of P4 Wistar rat pups. U6/cmv-EGFP or 
FBXO41 RNAi#5-cmv-EGFP together with myc-CMV, FBXO41-Res ΔCTR or FBXO41-
Res plasmids, at a concentration of 8 µg/µl were injected together with 1 µg/µl of Bcl-XL 
expression plasmid. After injecting the DNA, the animals were given five short electric 
pulses (160-170 V for 50 msec with intervals of 950 msec). The pups were allowed to 
recover under an infrared lamp and then returned to the dam. 5 days later, the electroporated 
pups were sacrificed, the cerebella isolated and screened for presence of GFP, which served 
as means to determine the transfection efficiency.  
The transfected cerebella were fixed in 4% PFA overnight at 4°C with gentle shaking and on 
the following day briefly washed with PBS and placed in 30% sucrose (in PBS) solution for 
4-5 hours, as a measure of cryoprotection. The cerebella were then mounted in OCT (Tissue 
TEKTM) and sectioned (40 µm) using a Leica cryostat. The coronal cerebellar sections were 
subjected to immunohistochemistry using the GFP antibody (Santa Cruz Biotechnology). 
GraphPad Prism was used to perform statistical analysis of neuronal migration and 
distribution using Two-way ANOVA (Bonferroni correction) test. Sections were imaged 
using the Leica SP5 confocal microscope. 
 
2.19 Generation of the FBXO41-/- knockout mouse line: 
The embryonic stem (ES) cells for the FBXO41 knockout mouse line were purchased from 
the KOMP repository (www.KOMP.org). In the ES cells, the entire Fbxo41 gene was 
replaced by a ß-galactosidase reporter cassette and a neomycin resistance gene under the 
human ubiquitin C promoter. ES cells were injected into a blastocyst from a C57/BL6 mouse. 
The blastocyst in turn was implanted into a foster mother mouse, and the resulting chimeras 
were then crossed to wild type C57/BL6 mice to achieve germline transmission. 
Tail probes from the mice were used to isolate DNA for genotyping. The tail samples were 
digested in 200 µl of “tail lysis “ buffer supplemented with proteinase K at 55°C for 5-6 




hours. The samples were centrifuged and the supernatant transferred into a fresh tube. 100% 
ethanol was used to precipitate the DNA from the supernatant. The samples were centrifuged 
for 10 minutes at RT, the supernatant discarded and the pellet washed twice in 70% ethanol. 
The supernatant was discarded, the pellet was air dried and dissolved in 100 µl of water. The 
DNA concentration of each sample was determined using a spectrophotometer (Amersham 
Biosciences, Ultro spec 3100 pro) at 295/296 nm. 
The genotyping of the DNA isolated from the mice tail probes were carried out using specific 
primers 2322/2323 (WT forward/reverse) and 2322/23560 (KO forward/reverse) as per the 
protocol listed below in table 2.16 and 2.17. 
Table 2.16 Genotyping PCR recipe of reagents 
Reagent Volume 
Forward primer (10 pmol/ µl) 1 µl 
Reverse primer (10 pmol/ µl) 1 µl 
5X GoTaq® buffer 5 µl 
2.5 mM dNTPs 2.1 µl 
GoTaq® DNA polymerase 0.1 µl 
DMSO 2 µl 
H2O 8.3 µl 
DNA 100 ng (0.5 µl) 
 
Table 2.17 Genotyping PCR thermocycler program 
Temperature Time 
95°C 5 minutes 
95°C 30 seconds                              







30 seconds         
1 minute  
20 cycles 
72°C 10 minutes 
16°C Stop 
 
2.20 Histological analysis: 
2.20.1 Perfusion and fixation of mouse tissue: 
Mice were anesthetized by injecting a ketamine/xylazine mixture (10% ketamine [v/v], 5% 
xylazine [v/v]) intraperitoneally. The successful anesthesia of the mice was determined by 
testing for inter digital pinching reflex of the hind limbs, following which the animals were 
stabilized with their ventral side facing upwards. Using dissection scissors and forceps, the 
abdomen was opened and the diaphragm removed so as to expose the heart. A small butterfly 
canula (Venoflix®, Braun) attached to a peristaltic pump was inserted into the left ventricle, 
simultaneously making an incision on the right atrium, thus creating a small opening. The 
blood was flushed out using PBS, following which 15-20 ml 4% PFA was to fix the tissue. 
Upon fixation, the tissues and organs of interest were harvested from the mice and placed in 
4% PFA overnight in 4°C for further fixation. Depending on the aim of the experiment, the 
tissues were further processed in different post fixation solutions. 
 
2.20.2 Immunohistochemistry of frozen sections: 
Tissues of interest extracted from mice or rats of indicated ages were post fixed overnight in 
4% PFA with gentle agitation. On the following day, tissues were placed in a 30% sucrose 
solution for cryoprotection for 4-5 hours at 4°C. Subsequently the tissues were embedded in 
OCT (Tissue TEKTM) and frozen and stored at -80°C. The tissue samples were either cut into 
12 µm thick sagittal sections or 30 µm thick coronal sections as per experimental design, 
using a cryostat (Leica, Wetzlar, Germany) and mounted onto glass slides. The cryosections 




were thoroughly rinsed in PBS to remove OCT (Tissue TEKTM). Then they were blocked in 
blocking buffer (10% NGS, 3% BSA, 0.5% TX-100 in PBS), followed by incubation with the 
appropriate primary antibody, which was diluted in the blocking buffer (without TX-100) 
overnight at 4°C. On the following day the sections were washed 3 times in PBS and 
incubated with the flourophore coupled secondary antibody diluted in blocking buffer 
(without TX-100) for 2 hours at RT. Next the slides were briefly washed in PBS and 
incubated with the DNA dye DAPI (1:8000) for 10 minutes at RT. Finally the slides were 
rinsed twice in PBS and mounted using the antifade mounting medium Mowiol. The sections 
were imaged using the Leica SP5 confocal microscope. 
2.20.3 ß-galactosidase staining: 
For the ß-galactosidase staining, P30 FBXO41+/- mice and their FBXO41+/+ littermates 
were subjected to transcardial perfusion under deep anesthesia (Ketamine/Xylazine). 
Subsequent to perfusion with PBS (pH 7.4), the tissues were perfused and fixed in situ with 
4% (w/v) PFA in PBS. The brains and spinal cords were extracted and post-fixed in the same 
fixative for 3-4 hours. Following a brief rinse in PBS, the tissues were transferred to 30% 
sucrose in PBS for cryoprotection (overnight). The brains were stored in PBS at 4°C. 40 µm 
thick sagittal brain and cerebellar sections and 40 µm thick cross sections of the spinal cord 
were obtained using a Leica VT1000s vibratome (Nussloch, Germany) and collected in PBS. 
The free-floating sections were incubated in the following solution: 2 mM MgCl2, 0.02% 
NP40, 0.01% sodium deoxycholate, 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, and 0.5 mg/ml X-gal, in PBS overnight at 37°C in the dark. The sections were 
washed in PBS and mounted onto glass slides, air-dried and coverslipped with 50% glycerol. 
The sections were imaged using the Zeiss Axio Z1 brightfield microscope with the Zen 2011 
software (Zeiss, Oberkochern, Germany). 
2.20.4 Post-fixation and paraffin embedding of tissue samples: 
Mice were transcardially perfused using 4% (w/v) PFA and their brains extracted and 
postfixed overnight in the same fixative. For achieving thin sectioning, brains were embedded 
in paraffin (Paraplast, Leica, Wetzlar, Germany), using an automated program listed in table 
2.18 in the embedding machine (HMP 110, MICROM). 
Table 2.18 List showing the automated paraffin embedding program used by the HMP 110, 




MICROM embedding machine. 
Procedure Time 
50%[v/v] Ethanol 1 hour 
70%[v/v] Ethanol 2 x 2 hours 
96%[v/v] Ethanol 2 x 2 hours 
100%[v/v] Ethanol 2 x 2 hours 
Isopropanol 1 hour 
Xylol 2 x 2 hours 
Paraffin 2 x 2 hours 
 
Subsequently, the brains were placed in metal moulds and casted into blocks using 60°C 
warm paraffin. The blocks were labeled and allowed to solidify by cooling, subsequently 
being stored at RT. 5 µm thick sections were cut from the tissues embedded in the paraffin 
blocks using the microtome (HM 430 Thermo Scientific) and dried at RT. 
2.20.5 Immunohistochemistry of paraffin embedded samples: 
5 µm thick sagittal brain sections from paraffin embedded samples were subjected to several 
deparaffinization steps listed in table 2.19 before subjecting them to immunohistochemistry. 
Table 2.19 List showing the deparaffinization steps the 5 µm thick paraffin sections were 
subjected to prior to staining. 
Procedure Time 
60°C 10 minutes 
Xylol 2 x 10 minutes 
Xylol/Isopropanol (1:2) 10 minutes 




100%[v/v] Ethanol 5 minutes 
90%[v/v] Ethanol 5 minutes 
70%[v/v] Ethanol 5 minutes 
50%[v/v] Ethanol 5 minutes 
dd H2O 5 minutes 
  
2.20.5.1 Haematoxylin and Eosin staining: 
For Haematoxylin and Eosin (H&E) staining after the deparaffinization steps the 5 µm thick 
sections were stained in haematoxylin (Merck) for 5 minutes, which stained the nuclei. 
Following a rinse in ddH2O, the sections were briefly differentiated in HCl/alcohol mixture 
and then rinsed again in ddH2O. Then the sections were incubated in Scott’s solution 
(Thermo Scientific) for 5 minutes. Scott’s solution is a bluing agent, which makes the 
haematoxylin dye bluer in color. After this the sections were again rinsed well in ddH2O and 
counterstained with 0.1% eosin [w/v] for 2-4 minutes. Eosin stained the cytoplasm pink. The 
sections were rinsed well in ddH2O to remove excess eosin, and were subjected to subsequent 
dehydration by immersing the sections in a gradient of alcohol (50%[v/v], 70% [v/v], 90% 
[v/v] and 100% [v/v] ethanol, 15 seconds each) and finally in isopropanol/xyol (1:2) for 3 
minutes, and 2 times in xylol for 3 minutes each. The sections were eventually coverslipped-
using Eukit (Kindler) mounting medium. 
2.20.5.2 Immunostaining using the LSAB2 detection system: 
For the purpose of immunostaining with either IBA1, GFAP, NeuN or PCNA antibodies, the 
paraffin embedded 5 µm thick sagittal brain sections from the FBXO41+/+ and FBXO41-/- 
mice were firstly deparaffinized as in table 2.19, following which they were incubated in 
citrate buffer for 5 minutes. The tissue sections were then permeabilized in cooking them in 
boiling citrate buffer for 10 minutes (in a microwave oven at 650 watts). The sections were 
allowed to cool down at room temperature for 20-30 minutes. Subsequently, slides were 
rinsed briefly in Tris-buffer containing 2% [w/v] milk powder and placed into Shandon 
coverplates (Thermo Scientific, Cheshire, UK), specially designed for even distribution of 




solutions across the slide. Once placed inside the coverplates, the slides were rinsed again in 
Tris buffer-containing 2% milk [w/v] powder. For visualization of the staining, HRP-
conjugated secondary antibodies were used, hence it was necessary to ensure inhibition of 
endogenous peroxidase activity, for which the sections were treated with 3% H2O2 for 5 
minutes and subsequently washed with Tris buffer with 2% milk [w/v] powder. The sections 
were blocked in blocking buffer (20% goat serum in BSA/PBS) for 10 minutes at room 
temperature. The slides were then incubated with the primary antibody diluted in PBS/BSA 
overnight at 4°C. Next day the sections were washed in Tris buffer with 2% milk [w/v] 
powder and the LSAB2 kit was used to detect the protein of interest bound to the primary 
antibodies. The slides were incubated with a biotinylated secondary antibody for 10 minutes 
at RT. Following a rinse with Tris-buffer with 2% milk [w/v] powder, a second HRP 
complex coupled secondary antibody was added onto the slides and incubated for 10 minutes 
at RT. The coverplates were dismantled and the slides washed in Tris-buffer without milk. 
The HRP substrate Diaminobenzidine (DAB) was applied onto the slides using the DAB kit 
(DAKO) and incubated for 5-10 minutes. Appearance of brown labeling indicated the 
recognition of target proteins by the specific antibodies. After being rinsed several times in 
ddH2O, the sections were incubated in 0.1% Haematoylin [w/v] for 30 seconds. Subsequently 
the sections were rinsed in water to remover excess unbound dye and briefly dipped in HCl-
alcohol solution to achieve better differentiation. Next the slides were again briefly rinsed in 
water and incubated in Scotts solution for 5 minutes at RT to achieve a desirable bluing of the 
nuclei stained by the Haematoxylin. The slides were again rinsed briefly in water and 
subjected to a gradient of alcohol steps (50% [v/v], 70% [v/v], 90% [v/v] and 100% [v/v] 
ethanol, 3 minutes each) to achieve dehydration. Then, the tissue samples were incubated in 
isopropanol/xylol and twice in xylol for 7 minutes each. Finally, the slides were coverslipped 
using the xylol-based mounting medium Eukit (Kindler).  
The DeadEnd™ Colorimetric TUNEL System kit from Promega was used as per the 
instructions from the manufacturer for specifically labeling apoptotic cells. The kit labels the 
fragmented DNA of apoptotic cells using TUNEL (TdT-mediated dUTP Nick-End Labeling) 
assay. Biotinylated nucleotides are incorporated at the 3´-OH of DNA ends by the Terminal 
Deoxynucleotidyl Transferase (TdT) enzyme. Horseradish-peroxidase-labeled streptavidin 
(Streptavidin HRP) then binds to these biotinylated nucleotides, which are detected using the 
peroxidase substrate, hydrogen peroxide, and the stable chromogen, diaminobenzidine 




(DAB). Using this procedure, dark brown stained apoptotic nuclei level can be detected at the 
single cell. The stained slides were coverslipped using Aqual-Poly/Mount (Merk) mounting 
medium. 
All the images for H&E and DAB based chromogenic stains were acquired using the Zeiss 
Axio Z1 brightfield microscope and the Zen 2011 software from Zeiss (Zeiss, Oberkochern, 
Germany). 
2.20.5.3 Analyses and quantification of chromogenically stained sections: 
For the samples stained for H&E and DAB staining (TUNEL, IBA1, NeuN and PCNA), 3 
anatomically matched sections per animal brain per genotype were included in the analyses. 3 
FBXO41-/- animals and corresponding wild type littermates of the indicated ages were 
analyzed manually in a blinded manner.  
The number of Haematoxylin-positive nuclei within the molecular layer of the sagittal 
cerebellar sections was quantified using a custom designed macro for ImageJ. Dr. Miso 











run("Gaussian Blur...", "sigma=4"); 





//ROI manager removes non-molecular layer portion 
n = roiManager("count"); 
  for (i=0; i<n; i++) { 
      roiManager("select", i); 
 run("Clear Outside"); 
} 
//Close ROI-Manager 
if (isOpen("ROI Manager")) { 
     selectWindow("ROI Manager"); 
     run("Close"); 
} 
//Thresholding and mask generation 
setAutoThreshold("Yen"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 




run("Analyze Particles...", "size=60-1800 circularity=0.5-1 exclude clear add"); 
//Set measurement types 




run("Set Measurements...", "area shape redirect=None decimal=3"); 
//Tell ROI-Manager to measure all ROIs 
 n = roiManager("count"); 
  for (i=0; i<n; i++) { 
      roiManager("select", i); 
      roiManager("Measure"); 
} 
beep(); showMessage("Feedback", "Counting finished!"); 
 
The area measurement tool in ImageJ was used to measure the thickness of the EGL. For the 
distribution of TUNEL-positive nuclei and of IBA1-positive cells, the counting was manually 
performed in a blinded manner.  
For the area distribution of DAB-positive signal of GFAP, another custom designed imageJ 
macro was used, which converted the picture into a black and white image, with the black 
representing the DAB signal. Then it measured the percentage of the area occupied the DAB 
signal relative to the total area of the region on interest.  The macro was designed by Dr. 





run("Set Scale...", "distance=0 known=0 pixel=1 unit=pixel"); 
setTool("polygon"); 
beep();                                               




waitForUser("Hi there", "Select the region of interest and click OK"); 
run("Add to Manager"); 
//// 
// Color Thresholder 1.45k 



























  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
///// 














For determining the density of cellular distribution for H&E and DAB stained pictures, the 
following formula was used: 
     Cell distribution (cells/mm2) =  N (number of cells counted in region)                                                                                                                                                                                                 
e                                                              Area of the region of interest (mm2) 
All statistical analyses were performed using Graphpad Prizm 5.0 Student’s t-test (Paired t -
test) or Two-way ANOVA. 
2.21 Mouse behavior: 
All experiments that involved live animals were conducted in agreement with the 
animal protocols approved by the Verbraucherschutz und Lebensmittelsicherheit of Lower 
Saxony, Germany. 
2.21.1 Mouse behavior at P16: 
At least 10 P16 animals per genotype  (FBXO41+/+, FBXO41+/- and FBXO41-/-) and 3 P30 
animals per genotype (FBXO41+/+ and FBXO41-/-) were subjected to an ataxia scoring 
protocol adapted from the previously described paper from Guyenet and colleagues (Guyenet 
et al., 2010). To evaluate their basic motor functions such as balance and coordination, P16 




(FBXO41+/+, FBXO41+/- or FBXO41 -/-) mice were subjected to four basic tests by a 
blinded investigator.  
2.21.1.1 The Clasping test: 
For the clasping test mice were suspended by their tails for 10 seconds and evaluated whether 
they clasped their fore and hind limbs close to their bodies or if they spread their limbs when 
suspended by their tail. The extent of clasping was scored on a scale of 0 to 3, where 0 
represented no clasping and 3 represented severe clasping of the limbs. Each mouse was 
subjected to the clasping test three times and an average of all three trials was considered as 
the final score. The presence of clasping is often regarded as a sign of disease progression 
and neurological deficits in several neurodegenerative diseases (Guyenet et al., 2010). 
2.21.1.2 Ledge test: 
The ledge test was performed as previously described (Guyenet et al., 2010). The mice were 
placed on a 5 mm wide and 30 cm long ledge of a Plexiglas box. The mice were encouraged 
to walk across from one end of the ledge to the other. The coordination and grace with which 
they crossed the ledge was scored from 0 to 3. 0 represented no phenotype and the ability to 
cross the ledge gracefully in a coordinated manner with no limb dragging, while 3 
represented the most severe phenotype, with inability to cross the ledge. 
2.21.1.3 Gait analysis: 
 The mice were subjected to a gait analysis test as previously demonstrated (Guyenet et al., 
2010). The test was performed in order to evaluate coordination and muscle function. The 
mice were placed on a flat surface with their heads facing away from the investigator. The 
mice were scored on how well they supported their body weight and moved on all four limbs. 
For the above test the mice were scored between 0 and 3 (0 was for best performance and 3 
for worst). Each mouse was subjected to the gait analyses test three times and an average of 
all three trials was considered as the final score.  
2.21.1.4 Rotarod: 
The rotarod test has been previously described (Radyushkin et al., 2009) and was used to 
assess the balance and motor coordination of P16 mice. Briefly, the rotarod is a rotating drum 
(Ugo Basile, Comerio, Varese, Italy), which accelerated from 4 to 40 rpm at a rate of 0.1 




rpm/sec. The mice were placed one by one on the rotarod, under a non-accelerating speed of 
12 rpm, and their latency to fall off was recorded using a stopwatch. The mice were kept on 
the rotarod for a maximum of 240 seconds during acceleration. Each mouse had three trials 
on the rotarod and an average of all three trials was considered as the final score.  
2.21.2 Adult mouse behavior: 
10-month-old adult FBXO41+/+ and FBXO41+/- mice were subjected to a battery of 
behavior tests. A total of 40 animals from 2 independent cohorts were analyzed. During the 
period of behavioral testing the animals were housed in groups of 4-6 along with their 
littermates in standard plastic cages (26.5 x 20 x 14cm) under standard 12-hour light/dark 
cycle with food and water being provided ad libitum. The temperature of the behavior room 
was maintained at 21+/- 2°C and all the experiments were conducted in a blinded manner 
during the light phase of the day. The experiments were conducted in the following order: 
Elevated plus maze, open field, clasping test, rotarod, balance beam, pole test, olfaction. 
2.21.2.1 Elevated plus maze: 
To evaluate anxiety in the mice, they were subjected to the elevated plus maze. The maze is 
made up of grey prespex having a 5 x 5 cm central platform and 2 open and 2 closed arms (30 
x 15 x 15 cm). The elevated plus maze was placed in a light room with 110 lx. Each mouse 
was placed in the central quadrant facing one of the open arms of the elevated plus maze. The 
exploratory behavior of the mice was monitored using an overhead video recorder, which was 
connected to the computer, using the “Viewer 2” software (Biobserve GmbH, Bonn 
Germany). Each animal was allowed to explore the elevated plus maze for 10 minutes and 
their behavior recorded and analyzed for the time spent in open or closed arms. Excessive 
time spent in open arms is readout for reduced anxiety. 
2.21.2.2 Open Field: 
The open field test was used to assess the general locomotor activity of the mice. The mice 
were placed at the center of an open circular grey persepx arena (120 cm in diameter, 25 cm 
high), in a room with a light intensity of 110 lx. The mice were allowed to explore the arena 
for 10 minutes. The behavior was recorded using the overhead camera connected to the 
computer equipped with the “Viewer 2” software. The velocity, distance travelled and the 
time spent in central, intermediate and peripheral zones of the arena were analyzed. 




2.21.2.3 Clasping test: 
The clasping test for the 10-month-old FBXO41+/+ and FBXO41+/- mice was performed as 
per section 2.21.1.1. 
2.21.2.4 Rotarod: motor learning paradigm: 
To assess the motor coordination and balance in the mice, the 10-month-old FBXO41+/+ and 
FBXO41+/- mice were subjected to the rotarod test. Each animal was placed on the rotating 
drum of the rotarod and its latency to fall off was noted. The time and speed that each animal 
can withstand on a rotarod accelerating at 4-40rpm was determined. To check if the animals 
show motor learning, the animals were subjected to the rotarod test at 3 hours after the first 
trial and after 24 hours. In cases where motor learning had occurred, the animals performed 
better with time. Each animal was allowed for a maximum of 5 minutes per trial on the 
rotarod. 
2.21.2.4 Pole test: 
The pole test has been previously demonstrated as a reliable measure to assess basal ganglia 
related motor function (Matsuura et al., 1997). Each animal was placed on top of a pole (50 
cm tall) with its head up. The base of the pole was placed inside the home cage of the animal. 
A healthy animal when placed on top of the pole head up orients itself downward and 
descends into the cage. Prior to testing each animal was trained on the previous day to 
descend into its home cage when placed onto the pole. On the test day each animal was 
allowed five trials. The time taken to orient itself down ward and descend into the cage was 
measured. The best of five trials per animal was included in the analyses. 
2.21.2.5 Balance beam: 
The balance beam test was performed as previously described by (Luong et al., 2011). Two 
wooden beams of 80 cm length and 12 mm and 6 mm thickness each were used to gauge the 
motor coordination and balance of the mice. The beams were placed onto a wooden stand 
with the end of the wooden beam leading into the home cage of the mouse. Each animal was 
trained to walk across the length of the beam from the start point to the end and into its home 
cage. All the animals were trained to walk across both the 12 mm and 6 mm beam for 2 days 
prior to the test day. On the test day the time taken by the animal to cross each of the two 




beams (12 mm and 6 mm) was measured. The animals were additionally scored from 0-7 on 
their motor coordination while walking on the beams. 7 represented normalcy and 0 
represented dragging of both hind and fore limbs and complete inability to cross the beam. 
Each animal was given 3 trials per beam. The average time and score of all three trials was 
analyzed per animal. 
2.21.2.6 Olfaction: 
Two days prior to habituation, 2 pieces of chocolate chips per animals were placed into the 
cages. For habituation of the testing environment, each animal was placed into the testing 
cage (29.5 x 18.5 x 13 cm) with a piece of chocolate chip visibly placed on the surface of the 
bedding inside the cage per trial. The chocolate chip was randomly placed at any of the four 
positions A, B, C or D as indicated in the illustration below. 
 
 
In every trial, the animal was released in the center of the cage and allowed to explore for 10 
minutes. Each mouse was subjected to 4 trials per day with an inter-trial interval of 50 
minutes per trial. The animals were habituated for 2 days, following which they were food 
deprived overnight, although the water was available ad libitum. 2 pieces of chocolate chip 
were placed into the home cage. 
On day 5 the animals were tested. Each mouse was placed into the test cage with a chocolate 
chip hidden randomly at positions A, B, C or D 1cm below the standard bedding. Each mouse 
was given five minutes to explore and find the chocolate chip. Each animal was tested twice 
with an inter-trial interval of 100 minutes. The time taken by the animal to find the hidden 
chip of chocolate from the time it was released into the cage was measured. The average of 
both the trials was analyzed and represented the measure of the integrity of the olfactory 




system. In order to account for other sensory and motor or motivational factors that might 
influence the latency to finding the chocolate chip, the test was performed a third time as 
described previously, but this time the chocolate chip was placed clearly visible on top of the 







3.1 In vivo characterization of FBXO41 function: 
Increasing evidence points to the important function of F-box proteins during 
neurodevelopment and progression of disease in various neurological disorders (Gong et al., 
2010; Jandke et al., 2011; Litterman et al., 2011; Liu et al., 2011; Saiga et al., 2009; 
Westbrook et al., 2008). However, of the ~70 known mammalian F-box proteins only a few 
have been extensively studied. Hence, it is crucial to further identify and dissect the various 
unknown or understudied molecular pathways governed by these F-box proteins, 
orchestrating brain development and disease. Previous results from the lab identified 
FBXO41 as a brain-abundant F-box protein, with a possible role in axon growth and neuronal 
migration. As the first aim of my study, I shed further light on the role of FBXO41 function 
in vivo using the FBXO41 knockout mouse. 
3.1.1 FBXO41 expression is restricted to the CNS: 
 A previous study from our lab reported FBXO41 to have a brain-specific expression, which 
was highly upregulated during pre- and postnatal neurodevelopment having a constant 
expression throughout adulthood in mice (Holubowska, 2013). In order to characterize the 
spatial distribution of FBXO41 within the nervous system, I performed an RT-PCR analysis 
using cerebellar, splenic, spinal cord and sciatic nerve cDNA isolated from P20 male mice 
(Figure 3.1 A). As previously reported, I observed that FBXO41 mRNA was detectable in 
the cerebellum but not in spleen. However, I observed an additional expression of FBXO41 
mRNA in the spinal cord, which was completely absent from sciatic nerve (exemplar for 
peripheral nervous system (PNS) tissue). I further validated the finding at the protein level, 






Figure 3.1 FBXO41 is exclusively expressed in the CNS: (A) RT-PCR analysis was performed from 
mRNA isolated from cerebellar, spinal cord, sciatic nerve and splenic tissues from P20 male mice. 
GAPDH served as loading control. (B) 50 µg of cerebellar, spinal cord, sciatic nerve and splenic lysates 
from P20 male mice were subjected to immunoblotting with the FBXO41-specific antibody. The pan 14-3-
3 antibody served as loading control.  
The lab has previously generated an FBXO41 conventional knockout mouse line, where the 
entire Fbxo41 gene has been excised after its promoter region and replaced by a ß-
galactosidase reporter cassette and neomycin selection cassette (Figure 3.2 A). The ß-neo 
cassette thus results in the expression of ß-galactosidase (ß-gal) driven by the endogenous 
FBXO41 promoter. We were able to identify and distinguish the homozygous and 
heterozygotes from the wild types by genotyping using specific primers, which recognize 
either wild type or mutant alleles (Figure 3.2 B).  
 
 
Figure 3.2 Genotyping of FBXO41-/- 
mice: (A) Schematic representation of 
cloning strategy used to generate the 
FBXO41-/- ES cells, from 
www.komp.org. A ß-gal reporter cassette 
and the neomycin resistance gene under 
human ubiquitin C promoter replaced the 
entire Fbxo41 gene. (B) Representative 
genotyping PCR of the mice after 
germline transmission was achieved. 
Arrows in A represent the location of the 
primers1, 2 and 3 used for genotyping. 
In addition to the biochemical validation of the expression of FBXO41, I further went on to 





subjected sagittal brain sections from P30 FBXO41 +/- (heterozygous) mice and their wild 
type littermates to X-gal staining. I observed intense ß-gal enzymatic activity throughout the 
brain of the FBXO41 +/- mice and to a weaker extent in the spinal cord (Figure 3.3 A, C). 
Apart from the striatum and the midbrain, I also found robust ß-gal activity in the cortex 
hippocampus and cerebellum (Figure 3.3 A). Higher magnification panels of the cortex, 
hippocampus and cerebellum revealed that FBXO41 has a neuron-specific expression, as the 
ß-gal enzymatic activity was absent from white matter regions in the brain as well as the 
spinal cord (Figure 3.3 B, D).  
Interestingly, a closer look at the various cerebellar layers revealed that FBXO41 expression 
was restricted only to the cerebellar granule neurons (CGNs) and the deep cerebellar nuclei 
(DCN). The Purkinje cell layer (PCL), molecular layer (ML) and white matter were 
completely devoid of ß-gal activity (Figure 3.3 D inset). Additionally, I observed no ß-gal 
activity in the 40µm sagittal brain section from P30 FBXO41+/+ mice, when stained for X-
gal, serving as a negative control (Figure 3.3 E). Collectively, these results establish 












Figure 3.3 FBXO41 expression within the CNS: (A) 40 µm thick sagittal sections of P30 FBXO41+/- mouse 
brain were subjected to X-gal staining. Ctx= cortex, CB= cerebellum, CC= corpus callosum, Fo= fornix, Hpc= 
hippocampus, Th= thalamus, HTh= hypothalamus, Str= striatum, Snr= substantia nigra, Olf= olfactory bulb, 
MB= midbrain, Sc= superior colliculus, Ic=inferior colliculus, P= pons, M= medulla oblongata, SC= spinal 
cord. Scale bars equal 1000 µm. (B) Insets marked in A depict higher magnification images of the hippocampus 
and the various cortical layers in B. CA1= cornu ammonis 1, CA2= cornu ammonis 2, CA3= cornu ammonis 3 
and DG= dentate gyrus. The roman numerals represent the various cortical layers. Scale bars equal 200 µm and 
100 µm respectively. (C) 40 µm cross section of the P30 FBXO41+/- mouse spinal cord was subjected to X-gal 
staining. SC= spinal cord, GM= grey matter, WM= white matter, SpC= spinal canal, D= dorsal, V= ventral. 
Scale bar equals 200 µm. (D) 40 µm thick sagittal section of the P30 FBXO41+/- mouse cerebellum was 
subjected to X-gal staining. The roman numerals I-X represent the various cerebellar folia. Inset depicts higher 
magnification of the cerebellar layers. WM= white matter, Dcn= deep cerebellar nuclei, ML= molecular layer, 
PCL= Purkinje cell layer, IGL= internal granule layer. Scale bars equal 500 µm for the panel depicting the 
cerebellum and 50 µm for the inset representing higher magnification. (E) 40 µm thick sagittal section of the 





control. Scale bar equals 1000 µm. 
 
3.1.2 FBXO41 has a dual localization at the cytoplasm and the centrosome: 
Having established the neuronal CNS-specific expression of FBXO41, we went on to study 
the subcellular localization of FBXO41. We resorted to transfection of cultured CGNs with 
GFP-tagged FBXO41 expression plasmids. Subsequently, these cultured neurons were 
subjected to immunocytochemistry with the GFP antibody. Previous findings from the lab 
reported a predominantly cytoplasmic localization of FBXO41, which was absent from the 
nucleus, localizing along both the axons as well as dendrites. Additionally, we verified and 
confirmed its dual localization at the centrosome, as we observed that GFP-FBXO41 also 
colocalized with the centrosomal protein pericentrin 2 (performed by Dr. A. Holubowska) 
(Figure 3.4 A). Centrosomal enrichment experiments performed by N. Schwedhelm-
Domeyer further validated the dual localization of FBXO41, as endogenous FBXO41 could 
be detected in the cytosolic as well as the enriched centrosomal fractions using the FBXO41-
specific antibody (Figure 3.4 B). 
 
Figure 3.4 FBXO41 localizes to the centrosome: (A) Confocal images of cultured CGNs, transfected 
with a plasmid expressing GFP-FBXO41 followed by immunocytochemistry using the GFP and 
pericentrin 2 antibodies with the DNA binding dye DAPI. Arrowheads indicate the centrosomal marker 





performed by Dr. A. Holubowska (B) Lysates harvested from cultured CGNs at DIV8 were subjected to a 
centrosomal purification protocol using a sucrose gradient, followed by immunoblotting with the FBXO41 
antibody. γ–tubulin served as marker for centrosomal enrichment in the bottom fractions. Cerebellar 
lysates from P16 wild type mice served as positive control. Experiment was performed by N.Schwedhelm-
Domeyer. 
3.1.3 Loss of FBXO41 results in retarded growth and severe motor deficits: 
Owing to its CNS-specific neuronal expression, an FBXO41 conventional knockout mouse 
line was generated to study the effects of loss of FBXO41 in vivo. The FBXO41-/- mice have 
been previously reported to have an extremely high mortality rate, with only 20% of all 
knockout mice born making it past the second postnatal week. Apart from the high mortality 
rate, a decreased body weight was also observed at P5 (Holubowska, 2013). Due to the 
limited availability of the knockout mice past P18, as a result of high mortality rate, I 
restricted my behavioral analysis to the age of P16. The most striking phenotype at P16 was 
the dramatically reduced body size of the FBXO41-/- animals in contrast to the FBXO41 +/+ 
and FBXO41+/- littermates (Figure 3.5 A).  This was accompanied with significantly 
reduced body and brain weights (Figure 3.5 B, C). 
 
Figure 3.5 Loss of FBXO41 results in diminished body and brain weights: (A) Representative image 
of the P16 FBXO41+/+ and FBXO41-/- littermates. (B, C). Average body and brain weights of the 
FBXO41+/+, FBXO41+/- and FBXO41-/- mice at P16, respectively. A total of 86 P16 mice were analyzed 
(ANOVA, **p<0.01, ***p<0.001, mean +s.e.m.). 
Apart from the diminished body size, the FBXO41-/- also displayed an abnormal ataxic gait 
and severe motor deficits when analyzed for motor coordination and function. In order to 
assess the extent of the ataxic phenotype observed in the FBXO41-/- mice, I subjected the 
animals to an ataxia scoring protocol previously described by (Guyenet et al., 2010). It 





and rotarod. While gait analysis is often used to assess motor coordination and muscle 
function, the ledge test and rotarod measure coordination. Hind limb clasping is a marker of 
disease progression and hints to neurological deficits (Guyenet et al., 2010). The performance 
of each animal was scored from 0 to 3, where 0 represented no phenotype and 3 being the 
worst manifestation of the phenotype. The results showed that while the healthy FBXO41+/+ 
and FBXO41+/- littermates were indistinguishable at P16 with no signs of hind limb 
clasping, the FBXO41-/- mice consistently performed worse in all the tests and adopted a 
severe hind limb clasping posture when suspended by their tails (Figure 3.6 A, B, C, D, E). 
Collectively, these results demonstrate that the CNS-specific expression of FBXO41 is 
crucial for proper growth and motor function in mice. 
 
Figure 3.6 FBXO41-/- mice display severe motor deficits: (A) P16 FBXO41+/+, FBXO41+/- and 
FBXO41-/- littermates were subjected to gait analysis. 0= normal phenotype, 3= worst manifestation of 
phenotype. (B) P16 FBXO41+/+, FBXO41+/- and FBXO41-/- littermates were subjected to the ledge test. 
0= normal phenotype, 3= worst manifestation of phenotype. (C) P16 FBXO41+/+, FBXO41+/- and 
FBXO41-/- littermates were tested for time spent on rotarod at a speed of 12 rpm, with 240 seconds being 
the cut-off time. (D) P16 FBXO41+/+, FBXO41+/- and FBXO41-/- littermates were tested for hind limb 
clasping. 0= normal phenotype, 3= worst manifestation of phenotype. (E) Representative images of P16 





behavioral tests, the observations and analyses were recorded in a blinded manner with at least 10 animals 
of each genotype being included in the analysis (ANOVA, ***p<0.001, mean + s.e.m.). 
  
3.1.4 P16 FBXO41-/- mice do not show signs of neurodegeneration: 
The brain-dominant neuronal expression of FBXO41 prompted me to verify whether the 
reduced brain weights observed in the FBXO41-/- mice at P16 were a consequence of 
increased cell death and neurodegeneration. To address this, I analyzed 5 µm thick sagittal 
paraffin sections from P16 FBXO41+/+ and FBXO41-/- mice brains for apoptosis using the 
TUNEL assay (Figure 3.7 A, B, C, D).  
 
Figure 3.7 FBXO41-/- mice display no signs of apoptosis or neurodegeneration at P16: (A) 
Representative images of the cerebellar region from 5 µm thick paraffin embedded sagittal brain sections 
of P16 FBXO41+/+ and FBXO41-/- mice. These sections were subjected to immunohistochemistry using 
a TUNEL detection kit, detecting apoptotic cells. The DNase-treated cerebellar tissue served as positive 
control. Scale bar equals 20 µm. (B, C, D) Quantification (cells/mm2) of the distribution of TUNEL-
positive cells within the cerebellar, cortical and hippocampal regions of FBXO41+/+ and FBXO41-/- mice 
from A. Quantifications were done manually, in an blinded manner. At least three different anatomically 
matched sections per animal were quantified, and at least three independent littermates per genotype were 
included in the analyses (Students’s t-test, *p<0.05, ns=non significant, mean+s.e.m). I performed sample 
collection, sectioning, imaging quantification and analysis, while Dr. A. Matz carried out histochemical 
procedures. 
Additionally, we also checked for signs of inflammation, namely microglia and astrogliosis, 







Figure 3.8 FBXO41-/- mouse brains show no signs of inflammation at P16: (A, E) Representative 
images of the cerebellar region of 5 µm thick paraffin embedded sagittal brain sections obtained from P16 
FBXO41+/+ and FBXO41-/- mice. Sections were subjected to immunohistochemistry using either the 
IBA1-specific antibody that binds to migroglia, with tissue from CNPaseCre/Cre mouse serving as a positive 
control (Lappe-Siefke et al., 2003)  (A), or the GFAP antibody to identify astrocytes (E). Scale bars equal 
20 µm and 50 µm for A, E respectively. (B, C, D) Quantification (cells/mm2) of IBA1-positive cells in the 
cerebellar, cortical and hippocampal regions of P16 FBXO41+/+ and FBXO41-/- mice from A. 
Quantifications were done manually, in a blinded manner. Three different anatomically matched sections 
per animal were quantified, and at least three independent littermates per genotype were included in the 
analyses (Students’s t-test, ns=non significant, mean +s.e.m). (F) Quantification (percentage of stained 
area/mm2) of GFAP-positive regions in the cortex, hippocampus and cerebellum of P16 FBXO41+/+ and 
FBXO41-/- mice in E. Three different anatomically matched sections per animal were quantified, and at 
least three independent littermates per genotype were included in the analyses. The quantification and 
analyses were carried out in a blinded manner using a custom-designed macro. (Two-Way, ANOVA, 
mean =s.e.m.). A-F, I performed the sample collection, sectioning, imaging, quantification and analysis, 
and Dr. A. Matz carried out histochemical procedure. 
At P16 the quantification of relative distribution of TUNEL-positive apoptotic cells, DAB-
positive IBA1 cells or relative area stained by GFAP showed no signs of ongoing apoptosis, 





suggested that the diminished sizes of the knockout mice brains are a result of developmental 
deficits rather than neurodegeneration. 
 
3.1.5 FBXO41-/- mice show abnormal cerebellar morphology: 
Apart from the severe motor deficits, I wanted to gain further insights on the consequence of 
loss of FBXO41 on brain morphology and architecture. I thus went on to analyze the wild 
type and knockout mice at three different time points, namely P12, P16 and P30. In order to 
assess if loss of FBXO41 results in any gross morphological alterations in the brain, I first 
subjected 5µm thick sagittal sections from FBXO41 +/+ and knockout animals at the 
indicated ages to H&E staining (Figure 3.9 A, B, C). While the overall brain sizes where 
reduced, there were no noticeable deformities in the cortical area and only a slight but not 
significant reduction of the P30 hippocampal area (Figure 3.9 D, E). However, the 
cerebellum seemed to shrink in size in P30 FBXO41-/- mice when compared to its healthy 
wild type littermates, especially adopting an abnormal morphology with intralobular 
























Figure 3.9 FBXO41-/- mice show reduced cerebellar size and abnormal cerebellar foliation:  (A, B, C) 
Panels depict 5 µm sagittal brain sections of FBXO41+/+ and FBXO41-/- mice at P12, P16 and P30 that 
were subjected to H&E staining. Scale bars equal 1000 µm. (D, E, F) Quantifications of the relative area 
occupied by the cortex, hippocampus and the cerebellum, respectively, as observed in the FBXO41+/+ and 
FBXO41-/- mice at the indicated ages (P12, P16 and P30). All quantifications were performed in a blinded 
manner. Areas are represented as percentages. At least 3 animals per genotype were analyzed (Two-way 
ANOVA, **p<0.01, *p<0.05, mean + s.e.m.). 
 
3.1.6 Loss of FBXO41 results in delayed neuronal migration: 
The observations indicating the absence of neurodegeneration and inflammatory processes in 
the P16 FBXO41-/- brain, suggested that the motor deficits and the accompanying 
morphological defects in the cerebella of these mice are a consequence of disruption of 
neurodevelopmental events. Prior results from the lab indicated a role for FBXO41 in 
neuronal migration, by means of the in vivo electroporation technique. Using the cerebellum 
as a model system (Holubowska, 2013) the study demonstrated that over-expression of 
FBXO41 resulted in enhanced neuronal migration in the cerebellum while knockdown of 
FBXO41 on the other hand resulted in delayed migration (Dr. A. Holubowska PhD thesis). 





developing cerebellum of the FBXO41 knockout mice. The newborn CGNs undergo radial 
migration, migrating from the pial external granule layer (EGL) to the internal granule layer 
(IGL). Since FBXO41-/- mice displayed a striking ataxic gait at P16, I first analyzed the 
cerebellar lamination of FBXO41+/+ and FBXO41-/- mice at P16, when migratory events 
subside (Altman, 1972b). Therefore, I subjected 5 µm thick paraffin sagittal cerebellar 
sections from P16 FBXO41+/+ and FBXO41-/- mice to H&E staining. Interestingly, at P16 
in the FBXO41+/+ cerebella, the EGL ceased to exist as a result of cells migrating through 
molecular layer (ML) and into the IGL, in contrast to the FBXO41-/- cerebella, where I could 
still observe a residual EGL together with a marked increase in the number of cells in the ML 
(Figure 3.10 A, B, C, D). To monitor the progression of this impaired migration at P16, I 
additionally analyzed the FBXO41+/+ and FBXO41-/- cerebella at P12, when there is active 
ongoing neuronal migration and at P30, when the neuronal migration is completed. At P12, I 
not only observed a thicker EGL in the FBXO41-/- mice (Figure 3.10 E, F), but also a higher 
number of cells in the molecular layer (Figure 3.10 G). In contrast at P30, however, both 
FBXO41+/+ and FBXO41-/- cerebella both no longer possessed an EGL. Interestingly, the 
FBXO41-/- mice still showed a significantly higher cell number in the ML of the cerebellum 








Figure 3.10 FBXO41-/- mice show impaired neuronal migration in the cerebellum: (A, E, H) 
Representative images of 5 µm thick sections from P16, P12, P30 FBXO41+/+ and FBXO41-/- cerebella, 
respectively that were subjected to H&E staining. Arrows and yellow asterisks in A and H indicate the 
residual EGL and migrating cells in the ML, respectively, in the FBXO41-/- cerebella at P16 and P30. 
EGL= external granular layer, ML= molecular layer, PC= Purkinje cell layer, IGL= internal granular layer. 
Scale bars equal 20 µm. (B) Quantification of the cell density (cells/mm2) in the EGL+ML of the cerebella 
of FBXO41+/+ and FBXO41-/- mice at P16. (C, D) Graphs represent the resulting fold change of cell 
number (cells/mm2) in EGL or ML (C and D) at P16 in the FBXO41+/+ and FBXO41-/- cerebellum. (F, 
G) Quantification of and the relative thickness of the EGL and the cell density (cells/mm2) in ML at P12 in 
the FBXO41+/+ and FBXO41-/- cerebella. (I, J) Graphs represent the quantification of the cell density 
(cells/mm2) in ML and resulting fold change of cell number (cells/mm2) in ML at P30 in the FBXO41+/+ 
and FBXO41-/- cerebella. (B, C, D, F, G, I, J)  Quantifications were done in a blinded manner using a 
custom designed macro. Three different anatomically matched sections per animal were quantified and at 
least three independent FBXO41+/+ and FBXO41-/- littermates were included in the analyses for all the 






In order to determine if the super numerous cells observed in FBXO41-/- cerebella were 
indeed migrating CGNs, I additionally subjected 5 µm thick sagittal cerebellar sections from 
FBXO41+/+ and FBXO41-/- mice to DAB staining using a NeuN-specific antibody at P12, 
P16 and P30 (Figure 3.11 A). NeuN is predominantly expressed by the CGNs in the 
cerebellum and is completely absent from, for example, the Purkinje cells. While in P12 
cerebella, within the EGL, NeuN expression was restricted to the lower EGL at P16 most of 
the cells of the residual EGL were NeuN-positive (Figure 3.11 A). Upon quantifying the 
density of NeuN-positive cells of wild type and knockout cerebella, I observed that at all 
three ages P12, P16 and P30, FBXO41-/- mice had significantly higher number of NeuN-
expressing cells in the ML (Figure 3.11 B). Taken together these results identify the super 
numerous cells observed in the ML of the FBXO41-/- as CGNs. 
 
Figure 3.11 FBXO41-/- mice show 
delayed neuronal migration in the 
cerebellum: (A) Representative images of 
the 5 µm thick sections of P12, P16, P30 
FBXO41+/+ and FBXO41-/- cerebella 
subjected to immunohistochemistry using 
the NeuN antibody. Arrowheads indicate 
NeuN-positive cells. Scale bar equals 20 
µm. (B) Graph represents the 
quantification of the density of NeuN-
positive cells (cells/mm2) in the ML at 
P12, P16 and P30. All the quantifications 
were carried out manually, in a blinded 
manner. Three different anatomically 
matched sections per animal were 
quantified and three independent 
FBXO41+/+ and FBXO41-/- littermates 
for all the indicated ages (P12, P16, P30) 
were included in the analyses (Two-way 








In addition to the NeuN staining, I also subjected 5 µm thick paraffin sections from P12, P16 
and P30 FBXO41+/+ and FBXO41-/- cerebella to DAB staining using the PCNA-specific 
antibody. PCNA is a nuclear transcription factor, which is exclusively expressed in mitotic 
cells and in the developing cerebellum for example in the neuronal progenitors (Dietrich, 
1993). Interestingly, while the PCNA staining was purely restricted to the upper EGL of P12 
FBXO41+/+ and FBXO41-/- mice (Figure 3.12 A), at P16, the residual EGL of the 
FBXO41-/- mice still had several cells that were PCNA-positive (Figure 3.12 A). This 
indicated that while most of the cells of the residual EGL at P16 had attained a neuronal fate, 
a significant number of cells still trailed behind in migration and possessed the neural 
progenitor characteristics (Figure 3.12 B). Expectedly at P30, both the FBXO41+/+ and the 
FBXO41-/- cerebella were PCNA-negative within the ML (Figure 3.12 A). These results 
further identify the nature of the cells residing in the residual EGL of the FBXO41-/- mice at 






Figure 3.12 FBXO41-/- mice display a residual EGL at P16: (A) Representative images of 5 µm thick 
sagittal cerebellar sections from FBXO41+/+ and FBXO41-/- cerebella at P12, P16 and P30 subjected to 
immunohistrochemistry using a PCNA-specific antibody. Arrowheads indicate PCNA-positive cells. Scale 
bar equals 20 µm. (B) Graph represents the quantification of the distribution of PCNA-positive cells 
(cells/mm2) in the ML at P16. All the quantifications were carried out manually, in a blinded manner. 
Three different anatomically matched sections per animal were quantified and three independent P16 
FBXO41+/+ and FBXO41-/- littermates were included in the analyses (Student’s t-test, **p<0.01, mean + 
s.e.m). 
After establishing the identity of the cells residing in the residual EGL of the P16 FBXO41-/- 
mice, I went on to check if the Purkinje cell layer was also affected due to these migrational 
deficiencies. I subjected sagittal sections from P16 FBXO41+/+ and FBXO41-/- mice to both 
calbindin and parvalbumin staining, which stain Purkinje cells as well as the interneurons of 
the ML in the cerebellum (Figure 3.13 A, B). I observed no differences in the Purkinje cell 
layer between the two genotypes; further suggesting the abnormal neuronal migration was 
CGN-specific. Interestingly, however, I observed that the dendritic arbors of the Purkinje 
cells spanning the ML were pushed back in the FBXO41-/- cerebella as a result of the cells in 
the residual EGL, when compared to the FBXO41+/+ cerebella, where the dendrites spanned 






Figure 3.13 Loss of FBXO41 does not affect the Purkinje cell layer: (A) Representative images of 5 µm 
thick paraffin sagittal cerebellar sections from P16 FBXO41+/+ and FBXO41-/- mouse stained for the 
Purkinje cell marker calbindin. Scale bar equal 20 µm. (B) Representative confocal images of 12 µm sagittal 
cryosections from P16 FBXO41+/+ and FBXO41-/- cerebella that were subjected to immunoflourescence 
staining using the parvalbumin antibody for visualization of Purkinje cells. Scale bar equals 100 µm. White 
arrowheads indicate Purkinje cell bodies; red arrowhead indicates residual EGL in the P16 FBXO41-/- 
cerebella. IGL= internal granule layer, ML= molecular layer, EGL= external granule layer. 
 
Taken together, these results demonstrate that loss of FBXO41 results in delayed migration 
speed, as the P30 FBXO41-/- cerebella almost catches up in migration. It additionally unveils 
the identity of the supernumerous cells within the EGL and ML of the FBXO41-/- mice 
cerebellum as CGNs and residual neural progenitors. Moreover, it also demonstrates that 






3.1.7 Cytoplasmic FBXO41 regulates proper neuronal migration: 
Since FBXO41 displays a dual cytoplasmic and centrosomal localization within the cell, I 
determined if either or both the cyplasmic and the centrosomal FBXO41 contributes to its 
role in neuronal migration. Previously, the lab has identified the region on FBXO41 (amino 
acids 179-354) responsible for its targeting to the centrosome, the so-called “centrosomal 
targeting region” (CTR). Consequently, while FBXO41 WT localizes to both the centrosome 
and the cytoplasm, the FBXO41 ∆CTR mutant failed to localize to the centrosome, localizing 
purely to the cytoplasm (Holubowska, 2013) (Figure 3.14). 
 
Figure 3.14 FBXO41 harbors a centrosomal targeting region: Schematic representation of the 
FBXO41 full-length and the deletion mutant FBXO41 ∆CTR that lacks aa 179-354 (the centrosomal 
targeting region). 
In order to assess whether centrosomal or cytoplasmic FBXO41 contributes to neuronal 
migration, I first validated the efficiency of the previously generated functional FBXO41 
RNAi#5 in cultured CGNs. I therefore nucleofected neurons with either control U6 or the 
FBXO41 RNAi#5. Four days following nucleofection, I analyzed the neuronal lysates with 
immunobloting using the custom made FBXO41-specific antibody (Figure 3.15 A). 
Subsequently, I used the validated FBXO41 RNAi#5, to carry out in vivo electroporation 
(Materials and methods section 2.18), wherein I electroporated P4 rat cerebella with either 
control U6 empty or FBXO41 RNAi#5 together with control vector, FBXO41-Res or 
FBXO41-Res ∆CTR plasmid (Figure 3.15 B). Both the FBXO41-Res and FBXO41-Res 
∆CTR plasmids are resistant to knockdown by the FBXO41 RNAi#5 as they harbor silent 
mutations in the RNAi-targeting region. The electroporated cerebella were isolated from the 
rat pups at P9, and coronal sections of the cerebella were subjected to immunohistochemistry 
using the GFP antibody. The distribution of GFP-positive neurons was determined across the 
different cerebellar layers, namely the EGL, ML and the IGL. The IGL of the cerebella was 





IGL. I observed that while FBXO41 RNAi#5 led to stalled neuronal migration, with most 
cells being stranded in the EGL, ML and outer IGL, the neurons in the control condition had 
migrated away from the EGL into the IGL, with most cells residing in the deeper regions of 
the IGL, namely the Mid and In IGL. The FBXO41-Res and FBXO41-Res ∆CTR were able 
to “rescue” this phenotype as most of the transfected neurons had migrated away from the 
EGL and ML. While the FBXO41-Res displayed only a partial rescue as most of the cells 
resided in the Outer IGL and Mid IGL, the FBXO41-Res ∆CTR on the other had could 
restore neuronal migration back to control levels, with most of the GFP-positive cells residing 
in the Mid and In IGL (Figure 3.15 C, D). These results recapitulate the impaired neuronal 
migration phenotype observed in FBXO41-/- mice, supporting the notion that FBXO41 
promotes neuronal migration. Lastly, it also indicates that FBXO41-regulated neuronal 














with either U6 control vector or the FBXO41RNAi#5 plasmid, and were electroporated with the Amaxa 
nucleofector. These electroporated neurons were then cultured for 5 days. Neuronal lysates were 
immunoblotted with the FBXO41 and the γ–tubulin antibodies, where the latter served as loading control. 
(B) Schematic of in vivo electroporation of P4 rat pup cerebella, redrawn from (Holubowska et al., 2014; 
Konishi et al., 2004). (C) Representative confocal images of cerebella of P4 rat pups were subjected to in 
vivo electroporation with bicistronic control vector (U6/cmv-GFP) or the bicistronic FBXO41 RNAi#5-
cmv-GFP plasmid, together with control, FBXO41-Res or FBXO41-Res ∆CTR. Five days later at P9, 
coronal cerebellar sections were subjected to immunohistochemistry with the GFP antibody and the 
distribution of GFP-positive neurons were analyzed, within each of the cerebellar layers (EGL, ML and 
IGL). The internal granule layer was further divided into 3 equal parts, namely the outer IGL, middle IGL 
(Mid IGL) and the inner IGL (In IGL) for the analysis. Dotted lines demarcate layers. Arrows indicate 
eletroporated neurons and scale bar equals 50 µm. (D) Graph represents quantification of C, wherein the 
distribution of GFP-positive neurons in each of the indicated layers are represented as percentages. 
Analysis was carried out in a blinded manner with a total of 5515 neurons from 5 control, 5 FBXO41 
RNAi#5, 5 FBXO41-Res and 5 FBXO41-Res ΔCTR cerebella being included in the analysis (Two-Way 
ANOVA, ***p< 0.001, **p<0.01 and *p<0.05, mean + s.e.m.). The electroporations were performed in 
assistance with Dr. J. Stegmueller, the cryosectioning and immunohistochemistry was performed by Dr. S 
.J. Lee and the electroporation in part, screening of GFP-positive cerebella, imaging, quantification and 
analyses was performed by me. 
  
3.1.8 FBXO41 is essential for neuronal survival: 
Since neuronal migration appeared to be slowly catching up in the P30 FBXO41-/- cerebella, 
I performed behavioral analysis on P30 knockout animals to assess if their ataxic motor 
symptoms had improved. Due to the high mortality rate of >80% the P30 FBXO41-/- mice 
are extremely rare. Hence, I restricted the behavioral analysis to 4 pairs of wild type and 
knockout littermates. I noticed that, while the FBXO41-/- mice gain weight over time, they 
were always significantly lighter than their healthy FBXO41+/+ littermates (Figure 3.16 A). 
The knockout mice were still motor impaired and too weak to reach the top of the cage for 
food or water. Thus, they required a special supply of food and water inside the cage. In order 
to gauge the extent of motor impairment, I subjected P30 FBXO41+/+ and FBXO41-/- 
littermates to the previously described hind limb clasping test, ledge test and gait analyses. 
P30 FBXO41-/- mice performed consistently and significantly worse than their healthy wild 
type littermates in all the three tests (Figure 3.16 B, C, D). Taken together these results 







Figure 3.16 P30 FBXO41-/- display persistent motor impairment: (A) Graph depicts the weight curve 
of FBXO41+/+ and FBXO41-/- mice over a period of 60 days. Four mice of each genotype (litter mates) 
from 4 independent litters from were included in the analysis (Student’s t-test, ***p<0.001, **p<0.01, 
mean +s.e.m.). (B-D) Graphs depict the performance of P30 FBXO41+/+ and FBXO41-/- mice 
(littermates) when tested for hind limb clasping in B, gait analysis in C and ledge test in D. (B-D) Three 
mice of each genotype from three independent litters were included in the analysis (Student’s t-test, 
**p<0.01, *p<0.05 mean + s.e.m.). 0= normal phenotype, 3= worst manifestation of phenotype.  
Owing to the persistent motor phenotype and the abnormal cerebellar morphology of the P30 
FBXO41-/- mice, I wondered if impaired neuronal migration and possible faulty wiring in the 
P30 knockout mice cerebella could impact its cellular integrity. To investigate this 
possibility, I analyzed 5 µm thick sagittal P30 FBXO41+/+ and FBXO41-/- mice brain 
sections for indications of apoptosis using the TUNEL assay (Figure 3.17 A). While there 
was no increase in the number of TUNEL-positive cells in the cortex, I observed a significant 
increase in apoptotic cells/mm2 in the P30 knockout mouse hippocampus and cerebellum 
(Figure 3.17 B, C, D). Interestingly, most of the apoptotic cells in the P30 FBXO41-/- 
cerebellum seemed clustered at the intralobular outfolding and collapsed lobule VI. These 
results suggest that loss of FBXO41 not only affects morphology but also the cellular 






Figure 3.17 P30 FBXO41-/- mice show increased apoptosis in the cerebellum: (A) Representative 
images of the cerebellum from 5 µm thick paraffin embedded sagittal brain sections of P30 FBXO41+/+ 
and FBXO41-/- mice. These sections were processed immunohistochemically using a TUNEL detection 
kit, detecting apoptotic cells. Insets A and B depict higher magnifications, where pink arrowheads indicate 
clusters of apoptotic cells and black arrowheads indicate individual apoptotic cells. Scale bar equals 500 
µm for panel1, 100 µm for inset A and 20 µm for inset B. (B, C, D) Quantification of TUNEL-positive 
cells (cells/mm2) within the cerebellar, cortical and hippocampal regions of P30 FBXO41+/+ and 
FBXO41-/- mice from A. Quantifications were performed manually, in an blinded manner. Three different 
anatomically matched sections per animal from three independent littermates per genotype were included 
in the analyses. (Student’s t-test, **p<0.01, *p<0.05, mean +s.e.m.). 
To corroborate this finding, I performed a survival assay in cultured rat CGNs using shRNA 
to acutely knockdown FBXO41. Here, I transfected neurons at DIV2 with either control 
vector, the FBXO41 RNAi#5, or the non-functional FBXO41 RNAi#8 along with ß-gal- 
expression plasmid, which served as a transfection marker. After analysis at DIV 6 for 





interestingly noticed that knockdown of FBXO41 resulted in increased cell death when 
compared to control (Figure 3.18 A, B). In order to establish the specificity of the FBXO41 
knockdown, I additionally performed a rescue experiment, where I transfected either control 
U6 or FBXO41 RNAi#5 plasmid together with the control or the RNAi-resistant FBXO41-
Res. The FBXO41-Res plasmid was previously generated in the lab. It is resistant to the 
knockdown by the FBXO41 RNAi#5 as it harbors silent mutations in the RNAi targeting 
region. While knockdown of FBXO41 lead to increased cell death, the FBXO41-Res plasmid 
was able to “rescue” the phenotype by restoring the number of dead cells observed to that of 
control levels (Figure 3.18 C). Collectively, these results support the notion that FBXO41 
might be crucial for neuronal survival. 
 
Figure 3.18 FBXO41 is essential for neuronal survival:  (A) Representative images of cultured CGNs at 
DIV2 were transfected with either control U6 vector or the functional FBXO41 RNAi#5 together with a 
plasmid encoding ß-gal that served as transfection marker. Four days after transfection at DIV6, the neurons 
were fixed and subjected to immunocytochemistry using the ß-gal and cleaved caspase 3-specific antibodies 
as well as the DNA binding dye DAPI. Sale bar equals 50 µm (B, C) Quantifications of percentage of 
cleaved caspase 3-positive apoptotic CGNs that were transfected at DIV2 with the indicated plasmids and 
processed as in A. Quantifications were done in a blinded manner. At least three independent experiments 
were included in the analyses (ANOVA, ***p<0.001 + s.e.m). 
 
3.1.9 FBXO41-/- mice show impaired axon growth: 
Proteins found to influence neuronal migration are frequently also found to be implicated in 





et al., 2013). Recently, pathways regulating migration and neuronal morphology, mediated by 
E3 ligases have recently gained importance, for example the E3 ligases Cdh1 and Smurf1 that 
act in the same pathway of axon growth and neuronal migration (Kannan et al., 2012b; 
Konishi et al., 2004). Another study also identified the centrosomal E3 ligase FBXO31 also 
as a regulator of neurite morphology, polarity and neuronal migration (Vadhvani et al., 2013). 
Previous work from the lab demonstrated that loss of FBXO41 results in stunted axon 
growth. Interestingly, both acute knockdown of FBXO41 induced by RNAi in cultured rat 
CGNs as well as chronic loss of FBXO41, as observed in cultured CGNs from FBXO41+/+, 
+/- and -/- mice resulted in a specific reduction of axon length, with little or no effect on 
dendrite length or complexity (Holubowska, 2013). I used the previously generated FBXO41 
knockout mice to recapitulate the in vitro findings of FBXO41 mediated axon growth 
regulation in vivo. Since the FBXO41-/- mice show most obvious gross morphological 
abnormality and neuronal migration in the cerebellum, I assessed the effect of loss of 
FBXO41 on axon length in the cerebellum by subjecting 30 µm thick coronal cerebellar 
cryosections from P10 FBXO41+/+ and FBXO41-/- animals to immunohistochemical 
analysis. Using the tau-specific antibody, I visualized the parallel fibers, which are the axonal 
tracts of the CGNs residing in the IGL within the cerebellum. I quantified the relative area 
occupied by tau positive parallel fiber tracts in the molecular layer. Interestingly, I observed a 
marked reduction in the percentage of relative area occupied by the parallel fiber tracts in the 







Figure 3.19 FBXO41-/- mice display thinner parallel fiber bundles in the cerebellum: (A) Representative 
confocal images of 30 µm thick coronal cerebellar cryosections from P10 FBXO41+/+ and FBXO41-/- mice, 
subjected to immunofluorescence staining using the tau antibody. Dotted lines indicate tau-positive parallel fiber 
bundles. EGL= external granule layer, ML= molecular layer, IGL= internal granule layer. Scale bar equals 100 
µm. (B) Graph represents the relative thickness of the parallel fibers from P10 FBXO41+/+ and FBXO41-/- 
mice from A. Thickness is represented as percentage area occupied by the tau-positive axon bundles in the ML. 
Three different anatomically matched sections per animal were quantified. At least three FBXO41+/+ and 
FBXO41-/- littermates were analyzed from three independent litters. All the analyses were carried out in a 
blinded manner (Student t-test, *p<0.05, mean + s.e.m). 
Other axonal tracts in the cerbelllum include those of Purkinje cells, the climbing fiber and 
mossy fiber axon bundles. The Purkinje cell axon bundles run outwards from the cerebellum 
and synapse on the deep cerebellar nuclei. The climbing fibers, originating from the inferiors 
olive, synapse on the dendrites of the Purkinje cell, while the mossy fiber axons send inward 
projections and synapse on the CGNs residing in the internal granule layer (Sillitoe and 
Joyner, 2007; Sotelo, 2004). Hence, I went on to evaluate the effects of loss of FBXO41 on 
the cerebellar white matter. Here, I subjected 5µm thick sagittal cerebellar sections obtained 
from FBXO41+/+ and FBXO41-/- littermates to H&E staining and quantified the percentage 
of area occupied by the white matter tracts within the cerebellum of both FBXO41+/+ and its 
FBXO41-/- littermates at 3 different ages, P12, P16 and P30. Interestingly, I observed 
reduced white matter tracts within the FBXO41-/- cerebella when compared to their healthy 
wild type littermates at all three ages, with a more pronounced reduction at P30 (Figure 3.20 
A, B). 
 
Figure 3.20 FBXO41-/- mice show reduced white matter tracts within the cerebellum: (A) Schematic 
diagram showing the sagittal view of the mouse cerebellum, with the area in blue representing the area 
occupied by the white matter tracts within the cerebellum. (B) The graph represents the area occupied by 
the white matter tracts relative to the total area of the cerebellum, in FBXO41+/+ and FBXO41-/- cerebella 





quantifications were done in a blinded manner, with three different anatomically matched sections being 
quantified per animal. At least three FBXO41+/+ and FBXO41-/- littermates from three independent litters 
were included in the analyses (Two-way ANOVA, ***p<0.001, **p<0.01, mean + s.e.m). 
These results, taken together with previous findings from the lab, bolster the notion that 
FBXO41 is a novel regulator of axon growth. Interestingly, similar to several previously 







3.2 Molecular mechanism of FBXO41-mediated axon growth regulation: 
Having described a role for FBXO41 in axon growth regulation, I wanted to understand the 
molecular mechanism of its function. FBXO41 belongs to the family of F-box proteins, 
which share the homologous F-box domain. Most F-box proteins form multi-subunit RING 
ligases, with various adaptor and scaffold proteins as well as the small RING finger proteins. 
While the RING finger protein is responsible for recruiting a specific E2 ubiquitin-
conjugating enzyme to the complex, the F-box protein is an interchangeable part of the E3 
ligase complex, conferring substrate specificity by recruiting individual substrates for 
ubiquitination (Jin et al., 2004; Kipreos and Pagano, 2000; Zheng et al., 2002). Based on the 
nature of ubiquitination, the ubiquitinated protein can have varying fates, ranging from 
proteolytic degradation to non-proteolytic events (Komander and Rape, 2012). Hence, to 
understand the nature of FBXO41-mediated events, I wanted to confirm whether it forms a 
functional E3 ligase, and if yes, identify putative substrates of this ligase, acting in the same 
pathway to exert their function. As a second aim of the study, I focused on identifying and 
characterizing the molecular players involved in FBXO41-mediated axon growth regulation. 
 
3.2.1 FBXO41 together with Skp1 and cullin7 forms an atypical SCF-like E3 ligase: 
Most F-box proteins comprise the interchangeable component of the multi-subunit Skp1-
cullin1-F-box (SCF) RING E3 ligase complex. They are thought to be responsible for 
substrate recruitment and thus conferring substrate specificity to the SCF E3 ligases (Jin et 
al., 2004; Kipreos and Pagano, 2000). Since the majority of F-box protein forming SCF 
complexes are known to bind to both Skp1 and cullin1, I went on to investigate if this was the 
case for FBXO41. In order to form a functional E3 ligase, F-box proteins interact with Skp1 
and cullin1 via their F-box domain (Deshaies, 1999; Deshaies and Joazeiro, 2009; Jin et al., 
2004; Kipreos and Pagano, 2000). Using HEK293T cells transfected with control, FBXO41 
or FBXO41 ∆Fbox, a deletion mutant lacking the F-box domain (Figure 3.21 A), I 
performed immunoprecipitation analyses and confirmed that while FBXO41 associated with 
Skp1 in an F-box-dependent manner, it failed to interact with cullin1, irrespective of the 
presence or absence of its F-box domain (Figure 3.21 B, C). This, even though surprising, is 





FBXO45 as an atypical F-box protein, which like FBXO41 associated with Skp1 but failed to 
do so with cullin1. Instead it interacted with Skp1 and Protein associated with Myc (PAM) to 
form a non-canonical E3 ligase (Saiga et al., 2009). 
 
Figure 3.21 FBXO41 interacts with Skp1 but not cullin1: (A) Schematic representation of the FBXO41 
full-length and the deletion mutant FBXO41 ∆Fbox that lacks aa 554-593 (the F-box domain) (B) 
HEK293T cells were transfected with control vector, a plasmid encoding GFP-FBXO41 or GFP-FBXO41 
ΔFbox together with the myc-Skp1 expression plasmid. 48 hours later, the cells were harvested and 1 mg 
lysate was subjected to co-immunoprecipitation (IP) using the myc antibody followed by immunoblotting 
(IB) with the GFP antibody. (C) HEK293T cells, transfected with control vector, a plasmid encoding myc-
FBXO41 or myc-FBXO31 (which served as positive control) were harvested 48 hours post transfection. 1 
mg of the procured lysates was then subjected to IP using the myc antibody followed by IB with the 
cullin1 antibody. Asterisk indicates non-specific band. 
Till date apart from cullin1, the only other member of the cullin family known to form an 
SCF complex is cullin7. The F-box protein FBXW8 has been reported to form such a 
functional atypical SCF complex (Sarikas et al., 2008). Thus, I went on to investigate if 
FBXO41 too might interact with cullin7. I identified and confirmed the interaction of 
FBXO41 and cullin7 in HEK293T by straight and reciprocal co-immunoprecipitation 
analysis using myc-tagged FBXO41 and Flag-tagged cullin7 and respective controls (Figure 
3.22 A, B). Additionally, I confirmed the interaction by performing a semi-endogenous co-
immunoprecipitaion analysis in HEK293T cells, immunoprecipitating for tagged FBXO41 





FBXO41 interacts with cullin7, we first confirmed whether the FBXO41-specific antibody 
immunoprecipitates endogenous FBXO41 (Figure 3.22 D). Subsequently, I carried out an 
endogenous co-immunoprecipitation analysis using mouse brain tissue, immunoprecipitating 
for endogenous FBXO41 using the FBXO41-specific antibody and was able to pull down 
endogenous cullin7 (Figure 3.22 E).  Further subcellular fractionation analyses by A. 
Gellerer confirmed that FBXO41 and cullin7 both localize to the cytoplasmic compartment in 
neurons (A.Gellerer Master’s, thesis). 
 
Figure 3.22 FBXO41 interacts with cullin7: (A, B) HEK293T cells were transfected with control vector 
and the myc-FBXO41 or the Flag-cullin7 expression plasmid or both expression plasmids together. Cells 
were lysed 48 hours after transfection and 1 mg of the harvested lysates were either subjected to IP with the 
myc antibody followed by IB with the Flag antibody as in A, or subjected to IP using the Flag antibody 
followed by IB using the myc antibody as in B. (C) 1 mg of lysates harvested from HEK293T cells, 
transfected with control or myc-FBXO41 expression plasmid, were subjected to IP with using the myc 
antibody followed by IB with the cullin7 antibody. (D) 1 mg of P14 mouse brain lysates were subjected to IP 
with either pre-immune serum (control) or the FBXO41 antibody, followed by IB with the custom made 
FBXO41 antibody. This experiment was performed by Dr. A. Holubowska. (E) 1 mg of P9 mouse cerebellar 
lysates were subjected to IP with either a control polyclonal antibody or the FBXO41-specific antibody with 
subsequent IB with the cullin7 antibody. Asterisk indicates non-specific band. 
The only other F-box protein known to bind to cullin7, FBXW8 is also known to bind to 
cullin1 and although FBXW8 on one hand forms a canonical cullin1-SCF complex via its F-





independent (Tsunematsu et al., 2006). Hence, I investigated if the interaction between 
FBXO41 and cullin7 was F-box domain-dependent. Using the various deletion mutants of 
FBXO41 generated in the lab (Figure 3.23 A, B), I carried out a mapping analysis to identify 
the binding regions of cullin7 on FBXO41. Using co-immunoprecipitation analyses carried 
out in HEK293T cells, I identified the amino acids 1-35 at the N-terminus and the amino 
acids 593-873 at the C-terminus of FBXO41 to be responsible for its interaction with cullin7, 
as deletion mutants of FBXO41 lacking these amino acids failed to interact with cullin7 
(Figure 3.23 A, B). 
 
Figure 3.23 FBXO41 interacts with 
cullin7 independent of its F-box 
domain: (A) 1 mg lysates of 
HEK293T cells, transfected with the 
Flag-cullin7 plasmid together with the 
indicated FBXO41 deletion mutants, 
were subjected to IP using the Flag 
antibody followed by IB using the myc 
antibody. (B) Schematic summarizes 
the mapping analyses of FBXO41 and 
cullin7 shown in A. 
 
Taken together, these results suggest that while FBXO41 interacts with Skp1 via its F-box 
domain, it interacts with cullin7 in an F-box-independent manner at its N- and C-terminus to 
form an atypical SCF-like complex.  
In order to investigate if FBXO41-Cul7 forms a functional E3 ligase, an autoubiquitnation 
assay was carried out by N. Schwedhelm-Domeyer. HEK293T cells were transfected with 
control, myc-FBXO41 or the ligase-dead deletion mutants myc-FBXO41 aa 35-873 or myc-
FBXO41 ∆Fbox, together with HA ubiquitin. After harvesting the cells, the lysates were 





immunoblotting with the HA antibody to detect ubiquitin. A specific ubiquitin-positive smear 
representing functional ligase activity only appeared in the condition harboring myc-
FBXO41. No smears were observed for control vector or for myc-FBXO41 aa 35-873 and 
myc-FBXO41 ∆Fbox, which cannot bind to cullin7 and Skp1, respectively and hence should 
not possess ligase activity (Figure 3.24). 
 
 
Figure 3.24 FBXO41-Cul7 is a functional E3 ligase: 
48 hours after transfection, 1 mg of HEK293T lysates 
transfected with control vector or indicated myc-
FBXO41 expression plasmids along with the HA-
ubiquitin plasmid were processed following the 
“denaturing protocol” (Materials and methods section 
2.17.6) and subsequently subjected to IP with the myc 
antibody followed by IB with the HA antibody. This 
experiment was performed by N. Schwedhelm-
Domeyer. 
This result not only demonstrates that FBXO41-Cul7 is a functional E3 ligase capable of 
ubiquitination, but also confirms that FBXO41’s interaction with both Skp1 and cullin7 are 
crucial for its ligase function. 
 
3.2.2 Cytoplasmic FBXO41 promotes axon growth in an E3 ligase activity-dependent 
manner: 
The previously established role of FBXO41 in the cerebellum along with prior results from 
the lab demonstrating on one hand that loss of FBXO41 resulted in shorter axons and excess 
FBXO41 resulted in longer axons (Holubowska, 2013) led me to investigate whether the 
integrity of the FBXO41-Skp1-Cul7 complex was crucial for its axon growth-promoting 
effect. In order to check if FBXO41’s association to the complex is essential for axon growth, 
I transfected the cultured rat CGNs at DIV1 with control, myc-FBXO41 or myc-FBXO41 
∆Fbox, which cannot bind to Skp1 or the myc-FBXO41 aa 35-873, that does not bind to 
cullin7.  After 4 days in culture, I analyzed the axonal lengths of the transfected neurons. 
Interestingly, while FBXO41 full-length was able to exert its function resulting in longer 





(Figure 3.25 A, B). This result suggests that the interaction of FBXO41 with both Skp1 and 
cullin7 are crucial for axon growth control. 
 
Figure 3.25 FBXO41 regulates axon growth in a ligase activity-dependent manner: (A) 
Representative images of rat CGNs transfected at DIV1 with control vector, FBXO41, FBXO41 aa 35-873 
or FBXO41 ΔFbox expression plasmid were fixed and subjected to immunocytochemistry at DIV5 using 
the GFP antibody. Subsequently, GFP-positive neurons were subjected to morphological analyses and 
their axonal lengths were measured (Materials and methods section 2.15). Arrows indicate axons. Scale 
bar equals 100 µm.  (B) Graph represents the quantification of axonal lengths from A.  The average axonal 
lengths are represented in µm.  All measurements and quantifications were done in a blinded manner. A 
total of 747 neurons from 3 independent experiments were measured (ANOVA, ***p<0.001, mean + 
s.e.m.). 
Additional results from the lab also illustrated that FBXO41 promotes axon growth 
independent of its localization to the centrosome, as deletion of its centrosomal targeting 
region had no effect on FBXO41’s ability to promote axon length (Holubowska, 2013).  
Collectively, these results indicate that FBXO41 together with Skp1 and cullin7 promotes 
axon growth in an E3 ligase activity-dependent manner, as the integrity of the FBXO41-
Skp1-Cul7 complex in the cytoplasm is vital for its function in axon growth regulation. 
 






In order to identify possible interaction partners of FBXO41 acting in the same pathway of 
axon growth regulation, the lab conducted yeast two-hybrid and identified the cyoskeletal 
component neurofilament medium polypeptide (NFM) among others as a putative interaction 
candidate. We confirmed the interaction of FBXO41 and NFM by co-immunoprecipitation 
analysis in HEK293T cells using tagged expression vectors of FBXO41 and NFM (Figure 
3.26 A). Having validated the suitability of FBXO41 as well as NFM antibodies for co-
immunoprecipitation analysis (Figure 3.26 B), I reconfirmed my Master’s thesis findings, 
where I was able to validate the interaction between NFM and FBXO41 by means of 
endogenous co-immunoprecipitation analysis experiments, where I either 
immunoprecipitated FBXO41 or NFM from mouse P9 cortical lysates, followed by 
immunoblot analysis using NFM-or FBXO41-specific antibodies, respectively (Figure 3.26 
C, D).   
 
Figure 3.26 FBXO41 interacts with NFM: (A) 1 mg of HEK293T lysates transfected with either Flag-
NFM, myc-FBXO41 together with appropriate control vectors, or both Flag-NFM and myc-FBXO41 were 
subjected to IP with the myc antibody followed by IB with the Flag antibody. (B) 1 mg of mouse P9 brain 
lysates were subjected to IP with either a control mouse monoclonal or the NFM antibody and subsequent 
IB with the NFM antibody. (C) 1 mg of mouse P9 brain lysates was subjected to IP with either pre-
immune serum (control) or the FBXO41 antibody followed by IB with the NFM antibody. Asterisk 





mouse monoclonal antibody or the NFM antibody, followed by IB with the FBXO41 antibody.  
Additionally, further results from the lab indicate that FBXO41 and NFM colocalize in the 
cytoplasm, within the cell body and along the axon in CGNs (Alina Gellerer, Master’s 
thesis). Taken together these results identify NFM as a novel interaction partner of FBXO41. 
 
3.2.4 NFM is a substrate of FBXO41-Cul7: 
Owing to the identification of NFM as an interaction partner of FBXO41, I reasoned that 
NFM could be an ubiquitination substrate of the FBXO41-Cul7 E3 ligase. I first determined 
whether NFM associates with other components of the FBXO41-Cul7 complex via FBXO41. 
Therefore, I subjected HEK293T cells transfected with plasmids expressing GFP-NFM, Flag-
cullin7 and or myc-FBXO41 along with appropriate controls to co-immunoprecipitation with 
Flag antibody and subsequent immunoblot analysis with GFP antibody. Interestingly, I 
observed that NFM associates with cullin7 only in the presence of FBXO41, as absence of 
FBXO41 abolished this interaction (Figure 3.27). Other results from the lab identified DISC1 
as another interactor of FBXO41. However, DISC1 was found to not interact with cullin7 
irrespective of the presence and absence of FBXO41 (Holubowska, 2013). These results 
taken together indicate that NFM is specifically recruited to the FBXO41-Cul7 complex via 
FBXO41. 
 
Figure 3.27 NFM associates with 
cullin7 in the presence of FBXO41: 
1 mg of lysates harvested from 
HEK293T cells, transfected with the 
indicated plasmids, were subjected to 
IP with the Flag antibody, followed 
by IB with the GFP and myc 
antibodies. 
 
Having established the association of NFM with FBXO41-Cul7, I went on to further 
investigate if NFM is ubiquitinated by FBXO41-Cul7. Therefore, I performed a cell-based 





myc-FBXO41 ∆Fbox and HA-tagged ubiquitin were expressed in HEK293T cells. In order to 
determine the ubiquitin chain type, the cells were additionally transfected with either HA-
wild type ubiquitin, or the ubiquitin linkage mutants K48R or K63R, which are not able to 
form lysine (K)48- or K63-linked ubiquitin chains, respectively. The harvested cell lysates 
were subjected to the denaturing protocol (Materials and methods section 2.17.6), followed 
by immunoprecipitation using Flag-sepharose beads and immunoblotting using the HA 
antibody. I observed that full-length FBXO41 promoted ubiquitination of NFM, whereas the 
ligase-dead FBXO41 ∆Fbox failed to do so. Furthermore, the ubiquitin-smear was severely 
diminished in the condition with K63R ubiquitin, wherein K63-linked polyubiquitin chain 
formation was abolished (Figure 3.28). Collectively these findings indicate that FBXO41-
Cul7 ubiquitinates NFM, mainly via K63-linked polyubiqutin chains. 
 
Figure 3.28 FBXO41 ubiquitinates NFM via K63-linked polyubiquitination: HEK293T cells were 
transfected with plasmids encoding Flag-NFM, either wild type or the indicated linkage mutants of HA-
ubiquitin together with myc-FBXO41, myc-FBXO41 ΔFbox or myc-FBXO31 (negative control) plasmids. 
48 hours after transfection, 1 mg of the HEK293T cell lysates were processed according to the denaturing 
protocol (Materials and methods section 2.17.6), followed by IP with Flag-Sepharose beads and 
subsequent IB with the HA antibody. 
 
3.2.5 Loss of FBXO41-Cul7 leads to destabilization of NFM: 
Most K63-linked ubiquitin modifications are thought to lead to non-proteolytic 





stabilization etc (Bocquet et al., 2009; Komander and Rape, 2012; Pickart and Eddins, 
2004). Hence, I wondered if the K63-linked ubiquitination of NFM led to any change of 
NFM protein function. Since NFM is robustly expressed along the axons and together with 
NFL and NFH forms the predominant cytoskeleton of axons (Li et al., 2012), I wondered if 
loss of FBXO41 affects the stability of NFM. To address this question, I evaluated the levels 
of NFM protein levels in vivo from the brain lysates of FBXO41+/+ and FBXO41-/- animals 
at P5 and P16. Cerebellar lysates obtained from wild type and knockout littermates from 
three independent litters at P5 and P16 were subjected to immunoblot analyses using the 
NFM antibody. Interestingly, the levels of NFM were significantly reduced in the FBXO41-/- 
mice at both P5 and P16 when compared to their FBXO41+/+ littermates (Figure 3.29 A, B, 
C, D).  
 
Figure 3.29 FBXO41-/- mice show diminished NFM levels: (A) 50 µg of P5 cerebellar lysates isolated 
from FBXO41+/+ and FBXO41-/- littermates were immunoblotted with the NFM and γ–tubulin 
antibodies. The latter served as loading control. Samples of lanes 1 and 2 and those of 3 and 4 are derived 
from littermates, respectively. Sample collection and preparation was performed by Dr. A. Holubowska 
while the immunolotting was done by N. Schwedhelm-Domeyer. (B) Densitometric quantification of NFM 
protein levels in A NFM protein levels are normalized to that of FBXO41+/+ NFM levels of each litter 
pair and then represented as percentage. (C) 50 µg of P16 cerebellar lysates isolated from FBXO41+/+ and 
FBXO41-/- littermates were immunoblotted with the NFM and γ–tubulin antibodies. The latter served as 





(D) Densitometric quantification of NFM protein levels in C. The NFM protein levels are normalized to 
the FBXO41+/+ levels of each litter pair. Normalized NFM protein levels are represented as percentage. 
At least 5 FBXO41+/+ and FBXO41-/- litter pairs were analyzed (Student’s t-test, ***p<0.001, mean + 
s.e.m.). 
Additional qRT-PCR analyses from the P16 cerebella of FBXO41+/+ and FBXO41-/- mice 
showed that NFM was not transcriptionally downregulated (Figure 3.30), suggesting that the 
downregulation of NFM in FBXO41-/- mice was not a consequence of transcriptional 
changes.  
 
Figure 3.30 NFM mRNA levels in the P16 FBXO41+/+ and 
FBXO41-/- mice: Graph represents the relative fold change in NFM 
mRNA levels obtained from quantitative RT-PCR analyses using P16 
FBXO41+/+ and FBXO41-/- cerebellar tissue. The obtained mRNA 
levels are relative to GAPDH, which served as a loading control, and 
are in turn normalized to the FBXO41+/+ of each litter. The graph 
shows fold change of NFM mRNA levels of 3 pairs of FBXO41+/+ 
and FBXO41-/- littermates. Sample collection and analyses was 
performed by me, mRNA isolation and the qRT-PCR was performed 
by N.Schwedhelm-Domeyer. 
Additionally, I checked if the destabilization of NFM was purely a result of the lack of its 
ubiquitination by FBXO41-Cul7. I expressed control, myc-FBXO41, myc-FBXO41 ∆Fbox 
or myc-FBXO41 aa 35-873 together with Flag-NFM, followed by immunoblot analysis. 
Interestingly, I observed that NFM was destabilized in the conditions when expressed 







Figure 3.31 Loss of FBXO41-Cul7 leads to destabilization of NFM: (A) 50 µg of lysates from 
HEK293T cells, transfected with plasmids encoding Flag-NFM, together with wild type FBXO41 or the 
ligase-dead mutants, FBXO41 ΔFbox or FBXO41 aa 35-873, were subjected to immunoblotting with Flag, 
myc or pan 14-3-3 antibodies. Pan 14-3-3 served as loading control. (B) Graph respresents the 
densitometric quantification of NFM protein levels of A. The NFM protein levels are relative to the 
loading in each lane and are further normalized to the wild type FBXO41 protein levels. The resulting 
difference in protein levels is represented as percentage. Quantifications were done from three independent 
experiments (Student’s t-test, **p<0.01, mean + s.e.m.). 
Collectively, these results demonstrate loss of FBXO41-Cul7 leads to severe destabilization 
and downregulation of NFM in vitro as well as in vivo most likely due to a loss of 
ubiquitination modification. 
 
3.2.6 Dysregulation of NFM levels leads to uncontrolled axon out growth: 
NFM is a type IV neuronal intermediate filament, expressed abundantly in the cytosol and 
along the axons. It is thought to be responsible for regulating radial axon growth (Cleveland 
et al., 1991; Li et al., 2012). However, its role in regulation of longitudinal axon growth is 
understudied. In order to establish the role of NFM in axon growth regulation in CGNs, I first 
established the temporal expression of NFM in the cerebellum at various postnatal ages. I 
subjected cerebellar lysates from various postnatal ages to immunoblot analysis with an 





expressed at developmental stages crucial for neurite outgrowth and lengthening of axons, 
rather than radial axonal growth (Figure 3.32).  
 
Figure 3.32 NFM is expressed in the developing 
cerebellum of mice: Cerebellar lysates from 
indicated ages were analyzed by immunoblotting 
with the NFM and γ–tubulin antibodies where the 
latter served as loading control. 
Owing to its predominant axonal localization and robust expression during cerebellar 
development, I used cultured CGNs as a model system to investigate if NFM had any effects 
on axonal length. Taking a gain-of-function approach first, I transfected CGNs at DIV1 with 
either control or and NFM overexpression plasmids. Upon morphometric analysis of the 
axonal lengths of the transfected neurons at DIV 5, I observed that excess of NFM led to 
remarkably increased axonal length when compared to control neurons (Figure 3.33 A, B). 
 
Figure 3.33 NFM promotes axon growth: (A) Representative images of rat CGNs that were transfected 
at DIV1 with either the control vector or the NFM expression plasmid, and subjected to axon growth 
assays (Materials and methods section 2.15) at DIV5. Arrows indicate axons. Scale bar equals 100 µm.  
(B) Quantifications of the axonal lengths from A. The average axonal length is represented in µms. All 
measurements and quantifications were done in a blinded manner.  A total of 254 neurons from 3 
independent experiments were measured (Student’s t-test, ***p<0.001, mean + s.e.m.).  
Given that overexpression of NFM results in increased axon growth, I wondered if loss of 
NFM would have the opposite effect. Hence, I first generated a short hairpin RNAi that 
specifically targets and knocks down NFM (NFM RNAi#5). In addition to the functional 
RNAi (NFM RNAi#5), I also generated an NFM-specific non-functional shRNA (NFM 
RNAi#3), which was unable to knockdown NFM. I validated the shRNAs using HEK293T 





confirmed the efficiency of the RNAi by knocking down endogenous NFM in cultured CGNs 
(Figure 3.34 B).  
 
Figure 3.34 Knockdown of NFM: (A) 
Lysates from HEK293T cells, transfected 
with the myc-NFM plasmid together 
with control, the functional NFM 
RNAi#5 or the non-functional NFM 
RNAi#3 plasmid, were lysed and 
immunoblotted using the myc and γ–
tubulin antibodies. The latter served as 
loading control. (B) Representative 
images of rat CGNs at DIV1 transfected 
with control vector, the functional NFM 
RNAi#5 or the non-functional NFM 
RNAi#3 plasmid together with the 
transfection marker GFP. Neurons were 
subjected to immunocytochemistry at 
DIV5 using the GFP and NFM 
antibodies. Scale bar equals 100 µm. 
I observed that while the functional NFM RNAi#5 robustly knocked down NFM, the non-
functional NFM RNAi#3 had no effect, both in HEK293T cells as well as in CGNs.  
To determine the effect of loss of NFM on axonal length, I transfected cultured CGNs at 
DIV1 with either control U6, the functional NFM RNAi#5 or the non-functional NFM 
RNAi#3 plasmids and subjected the transfected cells to morphometric analyses four days 
later. Surprisingly, I observed that loss of NFM resulted in a pronounced increase of axon 
length when compared to the controls. The non-functional NFM RNAi#3 on the other hand 
had no effect on axon length and hence served as an additional negative control (Figure 3.35 
A, B). While loss of NFM resulted in increased axonal length, it had no effect on primary 






Figure 3.35 Loss of NFM leads to uncontrolled axon growth: (A) Representative images of rat CGNs 
that were transfected at DIV1 with either control vector, the functional NFM RNAi#5 or the non-
functional NFM RNAi#3 plasmids together with the transfection marker GFP and subsequently subjected 
to axon growth measurements at DIV5. Arrows indicate axons. Scale bar equals 100 µm unless indicated 
otherwise. (B) Graph represents the quantifications of axon lengths from A.  The average axonal lengths 
are represented in µms. (C) The total dendrite length of the neurons from A was measured, represented in 
µm. (D) Moreover, the primary axonal branches of the neurons from A were quantified. (B, C, D) All 
measurements and quantifications were done in a blinded manner. A total of 348 neurons from 3 
independent experiments were measured (ANOVA, ***p<0.001, mean + s.e.m.).  
In order to rule out possible off-target effects of the NFM RNAi, I performed a rescue 
experiment, wherein we first generated an RNAi-resistant myc-NFM expression vector 
(NFM-Res), which harbored four silent mutations in the region targeted by the functional 
NFM RNAi#5 (Figure 3.36 A). The efficiency of rescue or resistance to knockdown by the 
myc-NFM-Res expression plasmid was validated by co-transfecting myc-NFM expression 
plasmids or myc-NFM-Res plasmid together with the functional NFM RNAi#5 in HEK293T 
cells, followed by immunoblotting analysis. While the NFM RNAi#5 efficiently knocked 





generation and validation of the NFM-Res construct, I transfected CGNs at DIV1 with either 
control U6 vector or NFM RNAi#5 together with either control or NFM-Res plasmids. Four 
days later at DIV5, morphometric evaluation of the transfected neurons revealed that while 
loss of NFM resulted in increased axon length, co-expression of the NFM-Rescue plasmid 
together with the NFM RNAi#5 nullified this effect and restored axon lengths back to 
baseline levels (Figure 3.36 B, C).  
 
Figure 3.36 NFM knockdown also promotes axon growth: (A) 50 µg of lysates harvested from 
HEK293T cells, transfected with control, the myc-NFM or myc-NFM-Rescue (Res) plasmid together with 
control vector or the NFM RNAi#5 plasmid, were immunoblotted with the myc or pan 14-3-3 antibodies. 
The latter served as loading control. Schematic on the right shows the NFM RNAi#5 targeting region with 
the silent mutations indicated in red. (B) Quantifications of rat CGN axonal lengths, that were transfected 
at DIV1 with control, NFM RNAi#5 together with control or the NFM-Res plasmids, were subjected to 
axon growth assay at DIV5. All measurements and quantifications were done in a blinded manner. A total 
of 369 neurons from 3 independent experiments were measured. (ANOVA, ***p<0.001, mean + s.e.m.). 
(C) Representative images of transfected neurons from B. Arrows indicate axons. Scale bar equals 100 
µm. 
Collectively these results indicate that dysregulation of NFM protein levels leads to increased 






3.2.7 NFM acts downstream of FBXO41 to promote axon growth: 
Since both FBXO41 and its interaction partner NFM seem to regulate axonal length, I asked 
if they both act in the same pathway of axon growth regulation. In order to establish a 
functional relationship between the two proteins, I conducted a series of axonal 
morphometric analyses to deduce the epistatic nature between FBXO41 and NFM. I applied 
varying combinations of loss of function and gain-of-function approaches using FBXO41-
specific RNAi and FBXO41 overexpression plasmids previously generated in the lab, 
together with NFM RNAi#5 and NFM overexpression plasmids. I first used the loss-of-
function approach, where I transfected cultured CGNs at DIV1 with either control U6, 
FBXO41 RNAi#5, NFM RNAi#5 or both (FBXO41 RNAi#5 + NFM RNAi #5). As 
expected, loss of FBXO41 resulted in short axons and loss of NFM in longer axons, 
interestingly though loss of both FBXO41 and NFM mimicked the short axon phenotype 
observed for loss of FBXO41 alone (Figure 3.37 A, B). Additionally, I transfected cultured 
CGNs at DIV1 with either control, U6, FBXO41, NFM RNAi#5 or both (FBXO41 + NFM 
RNAi#5) (Figure 3.37 C, D). Predictably all 3 conditions of FBXO41 overexpression, NFM 
knockdown and FBXO41 overexpression together with NFM knockdown resulted in longer 
axons when compared to the control. However, it is interesting to note that the longer axons 
observed on knockdown of NFM alone are shorter than those observed in FBXO41 
overexpression alone. Interestingly, in the fourth condition (FBXO41+NFM RNAi#5), the 
axonal lengths mimicked that of loss of NFM (NFM RNAi#5) and were significantly shorter 
than FBXO41 overexpression (Figure 3.37 C, D).  I then took the gain-of-function epistasis 
analysis for FBXO41 and NFM by transfecting CGNs with control, FBXO41 and/or NFM 
expression plasmids. Expectedly, when compared to control, overexpression of FBXO41 or 
NFM and overexpression of both resulted in longer axons. Interestingly, overexpression of 
both FBXO41 together with NFM resulted in significant increase in axonal length when 
compared to the single overexpression conditions (Figure 3.37 E, F). Subsequently, on 
performing further axonal morphometric analyses, where I transfected CGNs with either 
control, FBXO41 RNAi#5, NFM or FBXO41 RNAi#5 and NFM plasmids together, I 
observed that overexpression of NFM could not rescue the short axon phenotype observed 














Figure 3.37 The NFM / FBXO41 pathway of axon growth regulation: (A) Representative images of rat 
CGNs that were transfected at DIV1 with control vector, NFM RNAi#5, FBXO41 RNAi#5, or both and 
were subjected to axon growth assay at DIV5. (B) Quantification of axonal lengths from A. The average 
axonal length is represented in µm. A total of 498 neurons from 3 independent experiments were measured 
(ANOVA, ***p<0.001, mean + s.e.m.). (C) Representative images of rat CGNs transfected at DIV1 with 
control vector, NFM RNAi#5, FBXO41 overexpression plasmid, or NFM RNAi together with FBXO41 
overexpression plasmid that were processed and analysed for axon lengths as in A. (D) Quantification of 
axonal lengths from C. A total of 440 neurons from 3 independent experiments were measured (ANOVA, 
***p<0.001, mean + s.e.m.). (E) Representative images of rat CGNs that were transfected at DIV1 with 
control vector, FBXO41 expression plasmid, the NFM expression plasmid or both plasmids were 
processed and their axonal lengths quantified as in A. (F) Quantification of axonal lengths from E. A total 
of 444 neurons from 3 independent experiments were measured (ANOVA, ***p<0.001, mean + s.e.m.). 
(G) Representative images of rat CGNs, which were transfected at DIV1 with either control vector, 
FBXO41 RNAi#5, the NFM expression plasmid or the FBXO41 RNAi together with the NFM plasmid, 
were processed and their axonal lengths measured quantified as in A. (H) Quantification of axonal lengths 
from G. A total of 519 neurons from 3 independent experiments were measured (ANOVA, ***p<0.001, 
mean + s.e.m.). (A, C, E, G) Arrows indicate axons and scale bars equal 100 µm. 
Collectively, these experiments offer two possibilities. Firstly, it suggests that FBXO41 is 
epistatic to NFM, which in the “conventional” sense would mean that NFM acts upstream of 
FBXO41. Secondly and more likely, considering their biochemical relationship of an E3 
ligase (FBXO41-Cul7) and its non-proteolytic ubiquitination substrate (NFM), it is 
interesting to observe that NFM cannot exert its axon growth promoting effect in the absence 
of FBXO41 (Figure 3.37 G, H). Interestingly it also becomes clear that even though 
FBXO41 can still promote axon growth in the absence of NFM (Figure 3.37 C, D), the 
magnitude of its axon growth-promoting effect is reduced in the absence of NFM. Moreover, 





complete stimulation of axon growth. Additionally Figure 3.37 C, D, E, F hints at the 
existence of other NFM-independent FBXO41 axon growth regulation pathways, thus, 
indicating that FBXO41-Cul7 might act as a promiscuous ligase which interacts with several 
targets or substrates in control of axon growth regulation. 
In order to rule out either of the two possibilities and to bring further clarity into the 
FBXO41-NFM hierarchy I additionally carried out a localization analysis experiment in 
cultured CGNs. Given that NFM is a cytoskeletal protein implicated in axonal transport (Li et 
al., 2012; Rao et al., 2011), together with the finding that FBXO41 is epistatic to NFM, it is 
plausible that NFM acts upstream of FBXO41 to localize or transport it along the axons. To 
test this, I transfected cultured CGNs with GFP-FBXO41 together with either control U6 or 
the functional NFM RNAi#5 plasmids. Four days following transfection the neurons were 
subjected to immunocytochemistry with GFP antibody to visualize the localization of 
FBXO41. Interestingly, FBXO41 localization and distribution remained unchanged 
irrespective of the presence or absence of NFM (Figure 3.38).  
 
Figure 3.38 Loss of NFM has no effect on FBXO41 localization: Representative confocal images of 
cultured rat CGNs that were transfected with plasmids expressing GFP-FBXO41 together with control 
vector or NFM RNAi#5 at DIV1. The neurons were subjected to immunocytochemistry using the GFP 
antibody and the distribution of GFP-FBXO41 was assessed. Yellow arrows indicate cell body and axon 
of the transfected neuron. Scale bar equals 10 µm. 
Taking the reverse approach and testing whether NFM requires proper modification by 
FBXO41-Cul7, I additionally transfected cultured CGNs with GFP-NFM together with either 





at DIV5 with the GFP antibody to visualize NFM. Intriguingly, loss of FBXO41 led to 
defasciculated NFM within the axons of significantly more neurons when compared to 
control (Figure 3.39 A, B). 
 
Figure 3.39 Loss of FBXO41 leads to defasciculated NFM in axons: (A) Representative confocal 
images of cultured CGNs, that were transfected at DIV1 with a plasmid expressing GFP-NFM together 
with control vector or FBXO41 RNAi#5. The cells were subjected to immunocytochemistry using the GFP 
antibody and the nature of distribution of GFP-NFM was assessed. Insets show higher magnification of the 
indicated region. Scale bar equals 10 µm. Yellow arrowheads indicate defasciculated NFM along the 
axons (B) Quantification depicts the percentage of neurons having an abnormal distribution or localization 
of NFM along the cell body and axons as observed in A Results from least three independent experiments 
were included in the analyses (Student’s t-test, ***p<0.001, mean + s.e.m). 
These results taken together with the reduced NFM protein levels observed in the FBXO41-/- 
mouse cerebellum and in HEK293T cells in the presence of the ligase-dead versions of 
FBXO41, collectively establish FBXO41 as acting upstream of NFM to regulate its stability 





3.3 Behavioral analysis of the adult FBXO41+/- mice: 
While FBXO41-/- displayed a severe behavioral phenotype at P16 and P30, FBXO41+/- mice 
were found to be indistinguishable from their FBXO41+/+ littermates. To determine if only 
half the dosage of FBXO41 has any late onset motor phenotypes, which are not detectable at 
P16 and P30, I decided to behaviorally analyze adult FBXO41+/- mice and their FBXO41+/+ 
littermates. In order to determine if the adult FBXO41+/- mice develop any abnormal 
phenotypes as a result of aging, I analyzed 17 FBXO41+/+ and 23 FBXO41+/- male mice of 
two independent cohorts for a battery of motor and gait-tests at 10 months of age. 
 
 3.3.1 FBXO41+/- mice show no abnormal appearance and body weight: 
During the course of the experiment, the body weight of FBXO41+/+ and FBXO41+/- mice 
was monitored. While the P16 FBXO41-/- mice showed drastically reduced body weight, 
FBXO41+/- mice were indistinguishable from their wild type littermates. I wondered if 
partial loss of FBXO41 would have a effect on body weight as a result of ageing. The 
FBXO41+/- mice showed no abnormal changes in body weights when compared to their wild 
type littermates (Figure 3.40). 
 
Figure 3.40 FBXO41+/- do not show abnormal body weight at 10 months: Average body weights of 
17 FBXO41+/+ and 23 FBXO41+/- mice at 10 months of age (ANOVA mean + s.e.m). 
 
3.3.2 Adult FBXO41+/- mice show no signs of abnormal locomotion and anxiety: 
First, I tested the animals for both anxiety and general locomotors activity. Before the 
animals got used to the testing environment and the handler, I tested the anxiety of the 





typically consists of a elevated cross-shaped platform, having two open and two closed arms. 
Previously, several studies have established that while untreated mice tend to avoid open 
arms, mice that were treated with anxiogenic drugs spent longer time within the closed arms 
(Pellow et al., 1985; Pellow and File, 1986; Treit and Fundytus, 1988). These studies have 
collectively established the elevated plus maze as a valid test for measuring anxiety. During 
the test, the mice were placed at the center of the cross arms and allowed to freely explore the 
maze. The distance travelled by the mice and the time they spent in closed arms and the open 
arms was recorded. Upon analysis, I found no difference between the genotypes as both 
FBXO41+/+ and FBXO41+/- mice displayed a natural avoidance for the open arms and spent 
maximum time within the closed arms. They also showed no difference in their locomotor 
activities, with both genotypes displaying increased activity levels in the closed arms 
compared to the open arms (Figure 3.41 A, B).   
 
Figure 3.41 FBXO41+/- mice do not show elevated anxiety levels in the elevated plus maze paradigm: 
(A) Graph represents the time spent by the animals in the open arm, center and the closed arm (Two-way 
ANOVA mean+s.e.m) (B) Graph represents the track lengths representing the distance travelled by the 
animals within the elevated plus maze (Student’s t-test mean + s.e.m) (A, B) 17 FBXO41+/+ and 23 
FBXO41+/- animals  (littermates) were analyzed. 
Following the elevated plus maze, I subjected FBXO41+/+ and FBXO41+/- mice to the open 
field test. In the open field test the mice are placed in a circular arena that is enclosed by 
walls at the periphery and has an open space in the center. The mice are allowed to explore 
the arena freely for a fixed period of time and the amount of locomotor activity and the time 
spent in the center verses the periphery is measured. Untreated healthy wild type mice much 
like in the elevated plus maze paradigm, avoid the open space in the center and tend to spend 
most time close to the wall (Simon et al., 1994; Treit and Fundytus, 1988). I measured the 





intermediate and the periphery (Figure 3.42 A). In addition, I also quantified the distance 
travelled by them (Figure 3.42 B). FBXO41+/- mice were found to spend slightly more time 
in the intermediate zone than the periphery when compared to their FBXO41+/+ littermates. 
Although the differences were not striking and no observable difference was present between 
the genotypes when comparing their track lengths.  
 
Figure 3.42 FBXO41+/- mice display comparable locomotor activity in the open field arena: (A) 
Graph represents the time spent by the animals in the center, intermediate and periphery of the open field 
arena (Two-way ANOVA mean + s.e.m) (B) Graph represents the track lengths representing the distance 
travelled by the animals within the open field arena (Student’s t-test ** p< 0.01, * p<0.05 mean + s.e.m) 
(A, B) 17 FBXO41+/+ and 23 FBXO41+/- animals  (littermates) were analyzed. 
 
3.3.3 Absence of hind limb clasping in adult FBXO41+/- mice: 
After testing for anxiety levels, the FBXO41+/+ and FBXO41+/- mice were subjected to the 
“clasping test” as previously described in the Materials and Methods. Healthy mice when 
suspended by their tails tend to spread their fore and hind limbs away from the body, while 
mice suffering from neurological deficits tend to clasp their fore and hind limbs close to their 
body. The presence and increasing severity of clasping is often used as a hallmark for 
progressive neurodegeneration or neurological problems (Guyenet et al., 2010). 
 In order to determine if FBXO41+/- mice show age-related neurodegeneration or deficits, we 
evaluated the clasping behavior on the scale of 0-3. 0 represented absence of clasping and 3 
represented severe clasping of both fore and hind limbs close to the animals body (Figure 
3.43). No differences between genotypes were observed. This result suggests that most likely 






Figure 3.43 FBXO41+/- mice display no hind limb clasping: 
10 month old FBXO41+/+, FBXO41+/- were tested for hind 
limb clasping. 0= normal phenotype, 3= worst manifestation of 
phenotype. A total of 17 FBXO41+/+ and 23 FBXO41+/- 
animals were analyzed (Student’s t-test mean + s.e.m) 
 
3.3.4 Intact olfaction in adult FBXO41+/- mice: 
Loss of olfactory sensation is one of the earliest signs of several neurodegenerative diseases 
such as Parkinson’s or Alzheimer’s. It often precedes motor dysfunction in neurodegenerative 
diseases (Kurtz et al., 1989; Marras et al., 2005; Tolosa et al., 2007). I thus wanted to assess 
if the aged FBXO41+/- mice display any signs of diminished olfaction. I subjected the mice 
to the olfaction-testing paradigm. The time taken by each animal to find a hidden chocolate 
chip was measured. One chocolate chip was shallowly buried under the straw bedding in the 
cage (Materials and methods section 2.21.2.6). For the test, the mice were placed in the cage 
and allowed to search for the hidden chocolate chip. Each animal was subjected to three 
trials, with an interval of 50 minutes per trial. In the third trial, the chocolate chip was placed 
on the surface of the bedding, making sure that it was visible. This trial served as a control to 
ensure the animals preference for the chocolate chip. All animals performed better with each 
trial, which suggests olfactory learning and no differences between the genotypes were 
observed. (Figure 3.44) 
 





were tested for their olfactory acuity. The graph represents the time taken by the animals to find a hidden 
chocolate chip, relying on their sense of smell. A total of 17 FBXO41+/+ and 23 FBXO41+/- animals 
were analyzed (Two-way ANOVA, mean + s.e.m) 
 
3.3.5 Adult FBXO41 +/- display intact motor function and coordination: 
To test their motor coordination and function I subjected FBXO41+/+ and FBXO41+/- mice 
to the rotarod test. On trial day 1, the mice were placed on the rotarod at accelerating speed 
for 2 minutes. The time spent on the rotarod and the acceleration was recorded. To assess 
their motor learning I additionally repeated the rotarod paradigm 3 hours and 24 hours after 
trial 1, respectively and analyzed their latency to fall and the acceleration at which they fall 
from the rotarod (Figure 45 A, B). At the first two trials both genotypes showed no signs of 
motor deficits and both performed equally well. After 24 hours in fact the FBXO41+/- mice 
seemed to perform even better in comparison to their FBXO41+/+ littermates suggesting that 
their motor coordination and motor learning was not impaired. 
I additionally subjected the mice to the balance beam test, where the mice were trained to 
reach from point A to B (home cage) on balance beams that were either 12mm or slightly 
more challenging, only 6 mm thick. On the test day, not only was the time taken by the 
animal to walk across the balance beam measured, but also their coordination quantified. I 
scored their coordination and extent of limb dragging on a scale of 0-7, with 7 representing 
normalcy and 0 being completely unable to cross the beam balance. Each animal was tested 3 
times on the 12 mm and on the 6 mm wide beams. Expectedly, all animals performed worse 
on the narrower 6 mm beam when compared to the 12 mm beam. However, no differences 
were observed between the genotypes on neither the 12 mm nor the 6 mm thick beams for the 
time taken to cross as well as their scores for coordination (Figure 45 C, D). 
Since FBXO41 is also expressed highly in the striatum and basal ganglia, I supplemented the 
previous experiments with the pole test, which is often used to assess basal ganglia-related 
motor dysfunction. Each animal was placed head-up on top of a pole whose base was placed 
in the home cage of the mice. Healthy mice, when placed on the pole head-up, orient 
themselves downward and descend down into the home cage. The animals were trained on 
the pole one day prior to the test day. On the test day the time taken by the animal to orient 





per animal was considered in the analyses. No significant differences were observed between 
the genotypes (Figure 3.45 E). 
Taken together, these results indicate that FBXO41+/- mice show no obvious impairment in 




Figure 3.45 FBXO41+/- mice do not display any observable 
motor deficits: 10 month old FBXO41+/+, FBXO41+/- were 
tested for motor coordination by subjecting them to the rotarod 
paradigm, where their latency to fall (A) and the acceleration, at 
which they fall (B) from the rotarod was measured. Subsequently, 
the animals were also subjected to the balance beam test where the 
time taken (C) by the animals to cross a 12mm and 6mm beam 
respectively was measured. The animals were also scored on their 
performance (D) by crossing the 6 and 12 mm beams on a scale of 
0-7. 7= normalcy and 0= complete inability to cross the beam. (A-
D) A total of 17 FBXO41+/+ and 23 FBXO41+/- animals were 





time taken by the animals to reorient themselves downward and 
climb down a pole was measured. No differences in genotypes 
were observed (Student’s t-test mean + s.e.m). 
The aforementioned motor tests are usually used to identify obvious motor defects in rodents 
but often fail to point out subtle motor and gait abnormalities (Camera et al., 2014; 
Sashindranath et al., 2015). Since in the motor tests performed, FBXO41+/- mice showed no 
differences in comparison to their wild type littermates, I wondered if they may have minute 
gait abnormalities, which I may have missed. Thus to rule out this possibility, we additionally 
subjected the FBXO41+/- mice and their wild type littermates to Digigait analyses at 4,6 and 
8 months of age (These experiments were performed by C. Lancelin from the group of Dr. 
Till Marquardt at European Neuroscience Institute, Goettingen). The Digigait analyses 
consists of a treadmill-like scenario for rodents, wherein the animals are made to walk along 
a conveyer belt moving at either constant of accelerating speeds. There is a camera placed 
below the conveyer belt, which records the animal walking on the conveyer belt. The 
software then uses the recorded movie of the animal walking to analyze various parameters 
such as stride lengths for each limb, paw area and so on. On analyses we found that in all the 
parameters analyzed the FBXO41+/- mice showed no difference when compared to their wild 
type littermates (unpublished work from C. Lancelin). These results not only corroborated 
previous findings that suggest that the FBXO41+/- mice show no age dependent motor 








Neurodevelopmental events such as progenitor proliferation, differentiation, neuronal 
migration and neurite outgrowth need to be precisely timed in order to ensure the proper 
lamination and circuitry of the brain (Ghashghaei et al., 2007; Hatten, 1999). Apart from 
various cell-extrinsic factors, an array of cell-intrinsic regulators of neurodevelopment have 
been identified. The UPS and its components being one of the most recent additions to the list 
(Kawabe and Brose, 2011). E3 ligases are the most numerous of the UPS components and are 
critical for mediating spatial and temporal expression of proteins by recruiting specific 
protein substrates for ubiquitination (Artinian et al., 2008; Hershko and Ciechanover, 1998; 
Hochstrasser, 1996). Although previous studies have implicated several E3 ligases in the 
regulation of neurodevelopment, they still remain underexplored. A previous study from our 
lab identified the neuronal F-box protein FBXO41 as a potential regulator of axon growth and 
neuronal migration in the developing rat cerebellum (Dr. A. Holubowska PhD thesis). In this 
study, I explore the consequences of loss of FBXO41 function in vivo, using the FBXO41 
conventional knockout mouse line. I report that FBXO41-/- mice display a severely ataxic 
gait together with accompanying defects in neuronal migration, axonal growth and early-
onset neurodegeneration. Furthermore, I identify FBXO41-Cul7 as a novel CNS-specific E3 
ligase that regulates axon growth in cerebellar granule neurons (CGNs), together with its non-
proteolytic ubiquitination target NFM. Thus, providing new insights into the FBXO41-
mediated pathway of axon growth control in CGNs. Taken together, this study establishes 
FBXO41 as a crucial regulator of cerebellar development. 
4.1 Loss of the CNS-specific F-box protein FBXO41 results in an ataxia-like phenotype 
in mice along with impaired neuronal migration and neurodegeneration in the 
developing cerebellum: 
Neuronal migration is one of the key events that ensure proper layering and connectivity of 
the developing cerebellum (Ghashghaei et al., 2007; Gleeson and Walsh, 2000). The 
majority of the cerebellar development in rodents takes place postnatally, wherein the CGN 
precursors form a second germinal zone at the outer layer of the cerebellar anlage thereby 
forming the EGL. This event is followed by extensive proliferation and increase in CGN 





from the EGL, across the ML into the IGL (Alder et al., 1996; Altman, 1972b; Marzban et 
al., 2014; Sillitoe and Joyner, 2007; Sotelo, 2004). Various cell-extrinsic guidance and cell-
intrinsic mechanisms that regulate the cytoskeletal dynamics also govern successful CGN 
migration in the cerebellum (da Silva and Dotti, 2002; Kuijpers and Hoogenraad, 2011; 
Yacubova and Komuro, 2003). A previous study from the lab identified the F-box protein 
FBXO41 as a cell-intrinsic regulator of neuronal migration in the developing cerebellum, 
showing a brain-dominant and neuronal expression that localizes to the centrosome as well as 
the cytoplasm (Dr. A. Holubowska PhD thesis). My results establish FBXO41 as a CNS-
specific neuronal F-box protein with high levels of expression throughout the brain, including 
the cerebellum and some limited expression in the spinal cord. Using the FBXO41 knockout 
mouse line, I further investigated the role of FBXO41 in vivo.  
Due to their high mortality in the first two postnatal weeks, FBXO41-/- mice were analyzed 
at P16. While the FBXO41+/- mice were indistinguishable from their wild type littermates, 
the FBXO41-/- mice displayed a severely ataxic gait characterized by uncoordinated 
movements, poor performance in the ledge test and rotarod and presence of severe hind limb 
clasping.  
Upon histological analyses of the FBXO41-/- mouse brains, the most dramatic phenotype 
was observed in the cerebellum, which showed impaired neuronal migration. I analyzed the 
FBXO41-/- mice at three different ages, P12, P16 and P30 and found that all three ages 
showed more cells in the ML, most of which were CGNs. Interestingly, I also discovered that 
P12 FBXO41-/- cerebella displayed a thicker EGL as compared to wild type. Strikingly the 
P16 FBXO41-/- cerebella still possessed a residual EGL, while in FBXO41+/+ cerebella 
neuronal migration was almost completed and the EGL had vanished. These findings are 
indicative of impaired neuronal migration. Intriguingly, the residual EGL of P16 FBXO41-/- 
cerebella harbored, in addition to postmitotic CGNs, mitotic precursor cells, suggesting that 
there could be a delay in progenitor differentiation that may also contribute to the delayed 
neuronal migration phenotype.  
Further analysis revealed that impaired neuronal migration was CGN-specific and did not 
affect the Purkinje cell layer. This observation was consistent with the finding that FBXO41 
is abundantly expressed in the IGL, but is completely absent from the Purkinje cells and ML. 
However, effects of impaired CGN migration on the synaptic connections between the 





residual EGL of FBXO41-/- mice had disappeared, but it still harbored more migrating CGNs 
when compared to the wild type. Collectively, these findings indicate that loss of FBXO41 
decelerates migration of CGNs in the cerebellum, where they fail to migrate to the IGL 
within a developmentally appropriate time window. A similar developmental delay in CGN 
migration has also been reported in mouse models for the actin-binding protein profilin1 as 
well as the microtubule-binding protein adenomatous polyposis coli 2 (APC2) (Kullmann et 
al., 2012; Shintani et al., 2012). It is hence conceivable that FBXO41 might function as a 
cell-intrinsic regulator of the cytoskeleton either by directly influencing cytoskeletal 
dynamics or by intercepting extracellular, pro-migratory cues at the leading edge.  
Previous results from the lab identified a dual localization of FBXO41 at the centrosome and 
the cytoplasm (Dr. A. Holubowska PhD thesis). The centrosome is known to serve as the 
major site of microtubule nucleation resulting in the formation of a microtubule cage thereby 
aiding in nucelokinesis and proper radial migration during neurodevelopment (Higginbotham 
and Gleeson, 2007; Tsai and Gleeson, 2005). Several centrosome-associated proteins 
including DISC1, NDEL1, Lis1, and the Par/aPKC complex have been previously reported to 
influence neuronal migration (Kamiya et al., 2005; Sasaki et al., 2005; Solecki et al., 2004; 
Tanaka et al., 2004). Interestingly, a previous study from the lab also reported that FBXO41 
interacts with DISC1 and possibly NDEL1 to regulate neuronal migration (Dr. A. 
Holubowska PhD thesis). In order to establish if the centrosomal localization of FBXO41 was 
crucial for its neuronal migration regulating effect, we monitored the migration behavior of 
CGNs using in vivo experiments in the developing rat cerebellum. First and foremost the 
results showed that loss of FBXO41 is reproducible and confirms that the impaired neuronal 
migration phenotype observed in the FBXO41-/- mice is specifically due to loss of 
FBXO41.The results also suggest that the cytoplasmic FBXO41 is necessary and sufficient to 
stimulate neuronal migration, while the centrosomal FBXO41 has little or no influence 
highlighting FBXO41’s centrosome-independent control of neuronal migration. This finding 
is both surprising and interesting. Since DISC1 for instance is also expressed extensively in 
the cytoplasm, nucleus and mitochondria (James et al., 2004), it is possible that FBXO41 
interacts with DISC1 in the cytoplasm to exert its function on neuronal migration. 
Interestingly, FBXO41 was also previously reported to promote axon growth independent of 
its centrosomal localization (Dr. A. Houlubowska, PhD Thesis). These findings suggest that 
FBXO41 may have other important functions at the centrosome, e.g. regulation of progenitor 





Apart from impaired CGN migration, P30 FBXO41-/- mice also displayed abnormal foliation 
of the cerebellum, with reduced cerebellar size and intralobular outfoldings in folia IV and V. 
Since the most obvious histological phenotype observed in FBXO41-/- mice was in the 
cerebellum, the severely ataxic phenotype of the mice can be majorly attributed to the 
cerebellar defects. The absence inflammation and neurodegenration in the P16 brain suggests 
that the motor phenotypes observed at P16 might be due to developmental abnormalities 
including impaired neuronal migration. Several studies have previously attributed ataxia-like 
phenotypes to dysfunction in cerebellar development, for instance a recent study reporting 
that deletion of the CNS-specific TGF-ß signaling protein Smad2 results in aberrant 
cerebellar morphology, impaired CGN migration, impaired Purkinje cell synaptic 
connections and early postnatal ataxia (Wang et al., 2011). Moreover, several human 
cerebellar ataxias have also been successfully modeled in mice including the Ahi1 knockout 
mouse, which displays abnormal cerebellar development and is viewed as a mouse model for 
Joubert’s syndrome congenital ataxia (Lancaster et al., 2011a).  
Interestingly, several forms of ataxias are also associated with neurodegenerative events in 
the cerebellum (Assadi et al., 2008; Cummings et al., 1999), for example the SCA1 
transgenic mice modeling spinocerebellar ataxia type 1 displaying neurodegeneration of 
Purkinje cells as a result of nuclear localization and toxic accumiliation of ataxin1 (Klement 
et al., 1998). Although the P30 FBXO41-/- cerebellum appears to catch up in neuronal 
migration, FBXO41-/- mice still show a persistent ataxic gait, uncoordinated movement and 
severe hind limb clasping. Moreover, P30 FBXO41-/- mice display a significantly smaller 
cerebellum together with pronounced foliation defects in folia IV, V and IV, which turned out 
to be a result of ongoing neurodegeneration as FBXO41-/- brains revealed a significant 
increase in apoptosis in the cerebella. Interestingly, the majority of the apoptotic cells 
appeared to be clustered in the abnormal folias. These results suggest that while the motor 
deficits observed at P16 are largely due to neurodevelopmental defects, the persistent motor 
phenotype in P30 FBXO41-/- mice as well as the reduced cerebellar size are a result of faulty 
wiring and compromised cerebellar architecture. Additionally, in vitro survival assays on 
cultured CGNs confirm that the observation of cell death in the FBXO41-/- brain can be 
attributed to loss of FBXO41. This further highlights the prosurvial nature of FBXO41, and 





The delay in cerebellar development is accompanied by neurodegeneration and motor defects 
in the FBXO41-/- mice and thus accentuates the crucial function of FBXO41 in cerebellar 
development, cell health and proper motor coordination. The FBXO41-/- mice could hence 
be viewed as a model of cerebellar ataxia. Interestingly, several genes that are nowadays 
implicated in human cerebellar ataxias were first identified several decades ago in knockout 
mice models displaying cerebellar abnormalities and ataxia-like phenotypes. The staggerer 
mouse model, which is a knockout for the retinoic acid-related orphan nuclear receptor-α 
(ROR-α), has been generated more than 50 years ago, but its interaction with ATAXIN1 and 
the link to spinocerebellar ataxia 1 (SCA1) has only recently been made (Gold et al., 2003; 
Hamilton et al., 1996; Serra et al., 2004; Serra et al., 2006). Similarly, human mutations in 
GIRD2 gene associated with cerebellar ataxia were identified 60 years after the GIRD2 gain 
of function mouse (lurcher) was generated (Hills et al., 2013; Utine et al., 2013). Most 
recently, mutations in the TRCP3 gene as observed in the Moonwalker mouse, have been 
implicated in human cerebellar ataxia (Becker, 2014). Since ~40% of cerebellar ataxias 
originate from unknown causes (Sailer and Houlden, 2012), it is conceivable that 
unidentified SNPs or mutations in the Fbxo41 gene could be the underlying cause for some of 
them and hence genetic screens for mutations or variations in the Fbxo41 gene are essential 
to establish the link from mouse to human cerebellar ataxias. 
 
4.2 Molecular mechanisms guiding FBXO41-mediated axon growth: 
4.2.1 FBXO41-Cul7 is a CNS-specific neuronal E3 ligase: 
This study establishes FBXO41 as a neuronal and CNS-specific F-box protein that is highly 
expressed throughout the brain including the cerebellum. FBXO41 belongs to the F-box 
family of proteins that share a common F-box domain. Typically, most F-box proteins that 
form SCF complexes bind to Skp1 and cullin1 via their F-box domain (Zheng et al., 2002). 
However, unlike most F-box proteins, FBXO41 binds to Skp1 via its F-box domain, but fails 
to interact with cullin1. This is not surprising, as previously studies have unveiled the 
existence of F-box proteins that form non–canonical E3 ligase complexes that are cullin1 
independent (Skaar et al., 2013). Previously, Saiga and colleagues identified another F-box 
protein FBXO45 that, similar to FBXO41, binds to Skp1 but not cullin1. Instead FBXO45 





which regulates neuronal migration and synapse formation (Saiga et al., 2009). Recent 
studies have also identified Fbxw8 as another F-box protein that, although capable of forming 
a standard SCF complex with cullin1, forms an alternate E3 ligase complex with Skp1 and 
cullin7 (Sarikas et al., 2008).  
Cullin7 is the only other member of the cullin RING ligase family besides cullin1 that is 
known to bind to Skp1 and an F-box protein for substrate recognition. FBXW8 is the first 
identified F-box protein to assemble in an atypical SCF-like complex with cullin7 (Sarikas et 
al., 2008). My results introduce FBXO41 as the second F-box protein that assembles in an 
SCF-like complex with Skp1 and cullin7. While cullin1 binds to F-box proteins at their F-box 
domain, cullin7 on the other hand binds to Fbxw8 independent of its F-box domain 
(Tsunematsu et al., 2006). Correspondingly, through structure-function analysis using various 
FBXO41 deletion mutants, I observed that while FBXO41 binds to Skp1 via the F-box 
domain, its interaction with cullin7 is F-box-independent and is rather mediated by its N- and 
C- terminal domains. Further cell-based ubiquitination assays revealed that while the full-
length FBXO41 harbored ligase activity and was capable of ubiquitination, deletion mutants 
of FBXO41 that could not bind to Skp1 (FBXO41 ∆Fbox) or cullin7 (FBXO41 aa 35-873), 
showed no ubiquitination activity, and were considered ligase-dead. These results establish 
FBXO41-Cul7 as a novel CNS-specific neuronal E3 ligase. 
It is worthwhile to note that several studies have identified mutations in the cullin7 gene, 
which lead to truncated cullin7 that lacks its cullin domain resulting in a non-functional 
protein. These mutations have been associated with the 3M syndrome and the Yakuts short 
stature syndrome. Both diseases are characterized by severe pre-and post--natal growth 
retardation, facial dysmorphism and skeletal abnormalities (Huber et al., 2005; Maksimova et 
al., 2007). The cullin7-/- mice have been reported to be embryonically lethal, showing 
intrauterine growth restrictions, placental abnormalities, and death due to respiratory distress 
(Arai et al., 2003). Fbxw8-/- mice, on the other hand show less severe phenotypes, but also 
display pre- and postnatal growth retardation and placental abnormalities. Only 30% of the 
Fbxw8-/- mice live past the first two postnatal weeks to survive until adulthood. Their body 
weights are only 75% of that of their wild type littermates. Apart from the growth retardation, 
Fbxw8-/- mice show no other prominent phenotypes (Tsutsumi et al., 2008).  Interestingly, 
FBXO41-/- mice, similar to the Fbxw8-/- mice, show reduced life span, where >80% of the 





reduced body and brain size that already significantly differs at P5 and becomes 
progressively more pronounced by P16. Only few FBXO41-/- mice survive until adulthood 
with a lifespan of no more than 10 weeks. It is also worth noting that these knockout mice, 
even though gaining weight over time are always significantly smaller than their wild type 
littermates. In light of previous studied on cullin7-/- and Fbxw8-/- mice, the reduced lifespan 
as well as smaller body and brain sizes observed in the FBXO41-/- mice could be partially 
attributed to loss of FBXO41-Cul7 function.  
4.2.2 The FBXO41-Cul7–NFM pathway of axon growth control: 
Axon growth is one of the fundamental events during neurodevelopment that ensures the 
proper wiring and connectivity of the brain. Previous experiments in cultured rat CGNs 
identified FBXO41 as a cell-intrinsic regulator of axon growth. Furthermore, loss of FBXO41 
resulted in shorter axons in cultured CGNs from FBXO41+/+ and FBXO41-/- mice, with 
little or no effect on dendrites (Holubowska, 2013). Since FBXO41-/- mice display the most 
obvious phenotype in the cerebellum, I further analyzed the parallel fiber thickness and area 
occupied by white matter in the cerebella of the FBXO41-/- mice, wherein I observed 
significantly thinner, slightly defasciculated parallel fiber bundles in the P10 FBXO41-/- 
cerebella together with a progressive reduction in white matter area within the cerebellum of 
the FBXO41-/- mice at P12, P16 and P30. These findings support previous results from the 
lab and establish FBXO41 as an axon growth-promoting protein, wherein loss of FBXO41 
leads to axon growth defects in vivo. Previously, Berglund and colleagues have demonstrated 
that ablation of the axon growth-regulating cell adhesion protein contactin results in severely 
ataxic mice, characterized by impaired CGN migration and similarly reduced thickness and 
defasciculation of parallel fibers along with dendritic defects in the CGNs (Berglund et al., 
1999). Thus, apart form being linked to impaired neuronal migration, the ataxia-like motor 
phenotypes in FBXO41-/- mice can also partially be attributed to defects in parallel fiber 
bundles in vivo. 
Having established that FBXO41 associates with Skp1 and cullin7 to form a novel E3 ligase, 
I further went on to uncover the molecular mechanism governing FBXO41-mediated axon 
growth. Upon performing morphometric analysis of neurons, I observed that while full-length 
FBXO41 promoted axon growth in cultured CGNs, the ligase-dead versions of FBXO41 
were unable to do so. This suggests that FBXO41 regulates axon growth in CGNs in a ligase 





bolster the importance of FBXO41 in axon growth regulation and suggest that the axon 
growth deficits observed in FBXO41-/- mice could be due to loss of FBXO41-Cul7 E3 ligase 
function. A recent study from Litterman and colleagues demonstrated that Fbxw8-Cul7 
regulates the morphology of Golgi apparatus and dendrites but interestingly not axon growth 
and patterning in rat CGNs (Litterman et al., 2011). Since E3 ligases are known to spatially 
and temporally regulate the expression of their substrates, it is conceivable that while Cul7-
Fbxw8 specifically influences dendrite length, FBXO41-Cul7 is responsible for regulating 
axon growth in the developing cerebellum.  
In order gain insight into the FBXO41-Cul7-mediated axon growth regulation, we conducted 
a Yeast Two-hybrid screen to identify potential interaction partners of FBXO41. From the list 
of candidates, I was able to identify NFM as a novel interaction partner of FBXO41. NFM is 
a neuron-specific, cytoskeletal protein that belongs to the family of type IV intermediate 
filaments. It binds and forms heteropolymers together with the three other neurofilaments 
NFL, NFH and α-internexin (Li et al., 2012). NFL, NFH and NFM are structurally very 
similar containing a globular head, a α-helical rod domain and a tail domain differing in 
amino acid composition. All neurofilaments contain a highly conserved rod domain, which is 
crucial for mediating their co-assembly and filament formation (Bocquet et al., 2009). The C-
terminus of NFM and NFH is highly phosphorylated containing several KSP (Lys-Ser-Pro) 
repeats in their tail domains (Rao et al., 2011). NFM is predominantly expressed in the soma 
and in axons, where it has been implicated in regulation of radial axon growth, maintenance 
of axon caliber and as a result influencing its conduction velocity (Eyer and Peterson, 1994; 
Garcia et al., 2003; Garcia et al., 2009; Rao et al., 2003).  My results indicate that NFM is 
expressed extensively in the developing cerebellum, observable from E18 onwards. This is 
surprising, as radial axon growth is regulated during myelination and occurs only after 
neurodevelopmental events including neuronal migration, axon growth and guidance have 
been completed (Cleveland et al., 1991). Several studies have previously reported internexin-
α, NFL and NFM as one of the earliest intermediate filaments to be expressed during 
development much before radial axonal expansion, with NFM being expressed in conjunction 
with neurite formation (Lariviere and Julien, 2004; Li et al., 2012; Pachter and Liem, 1984). 
Interestingly, previous studies demonstrated that loss of NFM resulted in shorter axons and a 
slower axon elongation rate in Xenopus highlighting the potential role of NFM in axon 
outgrowth (Akao et al., 1994; Walker et al., 2001). In light of the previous studies and the 





role in axon elongation in mammalian neurons. In this study, I explored the function of NFM 
in neurite extension by either using an shRNA approach that acutely knocks down NFM or 
using full-length NFM overexpression system. Surprisingly, both gain and loss of function of 
NFM resulted in an increase of axon length with no effect on dendrite length and axonal 
branching. Interestingly, a recent study implicated NFH, the sister-filament of NFM, and its 
phosphorylation in axon growth and stabilization (Matz et al., 2015). The study demonstrates 
that overexpression of NFH promotes axon growth in cultured neurons, that was similar to 
my observations of NFM gain of function. Owing to their similarity in structure and function, 
loss of either NFM or NFH has been previously reported to be compensated by increased 
phosphorylation of the other (Shea and Chan, 2008). Thus, the long axon phenotype of NFM 
knockdown could be in part due to compensational upregulation of NFH phosphorylation. 
Alternatively, it could also mean that NFM levels need to be tightly regulated for controlled 
axon growth. This observation, although surprising, is not unique to NFM as it is also 
observed in small GTPases such as Rac1, where a tight regulation of protein level is crucial 
for its function (Kimberly et al., 2001). In summary, my findings confirm the role of NFM in 
axon elongation and identify it as a novel regulator of axon growth in mammalian neurons. 
Newly synthesized neurofilaments are transported as short heteromers along the axons via 
various microtubule motors, where they are highly phosphorylated by several kinases 
including JNK, Cdk5, MAPK and ERK1/2 (Ackerley et al., 2003; Grant et al., 2001; 
Veeranna et al., 2004; Zhu et al., 2001). The C-terminal phosphorylation of these 
neurofilament heteromers is crucial for integration and formation of the extremely stable 
internal cytoskeletal meshwork. The cytoskeletal infrastructure formed by these 
neurofilaments is extremely stable and is thought to be resistant to cell metabolic processes 
displaying a low turnover rate (Yuan et al., 2009). However, growing evidence suggests the 
presence of ubiquitinated neurofilament tangles in axons in several neurodegenerative 
diseases, suggesting ongoing ubiquitination and possible turnover of these cytoskeletal 
elements (Gou and Leterrier, 1995; Lowe et al., 1988; Perrot et al., 2008). The RING ligase 
TRIM22 was recently found to ubiquitinate and regulate the levels of NFL in several regions 
of the mouse brain, including the cerebellum. Loss of TRIM22 leads to an accumulation of 
NFL in axons, leading to neurodegeneration, and an ataxic phenotype in mice (Balastik et al., 
2008). Having established NFM as an axon growth regulator and interactor of FBXO41, I 
reasoned whether NFM was an ubiquitination target of FBXO41-Cul7.  After observing that 





ubiquitination assay to determine if NFM was a substrate of FBXO41-Cul7. I observed that 
while FBXO41 full-length ubiquitinated NFM, the ligase-dead variant FBXO41 could not. 
Additionally, I also found that FBXO41-Cul7 ubiquitinated NFM via K63-linked 
polyubiquitin chains. Several studies have previously reported that K48-linked polyubiquitin 
chains target proteins for proteasomal degradation, while K63-linked polyubiquitination often 
leads to non-proteolytic evens, such as DNA repair, regulation of signal transduction, kinase 
activation as well as lysosomal degradation (Komander and Rape, 2012; Pickart and Eddins, 
2004). Hence, in order to understand the consequence of FBXO41-Cul7-mediated K63-linked 
polyubiquitination of NFM, I checked for the levels of NFM in FBXO41-/- mice, as well as 
in HEK293T cells transfected with either FBXO41 full-length or the ligase-dead deletion 
mutants FBXO41. Interestingly, I observed that loss of FBXO41 or loss of its the ligase 
activity resulted in decreased NFM levels, which is likely due to misregulated post-
translational events rather than the transcriptional downregulation of NFM gene expression as 
NFM mRNA levels were unaltered. These results, when taken together identify NFM as a 
non-proteolytic substrate of FBXO41-Cul7, wherein it ubiquitinates and stabilizes NFM. 
Gain- and loss-of function approaches to dissect the molecular relationship between NFM 
and FBXO41 suggest that the two interaction partners FBXO41 and NFM act in the same 
pathway of axon growth regulation. However, the results provide three possible 
interpretations or scenarios. 1) The observation that the short axon phenotype of FBXO41 
knockdown was more dominant than both NFM over expression as well as NFM knockdown, 
suggests that FBXO41 is epistatic to NFM and thus acts downstream of NFM. This may be a 
possibility as NFM could influence the trafficking and distribution of FBXO41 along the 
axons. NFM as a cytoskeletal protein has been previously shown to bind to Myosin Va and 
influence the transport of organelles and distribution of axonal contents along the axon (Rao 
et al., 2011). 2) In light of the non-proteolytic substrate-ligase relationship of NFM and 
FBXO41-Cul7, it is also possible that lack of the FBXO41-Cul7-mediated ubiquitin 
modification on NFM hinders its ability to promote axon growth, thus making NFM the more 
downstream candidate. This is more likely, as K63-linked polyubiquitination modifications 
have been previously shown to influence protein function and stability (Di Marcotullio et al., 
2006). Subsequent epistasis experiments also revealed that while FBXO41 could still 
promote axon growth in the absence of NFM, the full magnitude of its axon growth-
promoting effect is significantly reduced without NFM. Additionally, it became apparent that 





growth. These results not only imply that FBXO41 and NFM act in the same pathway of 
axon growth, but also hint at other NFM-independent pathways of FBXO41-mediated axon 
growth regulation. The E3 ligase Cdh1/APC for example is known to ubiquitinate several 
targets such as FBXO31, Smurf1, p250GAP, SnoN and Id2, in parallel pathways to exert its 
function as an axon growth inhibitor (Kannan et al., 2012a; Kannan et al., 2012b; Lasorella 
et al., 2006; Stegmuller et al., 2006; Vadhvani et al., 2013). Taken together, my findings also 
offer a third interpretation where both scenario 1 and 2 are true. It could be that FBXO41 
ubiquitinates NFM in order to stabilize, resulting in a stable cytoskeletal architecture. This 
could in turn could act as a feedback influencing the distribution and trafficking of FBXO41 
along the axon for example to the growth cone, where it might exert its function on other 
downstream targets to influence axon growth. These findings highlight the complex 
relationship between FBXO41-Cul7 and its non-proteolytic substrate NFM.  
In order to provide more clarity on the hierarchical relationship between the two, I further 
conducted a localization experiment to address the question whether loss of either NFM or 
FBXO41 influenced the cellular distribution of the other. While knockdown of NFM did not 
affect the localization of FBXO41, interestingly loss of FBXO41 resulted in abnormal 
appearance of GFP-NFM along the axons. While in control neurons, GFP-NFM was 
incorporated into the axonal architecture, FBXO41 RNAi neurons displayed apparent 
defasciculation of GFP-NFM. These results not only strengthen the notion that NFM indeed 
acts down stream of FBXO41, but also suggest that the interaction with FBXO41 might be 
crucial for the proper integration and stabilization of NFM along the axons. Recently, a study 
by Rao and colleagues demonstrated that the stability of the neurofilaments and their 
integration into the cytoskeletal network is phospholylation-dependent. Interestingly, they 
demonstrate that loss of the phosphorylation tail of NFM or NFH resulted in destabilized 
neurofilaments that were readily turned over by the proteasome (Rao et al., 2012). Previously 
studies have also demonstrated K63-linked plyubiquitnation mediated kinase activation in the 
NFk-B signaling pathway, where in the K63-linked polyubiquitin chains serve as scaffolds 
facilitating the signaling hub necessary for activation of the kinases TAK1 and IKK 
(Kanayama et al., 2004). Hence, it is plausible that the K63-linked polyubiquitin chain 
modification of NFM by FBXO41-Cul7, serves as a recognition or activation signal for 
various kinases leading to phosphorylation of NFM at its C-terminus by, thus regulating its 
stability and axon growth. This in part can explain the defasciculated appearance and 





that loss of NFM leads to severe downregulation of other neurofilaments including NFL and 
NFH in the axons, leading to a compromised axonal cytoskeleton (Elder et al., 1998). 
Consequently, diminished NFM levels in FBXO41-/- mice could also lead to reduced NFH 
and NFL.  
The conventional “elongation and stabilization” model of axon growth states that axons 
achieve stable cytoskeletal architecture, supported by neurofilament scaffolds, only after 
reaching the target cell. A recent study by Lee and Shea demonstrates that NFH promoted 
axon growth and stabilization in differentiated NB2a/d1 cells, by means of its C-terminal 
phosphorylation (Matz et al., 2015). Owing to the structural similarity between NFM and 
NFH, it is plausible that NFM exerts its effect on axon growth in a similar manner. In their 
study, Lee and Shea propose an alternate axon growth model of “sequential stabilization”. 
They hypothesize, that the proximal regions of the growing axon undergoes sequential 
stabilization, achieved by a stable neurofilament-based cytoskeletal scaffold, which in turn 
provides further physical support for the distal part of the axon for continued growth and path 
finding. Based on their axon growth model and my experimental observations, I propose that 
the E3 ligase FBXO41-Cul7 regulates axon growth by ubiquitinating NFM via K63-linked 
polyubiquitin chains. This ubiquitin modification on NFM could directly lead to its 
stabilization, for example by preventing other ligases from ubiquitinating it, thus preventing 
its proteolytic turnover. Alternatively, the ubiquitination of NFM by FBXO41-Cul7 might 
serve as a signal recognition site for other posttranslational modifications, such as 
phosphorylation by specific kinases, ultimately leading to its stabilization. This could in turn 
provide the structural stability needed for further axon growth.  
 
4.3 FBXO41+/- mice do not show any signs of late onset motor phenotype: 
A previous study from the lab reported that FBXO41 is developmentally upregulated but is 
maintained at steady state levels in the postnatal brain including the cerebellum, suggesting 
post-developmental functions of FBXO41 (Holubowska, 2013). These might include 
maintenance of synapses, axonal transport and neuronal health. It is interesting to note that 
while FBXO41-/- mice display a striking motor phenotype characterized by an ataxic gait and 
uncoordinated movement at P16 as well as P30, the FBXO41+/- mice were indistinguishable 
from their wild type littermates. Since further analysis of the P30 FBXO41-/- mouse brains 





speculated if loss of one of the FBXO41+/- gene alleles would result in an ageing-related 
onset behavioral phenotype, possibly as a consequence of late-onset neurodegenerative 
events. Hence, I subjected a 10 month-old cohort of male mice to a battery of behavioral tests 
to assess their general anxiety, locomotor activity, motor coordination and olfaction. At 10 
months of age, I neither observed any differences in body weights nor did the genotypes 
show abnormal changes in anxiety when subjected to the elevated plus maze. Both genotypes 
had no differences in the amount of locomotor activity represented by track lengths. 
Interestingly, while FBXO41+/+ mice preferred to spend time in the periphery of the open 
field close to the walls,  FBXO41+/- mice showed a slight increase in the time spent in the 
intermediate quadrant compared to the periphery. This difference was very minute, however 
significant, which could be attributed to fewer numbers of wild types or be non-specific. On 
the other hand, it could suggest a mild decrease in anxiety levels in the FBXO41+/- mice. 
Some neurodegenerative disease patients as well as mouse models, for example those being 
affected by Parkinson’s disease, display disinhibition in behavior as one of the early 
symptoms (Paumier et al., 2013). Interestingly, a recent study analyzing a Chinese Han 
population implicated specific SNPs in the Fbxo41 gene as risk factors for Parkinson’s 
Disease in females (Liang et al., 2013). Additionally, I analyzed the mice for signs of 
neurological defects by subjecting them to the hind limb clasping test. Both FBXO41+/+ and 
FBXO41+/- mice were indistinguishable with no pronounced signs of hind limb clasping. I 
further subjected the animals to the balance beam test as well as rotarod to gauge their motor 
coordination. There was no difference between the genotypes in the balance beam test. In the 
rotarod test however, the FBXO41+/- mice seemed to outdo their wild type littermates, 
showing a steeper learning curve. This, however, should be considered as false-positive effect 
due to the fact that several wild type FBXO41+/+ animals were unmotivated and gave up 
easily. Additional tests on olfaction as well as the pole test showed no difference within the 
two genotypes. The results of behavioral testing revealed that FBXO41+/- mice show neither 
signs of motor impairment nor olfactory and neurological defects, suggesting that half the 
dosage of Fbxo41 is not enough to elicit obvious behavioral differences.  
Even though there were no significant differences observed in motor coordination and gait 
between FBXO41+/+ and FBXO41+/- mice, deficits in learning and memory, due to the high 
expression of FBXO41 in other areas of the brain, cannot be ruled out. On the other hand, the 
mice were only 10 months in age at the time of analysis, while most age dependent 





Further analyses of the FBXO41+/- mice with a larger cohort should be hence performed at 
older ages, followed up by thorough histological analyses, in order to rule out any age 
dependent phenotypes. 
 
4.4 Open questions and scope for further research: 
Apart from the high expression in the cerebellum, FBXO41 is also abundantly expressed in 
other parts of the brain, for example the cortex, hippocampus and striatum. Hence, it is 
conceivable that the FBXO41-/- mice display impaired neuronal migration and deferred 
wiring in other regions of the brain.  Analysis of the cortical and hippocampal regions at P12, 
P16 and P30 did not yield any obvious defects in these regions.  These results suggest that 
either FBXO41 related impaired neuronal migration phenotype is cerebellum-specific, or that 
the migrational defects in the cortex or hippocampus have caught up over the course of 
development, which might be likely. Preliminary data from the lab for instance suggests that 
FBXO41-/- mice also show improper neuronal migration in the embryonic and neonatal 
cortex (A.Gellerer, Master’s thesis; Dr. M Vadhvani, unpublished data). Thorough 
histological marker analysis of the developing cortex as well as the hippocampus would 
however be necessary in order to gain more clarity.  Since FBXO41 is also very highly 
expressed in the postnatal adult brain, including the cortex, hippocampus and cerebellum, it 
could also serve in the formation and maintenance of synapses, which requires further 
investigation.  
Owing to the increased apoptosis in the hippocampus it is also possible that along with the 
severe motor deficits the FBXO41-/- mice also suffer from impaired cognition. Interestingly, 
several studies have also associated the cerebellum to proper learning, memory, cognition and 
speech (Boyden et al., 2004; Ferrucci et al., 2012; Marien et al., 2001; Stoodley, 2012; 
Strata et al., 2011; Strick et al., 2009). For further analysis, generation of cortex and 
hippocampus specific conditional FBXO41-/- mice line might enable the study of the 
cognitive function in the FBXO41-/- mice and shed further light on FBXO41 function in 
other parts of the brain. 
My results also indicate that FBXO41-/- mice display axon growth abnormalities in the 
cerebellum. Usage of cultured CGNs as a model system identified that the novel E3 ligase 
FBXO41-Cul7 regulates axon growth together with NFM via its non-proteolytic 





neuronal proteins expressed abundantly in the brain, it is likely their function in axon growth 
regulation is also conserved in other neuronal types. However, further experiments for 
example in cortical or hippocampal neurons will be important as a proof of principal.  Since 
FBXO41 forms a cullin7 based E3 ligaseit is very likely that, similar to axon growth, it also 
regulates neuronal migration and cell death in a ligase activity-dependent manner. Further 
experiments using the ligase-dead FBXO41 mutants would be necessary to confirm the same. 
Apart from impaired cerebellar development, defects in neuronal migration, deferred wiring 
of the other regions of the mouse brain could also greatly contribute to the motor symptoms 
observed in the FBXO41-/- mice. Further identification of FBXO41-Cul7 targets would 
greatly shed light on other FBXO41- mediated pathways and their implications. 
 
4.5 Conclusion: 
The results from this study demonstrate that FBXO41 is indispensible for the timely 
migration of granule neurons during cerebellar development. Additionally, it also identifies a 
role for FBXO41 in neuronal survival and maintenance of proper cerebellar architecture and 
integrity. Behavioral analyses of the FBXO41-/- mice reveal a dramatic reduction in body 
size and severely ataxic gait. Since impaired cerebellar development is intimately linked to 
cerebellar ataxias, further research towards identifying possible mutations in the Fbxo41 gene 
may perhaps contribute to resolving some of the unresolved causes of congenital ataxias. 
Although FBXO41 is neurodevelopmentally upregulated, it was also reported to have a high 
expression in the adult brain. The behavioral analyses of the adult FBXO41+/- mice however 
remained inconclusive in determining the role of FBXO41 in the adult brain. 
At a molecular level FBXO41 has a dual localization, at the centrosome and the cytoplasm. 
My results identified the cytoplasmic FBXO41 to be responsible for regulating neuronal 
migration. Apart from regulating migration and neuronal survival, FBXO41 also promotes 
axon growth. In this study, I demonstrate that FBXO41 regulates axon growth in a ligase 
activity-dependent manner by forming the second known atypical SCF-like E3 ligase with 
Skp1 and cullin7. I additionally report that FBXO41-Cul7 interacts with the cytokeletal 
protein NFM where FBXO41-Cul7 ubiquitinates NFM via non-proteolytic K63-linked 
polyubiquitnation, leading to its stabilization. I further establish NFM as an axon growth-
regulating protein that operates downstream of FBXO41 in axon growth control. Based on 





of other targets of FBXO41-Cul7 will be crucial in understanding the molecular mechanisms 
underlying neuronal migration, survival and identify other functions of this protein in the rest 
of the brain. 
In conclusion, my work furthers our understanding of the F-box protein FBXO41 in the 
context of neurodevelopment. It provides a systematic overview of the role of FBXO41 in 
vivo, as well as gives new insights into the molecular mechanisms underlying its function, 







Figure 4.1 Current working model of the F-box protein FBXO41 in cerebellar development: the CNS-
specific neuronal F-box protein FBXO41 localizes to the centrosome and the cytoplasm. While the 
cytoplasmic FBXO41 promotes neuronal migration and axon growth, the function of the centrosomal 
FBXO41 remains elusive. It additionally plays a role in neuronal survival, which appears to be crucial for the 
integrity of the cerebellum. FBXO41 interacts with Skp1 and cullin7 to form an atypical SCF-like E3 ligase, 





protein NFM via non-proteolytic polyubiquitin chains, leading to its stabilization. (1) FBXO41-Cul7 
mediated ubiquitination of NFM could directly lead to its stabilization, by preventing other types of 
ubiquitination from taking place that might otherwise lead to its proteolytic turnover. (2) NFM is a highly 
phosphorylated protein and, its phosphorylation is key for its stability (Rao et al., 2012). FBXO41-Cul7 
mediated ubiquitin modification on NFM could also serve as a recognition signal for further phosphorylation 
of NFM leading to its stability. Both (1) and (2) would ultimately lead to stabilized NFM protein levels. 
NFM’s integration into the growing axons might strengthen the cytoskeletal scaffold thus providing the 
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List of plasmid constructs that were generated in the lab and used in this study along with 
their respective primer numbers: 




pCMV-myc-FBXO41-Res A. Holubowska 19036/19037 
pCMV-myc-FBXO41-Res ∆CTR A. Holubowska 19036/19037 
pCMV-myc-FBXO41 ∆Fbox C. Mukherjee 18556/19426/19427/18552 
pCMV-myc-FBXO41 ∆CTR N. Schwedhelm-
Domeyer 
18556/18031/18032/18552 
pCMV-myc-FBXO41 aa 35-873 N. Schwedhelm-
Domeyer 
18551/18552 








pEGFP-C2-FBXO41 J. Stegmüller  
pc3XFlag-CMV-10.dna-NFM C. Mukherjee 29301/29302 




pCMV-myc-Skp1 J. Stegmüller 15454/15455 
pBluescript-U6-FBXO41 
RNAi#5 
J. Stegmüller 16104/16105 
pBluescript-U6-FBXO41 
RNAi#8 
J. Stegmüller 20268/20269 
pBluescript-U6-NFM RNAi#5 C. Mukherjee 24562/24563 







Plasmids obtained from other sources: 
Plasmid Obtained from 
pEGFP-C2-NFM A. Brown (Ohio State University, USA) 









Sequence and primer numbers of primers used for Genotyping and qRT-PCR 
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